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Abstract
Thyrotrophin releasing hormone (TRH) is a small neuropeptide of three amino acids
originally isolated from hypothalamic extracts as a stimulator of thyrotrophin (TSH)
release from the anterior pituitary gland. TRH also has an auxiliary role in the pituitary
of modulating prolactin (PRL) secretion from lactotroph cells. However, since its
initial identification TRH has been shown to be widely distributed throughout the
central and peripheral nervous system where it is thought to act as a
neurotransmitter/neuromodulator, as well as in extraneural tissues where its action is
less well understood.
TRH stimulates hormone secretion via specific high affinity binding sites on target
anterior pituitary cells. The human homologue of the pituitary TRH receptor (hTRH-
R) has been cloned and shares a high degree of sequence homology with TRH-Rs
previously cloned from lower species including mouse and rat . The TRH-R is a
member of the superfamily of G-protein coupled receptors (GPCRs), and
communicates to the cell interior through the phospholipase C (PLC) second
messenger system.
The overall aims of this project were to determine whether naturally occurring TRH-R
mutations exist in relevant human clinical conditions, and if so, to investigate their
effects on receptor function in vitro. The molecular mechanisms of TRH action in
wild type and mutant TRH-Rs would be investigated using the techniques of site-
directed mutagenesis and expression of TRH-Rs in mammalian cell lines. The role of
specifically chosen sites within regions of the TRH-R believed to be important for
intracellular signalling would be studied simultaneously by the same methods.
Pituitary tumours secreting either TSH, PRL or GH may respond to TRH by
enhanced, blunted or paradoxical hormone release. Non-functioning pituitary
adenomas may also show abnormal responses to TRH. Little is understood of the
cellular and molecular mechanisms regulating inappropriate hormone release or
abnormal growth of these tumours. However, activating and inactivating mutations in
a number of GPCRs have been implicated in a variety of human diseases. Mutations
in the TRH-R may therefore be involved in the aetiology of pituitary adenoma
formation and/or activity. A group of pituitary adenomas collected at surgery,
comprising 11 TSH-secreting, 15 GH-secreting and 15 PRL-secreting adenomas as
well as 5 non-functioning tumours were screened for mutations in the TRH-R gene.
viii
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DNA extracted from these adenomas was screened for somatic TRH-R mutations by
polymerase chain reaction-single stranded conformational polymorphism analysis
(PCR-SSCP). No TRH-R mutations were identified in any of the tumour groups, so
it appears that the TRH-R is not of significant causative importance in aberrant TRH
responses or tumourigenesis of anterior pituitary cells.
Blood lymphocyte DNA was also obtained from two unrelated patients suffering from
isolated central hypothyroidism, a rare disease characterised by low circulating thyroid
hormone levels in the presence of normal plasma TSH levels and a lack of TRH-
inducible TSH or PRL secretion. The DNA obtained from these patients was screened
for germline TRH-R mutations. The first of these patients (Patient 1) retained normal
TRH-R structure suggesting that his hypothyroidism must have another aetiology (e.g.
abnormalities in downstream TRH-R signalling mechanisms). However, Patient 2
was found to have inherited a mutant TRH-R allele from each of his unaffected
parents. The maternally-derived mutation involved the substitution of one nucleotide
(C49-to-T) which altered the codon for amino acid 17 (Arg- CGA) such that it became
a premature stop codon (TGA), thereby severely truncating the TRH-R polypeptide.
The mutation inherited from the father affected the third transmembrane region. Three
amino acids were deleted (Serll5, Ilel 16 and Thrll7) and another was substituted
(Alal 18-to-Thr). It is presumed that this mutant will be translated into a full length
receptor (except for 3 amino acids). When the mutated TRH-R constructs were
transfected into mammalian expression systems no TRH binding or function was
measurable, explaining this patient's unresponsiveness to TRH administration. The
incidence of this novel cause of central hypothyroidism remains to be ascertained.
This is the first report of a mutation in a PLC-linked GPCR and for that reason alone it
is an important discovery. In addition, this patient appears to represent a naturally
occurring TRH-R knock-out, a condition which due to the postulated various and
widespread actions of TRH was presumed to be a lethal genetic condition.
In vitro mutagenesis of the hTRH-R was also carried out in combination with PCR-
SSCP analysis to further understanding of the underlying causes of pituitary tumours
and other TRH-related pituitary conditions.. Specific amino acids within the receptor
were altered by mutating the receptor cDNA. The function of the mutant receptors was
then measured in terms of ligand binding and second messenger activation.
Substitution of Glul22 (in the conserved (E)DRY motif in the second intracellular
loop) to Leu (E122L) resulted in complete ablation of TRH binding, and subsequent
inositol phosphate accumulation. In contrast, substitution of this same residue with
Asp (E122D) caused no change in either radioligand binding or second messenger
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stimulation. Substitution of Thr265 (a potential phosphorylation site at the interface of
transmembrane region Vl/intracellular loop 3) by any of the three residues Ser, Ala or
Asn (T265S, T265A and T265N respectively) resulted in mutant hTRH-Rs which
exhibited a three to six-fold increase in receptor expression at the cell surface compared
to wild type, and an increased affinity for ligand.
In order to address the issue of whether the inactivating TRH-R mutations from Patient
2 indeed represent a non-lethal TRH-R knockout the final aim of the project was to
determine those regions of the upstream, or 5'-flanking, region of the mouse TRH-R
(mTRH-R) responsible for transcriptional initiation and control. The mTRH-R 5'-
flanking region was analysed by cloning regions of various lengths into a luciferase
(luc) reporter vector and measuring resultant luc activity. The transcription start site
appears to lie within a region 300-350 bases upstream of the ATG translational start
site. Expression of the region -1045 to -182, (relative to the ATG translational start
site) in pituitary GH3 cells results in a 3.85 fold increase in luc activity over no
promoter controls. No increase in luc activity was seen with expression of this same
fragment in COS-1 cells (non-pituitary). By characterising the DNA elements
responsible for initiating and controlling TRH-R transcription it will be possible to
create a DNA construct and to produce a transgenic mouse lineage with no TRH-R
expression, a true TRH-R knock-out. Such an animal model will allow more detailed
analysis of the functions (if there are any) of TRH during embryogenesis and
subsequent postnatal development, both in the brain and in extraneural locations.
The results of the work described in this thesis indicate that the possession of
inactivated TRH-Rs results in central hypothyroidism in one out of two randomly
selected patients. It remains to be determined how prevalent such mutations may be in
patients with this rare disorder and indeed in other congruous diseases. Furthermore,
TRH-R inactivation was achieved by substitution of a single amino acid in a different
region of the hTRH-R (intracellular loop 2) suggesting that additional naturally
occurring inactivating mutations may be identified in additional patients as yet
unidentified. The effects of TRH-R knock-out will be studied in a transgenic mouse
model and comparison with the apparent human equivalent identified here will give
further insight into the functional roles of TRH and it's receptor both during
embryogenesis and in later stages of development. By uncovering how TRH and it's
receptor interact and the responses triggered by ligand binding, it may be possible to
fully understand the mechanisms underlying the effects of TRH and to improve TRH
treatments currently in use in the clinic.
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Thyrotrophin-releasing hormone was the first of the trophic neurohormones to be
isolated and purified from the hypothalamus (Schally et al, 1966). The role of TRH in
control of the thyrotroph and thyroid function is well established, although this is only
one of its diverse biological functions. In addition to additional effects on the anterior
pituitary gland, TRH is also widely distributed in extrahypothalamic brain regions, in
the spinal cord, and in several peripheral tissues, suggesting additional functions of
TRH in these areas. The recognised effects of TRH in neural tissues suggest a role as
a neurotransmitter/neuromodulator of central nervous system (CNS) activity. The
function(s) of TRH in the gastrointestinal and reproductive tracts, and in the retina are
poorly understood, but such wide spread distribution of this hormone suggests that it
may be a hormone involved in a complex set of interactions with other hormones and
transmitters which regulate normal bodily functions. Phylogenetic data indicates that
TRH exists in species which do not possess a pituitary gland. This suggests that the
putative paracrine role of TRH in extra-neural tissues may have pre-existed evolution
of the pituitary gland and that TRH has subsequently been recruited by this organ.
1.2 Aim of the study
The primary aim of this PhD study was to determine the role of the TRH-R in human
endocrine disorders by screening TRH-R genes from various patient and tissue
sources for somatic or germline mutations altering receptor function. Structure-
function relationships in the TRH-R were in addition, sought by functional assessment
of mutant TRH-Rs generated by site-specific mutagenesis of amino acids within the
receptor structure highlighted as playing a potential role in receptor function.
1
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1.3 Importance of the study
Since its identification TRH has been used in clinical practice to treat a wide variety of
disorders, including the treatment of patients with mild disturbance of consciousness
(due to head injury or subarachnoid haemorrhage) (Manaka et al, 1977; Sano et al,
1979), and foetal respiratory distress syndrome (Shennan and Peek, 1995). The
effects of TRH therapy in depression, based on its CNS stimulatory effects, remains
equivocal (Kastin et al, 1972; Prange et al, 1972). TRH has some clinical
disadvantages, including a short duration of action (due to its short half life resulting
from endopeptidase activity), its weak CNS effects relative to its TSH-releasing
activity, and its hypertensive effects. Elucidation of the structure and function
relationships of TRH and the TRH-R may facilitate the synthesis of TRH analogues
with increased resistance to metabolism, more specific activity as applicable to the
proposed treatment and with fewer or less marked side-effects..
Many human diseases have been linked to mutations in GPCRs and in light of this the
TRH-R may be implicated in certain conditions characterised by abnormal HPT axis
activity and may also be of significance in the discordant and paradoxical responses of
pituitary adenoma cells to TRH.
The hypothalamo-pituitary-thyroid axis bears strong relevance to reproductive
endocrinology. In addition to the well established prolactin-releasing effects of TRH,
it is known that the anterior pituitary gland becomes more sensitive to TRH at pro-
cestrous (Brandi et al, 1990; de Lean et al, 1977a) and under the influence of oestrogen
(de Lean et al, 1977b), which is probably a result of an increased number of TRH-Rs
on mammotrophic cells in response to oestrogen (Gershengorn et al, 1979). Therefore
it appears that there is some degree of interplay between the HPT and hypothalamo-
pituitary-gonadal (HPG) axes.
1.4 Structure of the thesis
The thesis begins in Chapter 2 with an extensive review of the current literature
concerning the TRH-R as an example of a GPCR, the function of TRH and the TRH-
R in the wider context of the HPT axis, disturbances of the HPT axis and the role of
GPCR mutations in pathogenesis.
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Chapter 3 describes in detail the experimental protocols used throughout the following
experimental chapters (Chapters 4 to 7) from basic molecular biology methods to more
specific descriptions of methods for expression in eukaryotic cells, receptor function
assays and promoter/transcription site isolation and characterisation.
Pituitary adenomas arise from the clonal expansion of a single transformed progenitor
cell, although the factors involved in oncogenic transformation in these neoplasms is
undetermined. Pituitary adenomas often show discordant responses to TRH,
suggesting that there may be a TRH-R abnormality in association with abnormal cell
proliferation and secretion. Chapter 4 describes the screening of 50 pituitary
adenomas for somatic mutations in the TRH-R genes contained in DNA extracted from
patient adenoma tissue samples. A rapid screening method was used in which
fragments of the TRH-R coding region were analysed for single-strand conformational
polymorphisms. The majority of the work constituting this study was performed by
the author in the laboratory of Dr Shlomo Melmed (Division of Endocrinology and
Metabolism, Cedars-Sinai Research Institute, UCLA, Los Angeles, California, USA)
during a four month working visit.
Chapter 5 describes the analysis of the TRH-R genes of two patients with central
hypothyroidism, a condition characterised by low plasma total and free T4
concentrations in the presence of normal TSH values. This is a rare disorder which
may arise from either hypothalamic or pituitary lesions. Inactivating mutations in the
TRH-R were sought as an explanation for the absent TRH-induced TSH and PRL
responses observed in these patients. It should be pointed out that this study was
performed in collaboration with two other investigators. Patient 1 DNA was obtained
from Dr David Repaske (Division of Endocrinology, Children's Medical Center,
Cincinnati, Ohio, USA) and was analysed by PCR-SSCP by the author. Patient 2
mutant TRH-R constructs were obtained from Dr Robert Collu (Hopital Sainte Justine,
Universite de Montreal, Montreal, Canada) who asked the author to perform the
experiments necessary for functional characterisation of these mutant TRH-Rs as his
own laboratory was finding this very difficult to achieve. In vitro translation
experiments were designed and performed by the author.
Site-directed mutagenesis is a powerful tool used by molecular biologists to help to
identify specific molecular interactions involved in GPCR structure and function. In
Chapter 6 the hTRH-R was subject to such mutation at two sites within the
cytoplasmic domains of the receptor. Glul22 and Thr265 were identified as having
potential roles in receptor structure and/or function and were subsequently mutated.
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The function of the mutant receptors was analysed by measuring radioligand binding
and TRH-induced G-protein activation of the phospholipase C second messenger
pathway.
In order to study the effects of TRH-R knockout it was decided to begin the process of
establishing a transgenic mouse line. In order to execute this plan it was first essential
to characterise the 5'-flanking region of the mouse (m)TRH-R gene. Clone 9, a
6.5kbp fragment of the mTRH-R gene had been isolated by a previous PhD student
working with the author's supervisor (Duthie et al., 1993b) and in the same article
400bp of the upstream sequence (with respect to the ATG translation initiation codon)
was published. Further sequence analysis and all of the characterisation experiments
were performed as an integral part of this thesis and this work is described in Chapter
7.
Chapter 8 summarises and concludes the work performed to establish the set of related
studies constituting this thesis and outlines future experimental research.
Chapter 2
Literature Review
2.1 The hypothalamic-pituitary axis
The idea that hypothalamic neurones might regulate normal pituitary function by
secreting specific chemical messengers into the blood flowing through the portal
vessels and thence into the adenohypophysis was first outlined by Harris almost 50
years ago in a monograph describing the hypothalamic control of anterior pituitary
hormones (Harris, 1948). The hypothalamus is now known to be the central regulator
of adenohypophyseal hormone release, forming the terminal links between the
neuronal circuitry of the brain and the endocrine cells of the anterior pituitary (Yen,
1991). The basic structural organisation of the hypothalamus is shown in Figure 2.1.
2.1.1 The hypothalamus
The hypothalamus is a poorly defined and primitive structure located at the base of the
vertebrate forebrain. In order to serve its neuroendocrine function the hypothalamus is
both highly vascularised and strongly innervated. Afferent and efferent fibres connect
the hypothalamus with other regions of the brain including the forebrain, limbic
system, visual cortex, thalamus and brain stem. The hypothalamus is composed of
various bundles of cells which secrete hormones either into the portal blood system for
transport to the adenohypophysis, or directly into the general circulation after storage
in the hypothalamus. On reaching target cells located in the anterior pituitary the
hypothalamic hormones, also known as releasing or inhibiting hormones because of
the nature of their actions, act to regulate the synthesis and secretion of various trophic
hormones. In turn these trophic hormones regulate gonadal, thyroid and adrenal
function, in addition to lactation, bodily growth and somatic development.
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Figure 2.1 The hypothalamus
Selected areas of the hypothalamus and a three-dimensional representation of the hypothalamic nuclei
seen in sagittal section relative to the position of the pituitary gland.
2.1.2 Hypothalamic hormones
To date five classical hypophysiotrophic peptide hormones, thyrotrophin-releasing
hormone (TRH) (Guillemin, 1978) gonadotrophin-releasing hormone (GnRH)
(Burgus et al, 1970); (Matsuo et al, 1971) somatostatin or somatotroph-releasing
inhibitory hormone (SRIH) (Brazeau et al, 1973) corticotrophin-releasing hormone
(CRH) (Vale et al, 1981) and growth hormone-releasing hormone (GHRH) (Speiss et
al, 1983) have been isolated, and their role in the regulation of anterior pituitary
hormone synthesis and secretion extensively studied. Other factors, e.g.,
neurotransmitters and neuropeptides, shown to influence anterior pituitary hormone
release include catecholamines (dopamine (DA), adrenaline and noradrenaline),
acetylcholine, y-aminobutyric acid (GABA), opioid peptides and vasoactive intestinal
peptide (VIP). The precise action ofmany of these factors is unknown but the roles of
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dopamine and VIP in the regulation of prolactin (PRL) secretion have been more
precisely established (Abe et al, 1985; Jonathan, 1985)
Many of the hypothalamic-releasing/inhibiting hormones have also been localised
outside the hypothalamic-pituitary axis in tissues including the brain, spinal cord,
autonomic nervous system, gastrointestinal, respiratory and reproductive tracts (Yen,
1991). A potential role for these peptides in cellular communication prior to the
development of the neuronal or endocrine systems has been postulated (Kreiger,
1983).
2.1.3 The pituitary gland
Figure 2.2 shows a diagrammatic representation of the anatomy of the pituitary gland.
The pituitary gland has two parts: the neurohypophysis (median eminence,
infundibular stem and neural lobe) is of neural origin whilst the adenohypophysis
(anterior pituitary and intermediate lobe) is of ectodermal origin, developing from the
embryonic pharyngeal evagination known as Rathke's pouch. The main part of the
neurohypophysis, the neural lobe, is connected to the median eminence by the
infundibular stem. Adenohypophyseal tissue (pars tuberalis) surrounds the median
eminence and infundibular stem creating the pituitary stalk. The adenohypophysis
consists of three main regions: the pars distalis (ventral portion commonly termed
anterior lobe), pars intermedia (adjacent to neural lobe; rudimentary in humans) and the
pars tuberalis.




















Figure 2.2 Structure of the pituitary gland
Diagram summarising the structure of the pituitary gland and its vascular network.
The posterior pituitary is composed of magnocellular neurosecretory nerve endings.
Oxytocin and vasopressin with their corresponding neurophysin molecules are
synthesised in the supraoptic nucleus (SON) and paraventricular nucleus (PVN; Figure
2.1), packaged into granules and transported through the nerve axons, via the pituitary
stalk, to the posterior pituitary. When stimulated, the neurosecretory cells fire action
potentials and exocytose hormones directly into the capillary vessels of the inferior
hypophyseal artery. Cholinergic and noradrenergic fibres synapse with the SON and
PVN and have been shown to stimulate hormone release, while inhibitory regulation
occurs by dopaminergic and opioidergic pathways. Purification of oxytocin and
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vasopressin (du Vigneud et al, 1954) revealed that both of these hormones have a
nonapeptide structure requiring a disulphide bond between cysteine residues (at
positions 1 and 6) for biological activity. Oxytocin is released in response to
peripheral stimuli from cervical stretch receptors or from suckling stimulus at the
breast. Oxytocin action in the cervix promotes foetal expulsion during labour,
whereas in the mammary gland it causes milk release. The main physiological
stimulus for the release of vasopressin is provided by alterations in body fluid balance,
an increase in osmotic pressure being counterbalanced by the action of vasopressin on
water reabsorption from the kidneys.
In contrast, the anterior pituitary is composed of a number of different endocrine cell
types. The mature anterior pituitary gland consists principally of five major main
endocrine cell types: somatotrophs (c. 50% of anterior pituitary cells), lactotrophs (c.
15%), gonadotrophs (c. 10%), thyrotrophs (c. 5%) and corticotrophs (15-20%)
(Figure 2.3). Hypothalamic-releasing/inhibiting hormones bind to specific receptors
located on the surface of anterior pituitary cells which facilitate coupling to a second
messenger cascade system, resulting in alterations in effector system activity, and
ultimately hormone exocytosis.
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Figure 2.3 Hormones released by the anterior pituitary gland
The five major cell types of the anterior pituitary gland are depicted in relation to the
adenohypophyseal trophic hormones which each cell type produces. The effects of the trophic
hormones on their downstream target tissues is shown.
2.2 Thyrotrophin-releasing hormone (TRH)
Like the other hypothalamic releasing/inhibiting factors TRH was initially isolated
from pituitary extracts (Boler et al, 1969; Guillemin, 1978), its existence having been
proposed by Greer as early as 1951 (Greer, 1951) Once isolated TRH was the first
hypothalamic releasing factor to be chemically synthesised and successfully
administered to humans which was able to disrupt the thyroid axis (Guillemin et al,
1971; Schally et al, 1984). TRH is released directly into the pituitary portal circulation
and has effects on two distinct target cell populations. The primary effect of TRH is to
stimulate the release of TSH from thyrotroph cells. TRH has the ancillary action of
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stimulating the release of PRL from lactotroph cells, although the physiological
significance of this action remains uncertain.
2.2.1 Structure of TRH
TRH was first isolated from porcine hypothalamus as a TSH releasing factor (Schally
et al, 1966). The characterisation of porcine and ovine TRH (Folkers et al, 1984;
Burgus et al, 1970) showed this compound to be a weakly basic, cyclic tripeptide,
pyroglutamyl-histidyl-prolineamide (Figure 2.4). At this time it was demonstrated that





Figure 2.4 Structure of TRH
The chemical structure of TRH [pyroGlu-His-Pro-NH2l (from Folkers et al., 1969)
2.2.2 Synthesis and metabolism of TRH
TRH is synthesised in vivo as part of a larger precursor molecule, or pro-hormone that
undergoes extensive post-translational processing to produce the mature peptide
(Jackson and Wu, 1985; Nillni et al, 1993; Richter et al, 1984). Interestingly the
prepro-TRH (amino acids 178-199) molecule has been suggested as an inhibitor of
ACTH secretion, that is as a cortocotrophin release-inhibiting factor (CRIF) (Redei et
al, 1995a; Redei et al, 1995b), although more recent work disputes these findings
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(Nicholson and Orth, 1996). Several TRH-like peptides have recently been
characterised, some of which may be produced by alternative post-translational
processing of the TRH pro-hormone. Others appear to be the products of distinct
genes (Bilek et al, 1992; Fuse et al, 1990)
TRH has a short half-life in both tissues and serum, being rapidly degraded into TRH-
free acid (diamino-TRH), histidyl-proline-diketopiperazine (His-Pro-DKP) and
constituent amino acids (Bower et al, 1978; Jackson et al, 1979; Jikihara et al, 1993).
His-Pro-DKP is proposed to be active in the rat hypothalamus as a dopamine-uptake
blocker (Jikihara et al, 1993; Peters et al, 1985).
2.2.3 Localisation of TRH to the hypothalamus
The highest concentration of TRH is localised in the paraventricular nucleus (PVN) of
the hypothalamus which is the classic thyrotrophic area of the hypothalamus (Jackson
and Reichlin, 1974; Lechan and Jackson, 1982). TRH can be detected in the nerve
fibres of the posterior pituitary, with a concentration second only to the hypothalamus.
Ablation of the PVN in the rat depletes hypothalamic TRH by 70% which results in
hypothyroidism. In addition, the same lesion reduces posterior pituitary TRH
suggesting that the TRH located in both the PVN and the posterior pituitary is of
hypothalamic origin (Jackson and Reichlin, 1977). TRH may be synthesised in the
pituitary and may act on local target cells as a paracrine regulator of anterior pituitary
hormone secretion (Childs et al, 1978)
2.2.4 TRH and the hypothalamic-pituitary-thyroid (HPT) axis
TRH release has not been extensively investigated but may be under CNS derived
adrenergic control and is likely to be pulsatile in nature. Pituitary regulation of TSH
secretion is primarily under the dual control of hypothalamic TRH and thyroid
hormones. TRH activates the phosphatidylinositol second messenger system on
binding to TRH receptors (TRH-Rs) on thyrotrophs and to a lesser extent on
mammotrophs. The TRH-R and its effects on the phosphatidylinositol second
messenger system will be discussed more fully in sections 2.5 and 2.3.3 respectively.
TSH secreted in response to TRH in the pituitary acts on the thyroid gland to stimulate
the synthesis and release of the thyroid hormones T3 and T4. Figure 2.5 shows in
schematic form the mechanisms of control in the hypothalamic-pituitary-thyroid axis.
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Hypothalamus
Figure 2.5 The hypothalamo-pituitary-thyroid (HPT) axis
Diagrammatic representation of the neuroendocrine regulation of TSH secretion. The rate of TSH
secretion is modulated by the positive TRH signal from the pituitary gland and by two negative
feedback signals; one from the brain (somatostatin) and another from the circulating thyroid hormones
T3 (triiodothyronine) and T4 (thyroxine). T3 is the more potent of the thyroid hormones although
both exert effects at the pituitary and hypothalamic levels. Specific enzymes (5' mono-deiodinases)
present in these two tissues remove an iodine moiety from generating T3. Lines with arrows
indicate positive effects; lines with bars indicate inhibitory control.
TSH is a member of the family of heterodimeric glycoproteins which includes FSH,
LH and hCG. All of these family members share a common a-subunit. The 0-
subunit however, is distinct, and it is this part of the molecule which confers the
specific biological activity of each hormone. TSH binds to cell surface receptors on
thyroid follicular cells and promotes adenylyl cyclase activity and hence increases
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intracellular levels of the second messenger cyclic AMP (cAMP). Cyclic AMP is able
to mimic the intracellular effects of TSH even in its absence.
In order to maintain homeostatic balance TSH secretion cannot be permitted to go
unchecked. In common with most other endocrine systems a set of positive and
negative control mechanisms interact to maintain normal hormone levels. The ability
of the thyrotroph to respond to TRH with increased TSH release is controlled by the
feedback inhibition of thyroid hormones. Both T4 and T3 are capable of inhibiting
TSH secretion; however, T3 formed by the removal of an iodine residue from T4 in the
pituitary appears to be more important as a mediator of feedback inhibition than is
circulating T3. The effects of thyroid hormones on TRH secretion are not known.
Studies in which exogenous TRH is administered to both normal subjects and to
patients with thyroid deficiency or thyroid hormone excess, indicate that feedback at
the pituitary level is sufficient to explain the regulation of TSH secretion. The TSH
response to administered TRH is enhanced in patients with thyroid hormone deficiency
compared to normal subjects. In contrast, thyroid hormone excess diminishes or
abolishes the TSH response to TRH. The release of TSH is not absolutely dependent
on TRH since low residual secretion of TSH remains even after TRH secretion has
stopped. Elimination of the source of TSH by removal of the pituitary gland reduces
thyroid function to a greater extent than does hypothalamic trauma.
In common with other pituitary hormones, TSH appears to be secreted in discrete
pulses (Samuels et al, 1990), approximately nine per 24 hours in normal subjects.
There also appears to be circadian rhythmicity of TSH secretion, with a nocturnal
increase in pulse amplitude.
2.2.5 Feedback regulation of hypothalamic TRH
Thyroid hormones may be involved in feedback at the hypothalamic level.
Administration of T3 to the hypothalamus of monkeys inhibited TSH secretion by the
pituitary (Belchetz et al, 1978), apparently by inhibiting the release of TRH and/or
regulating its breakdown (Jackson et al, 1979). However, the thyroid hormones may
be acting instead to stimulate the release of neurotransmitters, including dopamine and
somatostatin, known to be involved at both TRH and TSH levels of control
(Berelowitz et al, 1980; Chen and Ramirez, 1981; Montoya et al, 1979; Smythe et al,
1982).
Other substances of hypothalamic origin have been found to play some role in TSH
secretion. Somatostatin from the hypothalamus may tonically inhibit TSH secretion,
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since injection of anti-somatostatin antiserum into normal animals increases TSH
levels. Dopamine antagonists cause elevation of serum TSH in normal patients
suggesting that dopamine (a neurotransmitter) may also have a role as a tonic inhibitor.
TSH release is inhibited by dopamine acting directly on thyrotrophs (Besses et al,
1975) and by somatostatin, the distinctive inhibitor of GH (Maeda and Frohman,
1980), and it is stimulated by noradrenaline (Montoya et al, 1979). Excess
glucocorticoids also lead to a partial inhibition of TSH secretion (Re et al, 1976).
Oestrogens stimulate TSH release apparently by increasing the number of TRH-Rs on
thyrotrophs (de Lean et al, 1977b). Lastly, TSH may be able to inhibit hypothalamic
TRH release via a 'short-loop' feedback (Roti et al, 1978).
2.2.6 TRH and regulation of prolactin release
The synthesis and release of prolactin is under complex plurifactorial control,
including the interaction of prolactin-inhibiting factors (PILs; dopamine for example)
and prolactin-releasing factors (PRFs), including TRH.
The major regulatory role of the hypothalamus is inhibitory with respect to prolactin
secretion. It is now known that the withdrawal of dopamine results in the release of
prolactin from the anterior pituitary. This is brought about by the dissociation of
dopamine from its lactotroph receptors (dopamine type 2 receptors, D2-R) and the
subsequent release of adenylyl cyclase inhibition which results in activation of the
cAMP pathway. This process may potentiate PRE action (de la Escalera and Weiner,
1992). PILs other than dopamine, such as a-melanocyte-stimulating hormone and
possibly GABA may act in a more direct but less potent manner than dopamine (Yen,
1991).
TRH probably acts as a modulator of PRL secretion rather than as a true PRE. Initial
evidence suggesting a stimulatory role for TRH in PRL secretion has been contradicted
by more recent findings, including the observed inability of anti-TRH antiserum to
prevent PRL release in ewes (Fraser and McNeilly, 1982) or rats (Harris et al, 1978),
and the fact that circadian rhythms of PRL and TSH are dissociated in humans (Harris
et al, 1978). Vasoactive intestinal peptide (VIP) from the hypothalamus stimulates
PRL release in an autocrine manner (Nagy et al, 1988).
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2.2.7 TRH in extra-pituitary locations
Although TRH plays the central regulatory role in the hypothalamic-pituitary-thyroid
axis (Yamada and Wilber, 1990) it is also present in many extra-hypothalamic loci,
including the mammalian central nervous system, retina, testis, pancreas and gut.
Most of the early studies of TRH distribution ensued from the production of TRH-
specific antibodies which could be used for immunoassay and immunohistochemistry.
At early stages of mammalian development relatively high concentrations of TRH can
be localised in the embryonic pancreas (Martino et al, 1978) and gastro-intestinal tract
where it may be involved in the regulation of gastro-intestinal secretion and motility
(Morley et al, 1979a). These neonatal hormone levels decline to low levels in the adult
(Kawano et al, 1983; Morley et al, 1979b). A large literature exists concerning the
possible extra-pituitary roles of TRH as a neurotransmitter and/or neuromodulator in
the central nervous system (CNS) (O'Leary and O'Connor, 1995; Sharif, 1985)).
TRH is present in the preoptic area of the brain where it is postulated to be involved in
thermoregulation and alertness, in the hippocampus where it may have a role in
controlling seizure thresholds, in the brain stem where it may modulate the autonomic
nervous system (ANS; respiration, gut motility, gastric acid secretion, heart rate and
blood pressure for example), and in the spinal cord where it may have a neurotrophic
effect on a motorneurones. The adult rat testis has been identified as a source of
hypothalamic neuropeptides including TRH. In the adult rat testis prepro-TRH mRNA
was 13% of that found in the hypothalamus, and was especially evident in Leydig cell
extracts (Feng et al, 1993). In the same study prepro-TRH mRNA and TRH were
measured during rat testicular development. The concentrations of TRH (measured by
radioimmunoassay), paralleled the observed changes in prepro-TRH mRNA,
suggesting that TRH may be acting as a novel paracrine or autocrine regulator of
testicular function and perhaps also of development. Wilber et al. (1996) describe the
expression of the TRH gene in testis and also in the heart. TRH appears to be
regulated by environmental lighting in the retina (Schaeffer et al, 1977).
The authenticity of the findings described in many of the original reports of the
localisation of TRH has recently been questioned in light of the identification of TRH-
like peptides which may have cross-reacted with the antibodies previously presumed to
be TRH-specific (Fuse et al, 1990; Gkonos et al, 1993).
Respiratory distress syndrome (RDS) and its complications is one of the-main causes
of perinatal morbidity and mortality in premature babies. Prevention of RDS currently
depends on (3-adrenoceptor agonist therapy and on medications which accelerate
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functional development of the antenatal lung, and optimisation of neonatal care,
including the use of exogenous surfactants. The use of corticosteroids during the
antenatal period has been well studied and is known to result in a 50% reduction in the
risk of RDS before 34 weeks gestation. Prenatal morbidity and mortality are
decreased without adverse effects. TRH, in conjunction with corticosteroids, is
effective in promoting lung maturation and preventing RDS and its long-term
complications (Zauli et al, 1996) and appears to be a promising antenatal therapy. In a
comparison of antepartum combined TRH-betamethasone treatment of women at risk
of preterm delivery, the incidence of RDS was reduced from 52% in the
betamethasone treatment only group to 31% in the combination therapy group. The
incidence of severe RDS was reduced from 42% to 20% in the same groups (Knight et
al, 1994). This treatment gives better results than corticosteroids alone, without
unfavourable neonatal consequences. In vitro studies of rat and rabbit lung suggest
that the action of TRH on the lung may be mediated in part by one of the numerous,
non-hormonal pathways known to be stimulated by TRH, particularly the ANS
(Liggins, 1995). A study of TRH-cortisol treated foetal sheep indicates that the
hormones function synergistically to increase connective tissue maturation in the lung,
which is associated with increases in collagen and elastin content, and lung
distensibility and stability (Campos et al, 1992). Rats with congenital diaphragmatic
hernia (CDH) have been shown to benefit from TRH-dexamethasone (Suen et al,
1994), which supports the potential clinical use of pharmacological therapies to treat
human foetuses with prenatally diagnosed CDH. At present the optimum dose,
frequency and method of hormone administration have not been established. It has
been suggested that TRH therapy should not be used in women with pre-eclampsia as
it significantly raises blood pressure in this group and should definitely not be used in
women at high risk of preterm delivery as this treatment is associated with
unacceptable maternal and perinatal risks (Crowther et al, 1995). In light of
conflicting evidence, it is clear that further trials are needed to confirm the beneficial
effects, if any exist, of combined TRH-corticosteroid antenatal treatment. Moreover,
its use in growth retarded foetuses and its long-term effects have not been addressed.
It is unlikely that TRH exerts its effects through the promotion of surfactant synthesis
and secretion, as Yokoyama et al. (Yokoyama et al, 1995) found that there was no
difference in the surfactant mRNA levels or in disaturated phosphatidylcholine (DSPC)
levels in control, dexamethasone or TRH and dexamethasone treated rats. If TRH-
corticosteroid therapy does indeed accelerate lung maturation, the mechanism by which
this action is mediated remains to be determined.
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2.3 G-protein-coupled receptors (GPCRs)
2.3.1 Structure and function of GPCRs
The proteins which are assigned to the superfamily of GPCRs share common
structural, as well as functional properties. GPCRs are integral membrane proteins
which couple primary messengers (external stimuli) to changes in cellular metabolism
by stimulating the exchange of bound GDP for GTP on associated G (guanine-
nucleotide-binding) protein a-subunits. Extracellular signals as diverse as hormones,
growth factors, neurotransmitters, photons and odourants cause second messenger
responses by acting via the increasing multitude of GPCR superfamily members.
There is as yet no definitive 3-dimensional model of GPCR structure. As these
molecules exist only within the context of a cell membrane, X-ray crystallographic
studies have been fraught with technical difficulties. However, based on physical
studies of the evolutionarily-related proteins bacteriorhodopsin (Bonatti et al, 1989)
and rhodopsin (Omary and Trowbridge, 1981) and in the light of X-ray
crystallographic and molecular modelling work originating from the Cambridge
Laboratory for Molecular Biology (Baldwin, 1993; Henderson et al, 1990)
extrapolations have been made which allow computer modelling of members of the
GPCR family. When combined with other methods such as site-directed mutagenesis
and expression studies of chimeric receptors, the hypotheses made from computer
models of receptor structure can be tested and the model refined accordingly. The
amino tail portion of GPCRs is extracellular and the carboxy tail is intracellular as
shown by protease digestion studies and immunological mapping (Dohlman et al,
1987a; Wang et al, 1989). The greatest degree of sequence homology between
different GPCRs exists in the transmembrane (TM) domains.
The main structural feature shared by GPCRs is based on hydropathicity analysis of
the amino acids forming the receptor peptide. The protein is believed to span the
plasma membrane seven times (hence the supplementary terminology, seven
transmembrane or heptahelical receptors), with the transmembrane domains (TM I-
TM VII) adopting a-helical formation. The TMs generally contain between 20 and 25
amino acids and based on structural similarities with the extensively studied protein
bacteriorhodopsin (Henderson et al, 1990), are believed to be oriented to form a ligand
binding pocket (Findlay and Eliopoulos, 1990). The helices are conjoined by intra-
and extracellular domains for which less structural information is available. Figure 2.6
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below, shows a cartoon example of a general GPCR showing only its primary
structure.
It is thought that ligand binding properties of the GPCRs reside principally within the
pore created by the TM bundle (Grand, 1989). The reason for conservation of TM
region sequences are unknown, although, within a given receptor family conserved
amino acids with key roles in agonist binding have been identified. For example, a
conserved TM II aspartate and two conserved cysteines in TM V of the adrenoceptor
family interact with the catecholamine nitrogen and the hydroxyl groups of the
chatechol ring respectively (Strader et al, 1989). In the TRH-R it has been suggested
that two hydrogen bonds form on ligand binding. The hydroxyl group of the pyroGlu
of TRH interacts with tyrosine 106 in TM III (Perlman et al, 1994a) and additionally
the N-H of pyroGlu associates with the C=0 of Asn 110 in TM III (Perlman et al,
1994b).
2.3.2 Disulphide bridge formation
Disulphide bridge formation is proposed between two conserved cysteine residues of
the extracellular loops (el 1 and el 2, Figure 2.6). The purpose of these bonds is
apparently to stabilise the 3-dimensional conformation of the receptor to ensure
function, as shown by two independent studies of disulphide bond formation between
extracellular cysteines of the TRH-R (Cook et al, 1996; Perlman et al, 1995). Each of
these studies show that by both site-directed mutagenesis (thereby removing the
cysteine residues) and by the addition of strong reducing agents to receptor assays
(which disrupt the disulphide bonds) ligand binding is subsequently perturbed. These
results indicate that the cysteine residues do indeed form a bond which maintains the
receptor in a conformation required for high affinity ligand binding. In addition to
maintaining the receptor in its binding conformation the extracellular domains may be
involved in assisting ligand insertion into the binding pocket as has been shown for
some small peptides (Fong et al, 1993) and glycoprotein hormones (Reichert et al,
1991).
GPCRs also share the potential to be posttranslationally modified, for example by
glycosylation, phosphorylation or myristoylation.
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2.3.3 GPCR glycosylation
Asparagine residues lying within glycosylation consensus sequences (Asn-X-Ser/Thr,
X= any amino acid), especially in the amino tail, may be modified. Glycosylation is
responsible for the discrepancy observed between the predicted molecular weights of
GPCRs and that which is experimentally determined. Deglycosylation of the (32-
adrenoceptor reduces its molecular weight by approximately 16 kDa (Benovic et al,
1987). Glycosylation is not believed to be of major importance in ligand binding but
may play a role in determining correct cellular distribution of receptors. Of note is the
observation that removal of a consensus glycosylation site by mutation of Thr 17 of
human rhodopsin is responsible for causing retinitis pigmentosa (Sung et al, 1991).
2.3.4 GPCR palmitoylation
Palmitoylation, thioester-linked palmitic acid addition, occurs at intracellular cysteine
residues located in the carboxy tails of the (^-adrenoceptor and rhodopsin and appears
to create a fourth intracellular loop by intercalation of the palmitate into the lipid bilayer
(O'Dowd et al, 1989; Ovchinnikov et al, 1988). Removal by mutation of the
appropriate cysteine in the (^-adrenoceptor negates Gs coupling indicating a role for
its posttranslational modification in receptor coupling to G-proteins (O'Dowd et al,
1989). This palmitoylation might represent another common structural feature of
GPCRs as other superfamily members include cysteine residues in similar positions
and may therefore be similarly modified.
2.3.5 GPCR phosphorylation
Serine and threonine residues in il 3 and in the carboxy tail may act as sites for
regulatory phosphorylations by second messenger-dependent or receptor-specific
protein kinases (Lefkowitz et al, 1993) and may play a role in receptor desensitisation.
Consensus sites for phosphorylation by protein kinases A and C (PKA and PKC) are
Arg/Lys-Arg/Lys-X-Ser/Thr and Ser/Thr-X-Arg/Lys respectively. Phosphorylation of
photo-excited rhodopsin leads to multiple intracellular phosphorylations and a
concomitant conformational change. The phosphorylated rhodopsin then becomes a
target for arrestin binding which prevents activation of transducin (Hargrave and
McDowell, 1992). (3-adrenergic receptor kinase ((3-ARK) and (3-arrestin are believed
to perform the same function at the (32-adrenoceptor and perhaps for other adenylyl
cyclase-linked receptors. Other receptor kinases, including PKA and PKC may
provide alternative desensitisation pathways for other receptors.
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Sites of potential posttranslational modifications
# N-linked glycosylation
# Phosphorylation
^ Cysteine residue-disulphide bond formation j
Figure 2.6 Schematic representation of GPCR structure
G-protein coupled receptors have a hypothetical structure based on the hydrophobic nature of stretches
of amino acid residues which suggests that these will be buried in the plasma membrane (I-VII). The
transmembrane helices are connected by a series of extracellular loops (el 1-3) and intracellular loops
(il 1-3). The carboxy tail is intracellular and the amino tail is to the outside of the cell. GPCRs may
be modified by the posttranslational addition of various types of molecules at sites as indicated by
differently coloured circles. Disulphide bonds in the extracellular portion of the receptor maintain the
3-dimensional conformation required for ligand recognition and binding.
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2.3.6 GPCR-induced G-protein activation
Studies of the [^-adrenoceptor have highlighted two regions of GPCRs with potential
functions in G-protein-coupling (Ostrowski et al, 1992). These sites occur at the Isl¬
and C-regions of il 3, but il 2 is also involved in the overall 3-dimensional receptor
structure which facilitates receptor-G-protein association.
Prior to ligand binding GPCRs exist in an inactive 3-dimensional conformation which
shields or otherwise constrains the regions of the peptide involved in G-protein-
coupling. An allosteric transition is believed to be elicited by agonist binding, thereby
overriding the constraining function of the prevailing molecular determinants of
structure and allowing the receptors to relax into the active conformation at which point
G-protein-coupling can take place.
2.4 G-proteins
G-proteins form a subgroup of the superfamily of GTP-binding G-proteins that
includes the ras and ras-like proteins. Despite the diversity within the G-protein
subfamily, just as with the GPCRs, its members share common structural and
functional properties. G-proteins are heterotrimers consisting of a-, (3- and y-
subunits. The majority of the sequence homology with other members of the GTP-
binding G-protein superfamily resides within the a-subunit which is also the location
of both specific high affinity guanine nucleotide binding and intrinsic GTP-ase
activity. Certain regions of all a-subunits are highly conserved probably due to the
common functions subserved by these regions of this subunit, GTP binding and
hydrolysis for example, and have therefore been under evolutionary pressure to
maintain these essential features. The less well conserved regions are presumably
those areas responsible for subunit-specific functions such as receptor and effector
coupling. The |3- and y-subunits form a tightly coupled dimer but otherwise the
particular functions of the dimer are less well understood in comparison to what is
known of the a-subunit. G-proteins couple many kinds of cell surface receptors to
intracellular effector enzymes or ion channels. Each cell contains a variety of GPCRs,
G-proteins and effectors. Whether a cellular response to an external signal is diffused
through several pathways or is focused to a single pathway is determined by the
specificity of G-protein interactions with both GPCRs and effectors, making the G-
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protein a critical control point in signal transduction. Some of the G-proteins which
have been identified in mammalian species are presented in Table 2.1.
G-proteins are located at the cytoplasmic face of the cell membrane. Although the
primary amino acid sequence of heterotrimer subunits does not indicate regions of
hydrophobicity, co- and post-translational modifications are believed to increase
protein lipid-solubility which facilitates anchorage to the membrane. Many of the a-
subunits are known to undergo N-terminal fatty acylation (at glycine residue position
2) by addition of myristic acid. Substitution of this glycine for alanine within both a;i
and a0 results in unpalmitoylated peptides which are found predominantly in the
cytosol (Jones et al, 1990; Mumby et al, 1990). However, as does not myristoylate
(Buss et al, 1987), and both an and aq lack a consensus myristoylation signal
(MGXXXS; X= any amino acid: (Gutowski et al, 1991; Pang and Sternweis, 1990;
Wu et al, 1992), yet all three are membrane associated. Therefore, some other
mechanism of membrane anchorage must exist. There have been suggestions that
cysteine residues in the N-terminal domain may be palmitoylated (Parenti et al, 1993).
A role for the C-terminal region of as and other a-subunits with similar C-terminal
consensus motifs has been proposed. Py-dimers can only be isolated from membrane
preparations by detergent extraction, although, like the a-subunits, their amino acid
sequences do not predict regions of high hydrophobicity. As established for p21ras,
which shares the isoprenylation motif (CAAX; A= aliphatic residue) with y-subunits, y
undergoes a post-translational modification at a C-terminal cysteine, which increases
protein hydrophobicity. Both farnesyl (C-15) and geranylgeranyl (C-20) isoprenyl
chains have been identified on different y-subunits. Mutation of the crucial cysteine
residue within the consensus motif results in y-subunits which are both functionally
inactive and localised to soluble fractions (Fukada et al, 1991; Katz et al, 1992;
Ohguro et al, 1991; Simonds et al, 1991; Spiegel et al, 1991) underscoring the role of
this type of protein modification in y-subunit structure and function. It can be seen
then, that a-subunits may be membrane anchored either independently or by
association with an anchored Py-dimer.
G-proteins transduce information across the cell membrane by coupling diverse
receptors to intracellular effector systems. G-protein association with receptors
activated by extracellular signals enables tightly bound GDP to be released from the a-
subunit and replacement by GTP. GTP binding results in a conformational change of
the a-subunit which leads to G-protein activation and dissociation from the Py-dimer.
Both the activated a-subunit and the Py-dimer have been shown to be important
regulators of intracellular effectors. G-protein activation is terminated by
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dephosphorylation of GTP to GDP by the intrinsic GTP-ase activity of the a-subunit.
Subsequently, the a-subunit regains both its inactive conformation and its high affinity
for the (3y-dimer. Formation of the heterotrimer is essential for high affinity coupling
between the G-protein and the receptor. Figure 2.7 shows the cycle of G-protein
activation/inactivation.
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Oc¬ Expression Effector Receptor
t's Gs ubiquitous T adenylyl cyclase, Ca2+ channel PAR, TSH,
glucagon,
others
Golf olfactory T adenylyl cyclase Odorant
Gj GU rod photoreceptors T cGMP-phosphodiesterase Rhodopsin
Gt2 cone photoreceptors T cGMP-phosphodiesterase Cone opsin
Gil neural > other tissues I adenylyl cyclase, T K+ channel a2AR, M2,
others
Gi2 ubiquitous ■I adenylyl cyclase, T K+ channel t!
Gl3 other tissues > neural •l adenylyl cyclase, T K+ channel It
Go neural, endocrine -I Ca2+ channel
M
Gz neural, platelets ? ? M2, others
Gq Gq ubiquitous T phospholipase C-(3 M2 ajAR,
TRH, NT,
GnRH
Gn ubiquitous T phospholipase C-P tt
G14 liver, lung, kidney T phospholipase C-p ?
G15/I
6
blood cells t phospholipase C-P ?
G G12
12
ubiquitous regulation ofNa+/K+ exchange ?
Gl3 ubiquitous regulation of Na+/K+ exchange ?
Table 2.1 Mammalian a-subunits previously identified
Some of the G-proteins which have been identified. The proteins shown are divided into their family
groups (Gs, Gj, Gq and G12) and the effectors which they activate are shown as is their tissue
distribution. Where known the receptors to which a-subunits couple are shown. Information in this
table is adapted from Neer (1995)
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inactive form
Figure 2.7 The GTPase cycle.
On association with a ligand-bound receptor (LR) GDP bound to the inactive G-protein is exchanged
for GTP, which switches the cascade system on. The activated a-subunit dissociates from the py-
dimer which are both believed to be capable of regulating downstream effectors. The endogenous
GTPase activity of a-subunit hydrolyses the bound GTP with the liberation of inorganic phosphate
(Pi). The a-subunit thus inactivates itself enabling reassociation with the Py-dimer. The system is
now switched off. Pertussis and cholera toxins act at the indicated sites to perturb signal transduction.
Several crucial roles have been assigned to the G-protein Py-dimers. These dimers
may be important for presenting a-subunits in the correct orientation for receptor
activation, facilitating guanine nucleotide exchange and targeting certain kinases to
enhance agonist-induced receptor phosphorylation and desensitisation (Cerione et al,
1986; Fung and Nash, 1983; Phillips et al, 1992; Pitcher et al, 1992). Py-dimers may
also be direct mediators of signal transduction. Both purified and recombinantly
expressed Py-dimers have been shown to be capable of activating phospholipase C
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(PLC) to cause phosphatidylinositol 4,5-bisphosphate breakdown. PLC-(32 and PLC-
(33 appear to be particularly sensitive to activation by G-protein (3y while PLC-yl and
PLC-51 are unresponsive (Camps et al, 1992; Carozzi et al, 1993; Katz et al, 1992;
Park et al, 1993). It is possible that (3y derived from Gj or G0, rather than oc-subunit,
may be responsible for the pertussis-toxin-sensitive activation of phosphoinositide
hydrolysis identified in some cell types.
Bacterial toxins are known to interrupt G-protein activity by interfering with either
GDP/GTP exchange (pertussis toxin effect on a; and a0 subunits) or by inhibiting
GTP-ase activity (cholera toxin-modification of as resulting in persistent GTP
activation).
2.5 Effectors and second messenger systems
G-protein linked effector and second messenger systems are structurally and
functionally more diverse than their upstream signalling partners. Effector systems
include retinal cyclic GMP phosphodiesterases (GMP-PDE), ion channels (e.g. K+
and Ca2+) and several phospholipase and adenylyl cyclase subtypes.
2.5.1 The phosphatidylinositol phosphate (PI) pathway
Phosphoinositide-specific phospholipase C (PLC) plays an important role in mediating
the cellular actions of many hormones, neurotransmitters and some growth factors.
Agonist-dependent activation of PLC, via the Gq proteins, results in the hydrolysis of
the membrane phospholipid, phosphatidylinositol 1,4-bisphosphate (PIP2) by the (31
and (32 PLC isoforms (Park et al, 1992; Taylor, 1991). This process results in the
production of two major second messengers, inositol 1, 4, 5-triphosphate (IP3) and
diacylglycerol (DAG) (Limor et al, 1989) (Figure 2.8). IP3 production results in the
release of calcium ions (Ca2+) from intracellular Ca2+ stores via binding and activation
of IP3 receptors/Ca2+ channels located on the surface of Ca2+-containing vesicles.
DAG-induced protein kinase C (PKC) activation stimulates the phospholipase A2 and
phospholipase D2 pathways which result in the production of arachidonic acid (which
is further metabolised to prostaglandins and leukotrienes) and DAG respectively. This
secondary production of DAG prolongs PKC activation.
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2.5.2 The adenylyl cyclase (AC) pathway
Cyclic AMP (cAMP) is the second messenger associated with the AC pathway and is a
ubiquitous molecule of critical importance, regulating a variety of cellular processes
including gene transcription, mitogenesis, metabolism, smooth muscle contractile state
and ion channel activity. Cyclic AMP is capable of regulating many different
biochemical pathways. GPCR-induced activation of AC catalyses the conversion of
ATP to cAMP. Cyclic AMP production occurs more rapidly than the intrinsic GTPase
activity of the activated G-protein a-subunit is able to switch off the system, resulting
in an amplification of the original signal. Cyclic AMP exerts its effects on the
intracellular environment through the cAMP-dependent protein kinase A (PKA)
(Levitski, 1988). This AC activity is inhibited by Gi proteins. In addition, AC may
be regulated by calcium/calmodulin (Tang and Gilman, 1992) and Py-subunits
(Gilman, 1987) as shown in Figure 2.8.
Figure 2.8 The Gq and Gs/Gj effector (following page)
In this schematic representation of effector systems the Gq effector system is shown in the upper
section and the Gs/Gj system is shown below. Three different agonists (A, shown in different colours)
are shown to be activating the GPCRs (R). The agonist-bound Rs cause the dissociation of G-
proteins. At the top, Gq mediates the activation of phospholipase-p 1 (PLC-pl) to hydrolyse
phosphatidylinositol 4,5-bisphosphate (PIP2). This degradation causes formation of the second
messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) which elevate intracellular
Ca^+ and activate protein kinase C (PKC) respectively. The Py-dimer may also stimulate PLC-0, in
particular the -02 and -03 isoforms. In the lower section interaction of free as and the adenylyl
cyclase (AC) catalytic region results in increased cytosolic cyclic AMP in response to agonist binding
(A(s)). Some AC subtypes may also be stimulated by py-dimers from other G-proteins or by
calmodulin in the presence of increased intracellular Ca^+. The mechanism by which Gj inhibits AC
is not yet clear, but may involve oq and py.
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AC system
cyclic AMP
Ca2+ Ca2+ - calmodulin
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2.6 G-proteins, GPCRs and disease
Many and varied extracellular signals reach the interior of the cell as second
messengers through the hormone-GPCR-G-protein complex which acts as a signal
transducer to modulate a number of key signalling enzymes (adenylyl cyclase and
phospholipases for example) or cellular effectors such as ion channels. Defects which
alter the function of the first messenger (hormone, neurotransmitter, autocrine or
paracrine substance) or either of the transducing elements (GPCR or G-protein) can
lead to defective signalling and, ultimately, to disease. The clinical manifestations of
hereditary or acquired defects of all of these signalling components have been
described. The existence of diverse families of GPCRs, G-proteins and effectors
means that a large number of signalling pathways can be mediated through a relatively
small number of signalling components. The complexity of the interactions involved
in cellular signalling allows many opportunities for small or large scale dysregulation
of the normally finely tuned signalling network.
2.6.1 G-proteins, signal transduction and disease
Mutations in the genes encoding G-protein polypeptides have been identified as the
primary lesion leading to the development of several clinical pathophysiologies.
One of the lines of research which led to the identification of G-proteins as a
component of hormonal cAMP stimulation was investigation into the role of Vibrio
cholerae toxin (cholera toxin, CTX) in the diarrhoeal disease cholera. It was
discovered that CTX, which was already known to increase cAMP levels in cells,
covalently modified a 45 kDa, GTP-dependent, polypeptide coupling factor. It
transpired that the diarrhoea produced by V. cholerae is the result of efflux of CI" and
water from intestinal epithelial cells in response to elevated levels of cAMP caused by
inappropriate activation of Gs. This happens because the G-protein's GTPase activity
is reduced by CTX-induced modification, locking the G-protein in its active, GTP-
bound state. Gs was eventually purified from the reconstitution of rabbit liver GTP
regulatory protein fractions into the S49 eye" cell line (Bourne et al, 1975) which does
not produce endogenous Gs due to a gene mutation predicted to be located in the
promoter region of the Gs gene. Pertussis toxin (PTX) also causes disease by
modifying several members of the Gj subunit G-protein subfamily. PTX effectively
uncouples the G-protein from the receptor (Figure 2.7), resulting in a disinhibition (=
stimulation) of adenylyl cyclase activity.
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More recently Ga mutations have been identified in human tumours (Table 2.2), the
most common of which are the Gsa, or gsp oncogenic mutations which cause
constitutive activity of adenylyl cyclase. Originally discovered in a subset of GH-
producing pituitary adenomas, gsp mutations have also been found in thyroid
tumours. Gin 227 is equivalent to Gin 61 of p21ras and mutation of this site leads to a
reduction in GTPase activity and a promotion of oncogenic activity. The oncogenicity
of these mutations arises from the stimulatory effects that intracellular cAMP has on






Gsa R201C Pituitary Landis et al. (1989)
Gsa R201H Pituitary Landis et al. (1989)
Gsa Q227R Pituitary Landis et al. (1989)
Gsa Q227L Pituitary Vallar (1990)
Gsa Q227C Thyroid Lyons et al. (1990)
Gi2a R179C Adrenal Lyons et al. (1990)
R179C
Gi2a R179C Ovary Lyons et al. (1990)
R179C
Table 2.2 G-protein mutations in human tumours.
Amino acid substitutions use the one letter amino acid nomenclature, for example, R179C indicates
the substitution of Arg at position 179 with Cys.
With the recent identification of G-proteins in novel systems or in those where their
function remain undetermined, it is clear that the potential for implicating alterations in
the level of expression or function of these proteins with disease states is vast.
2.6.2 GPCR dysfunction and disease
Alterations in the primary, secondary or tertiary structure of GPCRs could lead to
various functional aberrations, as could defects of receptor processing, intracellular
transport, G-protein coupling, recycling or phosphorylation. The clinical
manifestations of any receptor defect will depend on its severity and the tissue
distribution of the defective receptor. Mutation of a receptor of wide tissue distribution
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and of critical function could be lethal, perhaps in utero, whereas a defect in a more
specifically expressed and functional receptor might have a more distinctive pattern of
clinical symptoms. An increasing number of GPCRs have been found to be involved
in the pathogenic mechanisms of disease, both in vivo and in vitro.
Table 2.3 Some of the GPCRs in which in vivo mutations cause disease
(following page)
The references are numbered for brevity: 1. (Dryja et al, 1990a), 2. (Dryja et al, 1990b), 3. (Dryja
et al, 1991), 4. (Farrar et al, 1990), 5. (Humphries et al, 1993), 6. (Ingelhearn et al, 1992), 7.
(Min et al, 1993), 8. (Sheffield et al, 1991), 9. (Sung et al, 1991), 10. (Rosenfeld et al, 1992), 11.
(Weitz et al, 1992a) 12. (Weitz et al, 1992b), 13. (Bichet et al, 1992), 14. (Bichet et al, 1993),
15. (DeMarco et al, 1993), 16. (Holtzman et al, 1992), 17. (Clark et al, 1993), 18. (Robbins et
al, 1993), 19. (Shenker et al, 1993), 20. (Parma et al, 1993), 21. (Kosugi et al, 1993), 22.
(Wilkin, 1990), 23. (Pollack et al, 1994), 24. (Godfrey et al, 1993), 25. (Reihaus et al, 1993),
26. (Limas and Limas, 1991)
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Receptor Disease Reference
Rhodopsin autosomal dominant retinitis pigmentosa 1-9
Rhodopsin autosomal recessive retinitis pigmentosa 10
Blue opsin tritanopia colour blindness 9, 11, 12
Vasopressin V2 X-linked nephrogenic diabetes insipidus 13-16
ACTH familial glucocorticoid resistance 17
MSH pigmentation phenotypes (mouse) 18
LH male precocious puberty 19
TSH Thyroid adenoma, Grave's disease,
hypothyroidism
20-22
human CaR familial hypocalciuric hypercalcemia, neonatal
severe hyperparathyroidism
23
GHRH little mouse phenotype 24
(32-adrenergic steroid dependent asthma 25
Pi-adrenergic idiopathic dilated cardiomyopathy 26
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2.7 The pituitary TRH receptor (TRH-R)
2.7.1 Isolation and characterisation of TRH-R cDNAs
The TRH-R cDNA was originally isolated from mouse by expression cloning of a
cDNA library constructed from mouse TSH-producing tumours (Straub et al, 1990) at
a time when there was no sequence data available on which to base DNA probe
design. The mouse TRH-R (mTRH-R) was recognised to be a member of the GPCR
superfamily of receptors. Subsequently, the TRH-R has been cloned from several
species including rat (de la Pena et al, 1992a; Sellar et al, 1993) and human (Duthie et
al, 1993a; Hinuma et al, 1994; Hirata et al, 1994; Yamada et al, 1993) There is very
high sequence homology between all three of these receptors at both the nucleic acid
and protein levels. At the extreme 3' end of the carboxy-tail there is a point of
sequence divergence which results in each species of receptor having a different tail.
All isoforms share amino acid 392 as this common point of sequence divergence. This
site marks the position of an intron/exon boundary in the mouse gene, beyond which,
only one more amino acid is encoded on exon 3 before the stop codon (Duthie et al,
1993b). The hTRH-R encodes five amino acids beyond position 392 and the rat (long
form, 412 amino acids) receptor encodes 19 amino acids beyond this site. The short
form of the rTRH-R (387 amino acids; de la Pena et al, 1992b) also has position 392
as a 3' exon/intron junction. All isoforms of the TRH-R are functional. The role of
the variant carboxy-tails is not known. As the carboxy-tail of other GPCRs is
implicated in G-protein coupling and perhaps in desensitisation and internalisation it is
possible that the alternative sequences could engender receptor stability or cell specific
variations in function. However, it is equally feasible that the divergent sequences
identified represent nothing more than functionless sequence polymorphisms.
The hTRH-R gene has been mapped to chromosome 8q23 (Morrison et al, 1994).
The hTRH-R is encoded on two exons, with the intervening intron site located at Val
264 of the receptor's amino acid sequence (Figure 2.8).
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Figure 2.9 Two-dimensional representation of the primary sequence of the
hTRH-R.
The hTRH-R is a member of the GPCR superfamily and as such displays the classical features of this
group of receptors; namely, the seven membrane spanning a-helices linked by intra- and extra-cellular
loops, an extracellular amino tail, an intracellular carboxy tail and consensus sites of post-translational
modification. Amino acids are shown in the single letter code. The intron/exon junction at Val 264
is indicated by the white circle in il 3, the consensus ERY sequence at the amino end of il 2 is also
shown, as is the location of Met 75 in TM I (the significance of which will be discussed in Chapter
5).
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2.7.2 The TRH-R in extra-hypothalamic tissues
The TRH-R receptor, similar or identical to that of the pituitary isoform has been
detected by Northern blot analysis in the hypothalamus, cerebrum, cerebellum, brain
stem, spinal cord, and eye (Satoh et al, 1993a). In another study the TRH-R has been
identified in the rat testis (Satoh et al, 1994), with the transcript exhibiting
approximately 10% of the anterior pituitary expression level, and the receptor
exhibiting binding (to 3Me-His2-TRH) and antagonism (by chlordiazepoxide)
comparable to the cloned rTRH-R. The role of the TRH-R in such tissues is not
currently known.
2.7.3 Control of TRH-R expression
The responsiveness of cells to external signal molecules can be modulated by the
down-regulation of the number of cell surface receptors, either by the action of the
receptor ligand (homologous down-regulation), or by the action of other extracellular
substances which interact with other receptors (heterologous down-regulation).
Several steps in the turnover of receptors have been shown to be involved in down-
regulation (Collins et al, 1991; Hadcock and Malbon, 1991). The processes involved
in receptor down-regulation have been shown to include both pretranslational
processes such as inhibition of receptor synthesis as a result of decreased receptor
mRNA levels (Burnstein et al, 1990; Hadcock and Malbon, 1988), and
posttranslational processing, such as internalisation and subsequent intracellular
receptor degradation (Chen et al, 1990; Valiquette et al, 1990). Studies of regulation
of mRNA levels include those which investigate actual mRNA synthesis (i.e. gene
transcription) and those which investigate alterations in mRNA stability and
degradation in response to transduced signals. The regulation of mRNA stability has
been linked to GPCR expression by several groups of investigators (Akamizu et al,
1990; Hadcock et al, 1989; Saji et al, 1991).
Down-regulation of the number of TRH-Rs on anterior pituitary cells has been well
documented (Hinkle, 1989) and leads to diminished TRH responsiveness. The TRH-
R has been shown to undergo both homologous down-regulation (Gershengorn,
1978; Hinkle and Tashjian, 1975) and heterologous down-regulation in response to
molecules such as the thyroid hormones (Gershengorn, 1978; Perrone and Hinkle,
1978), epidermal growth factor (Hinkle et al, 1991) and VIP (Fujimoto et al, 1991;
Imai and Gershengorn, 1985). It is believed that the homologous down-regulation
observed in the TRH-R is the result of decreases in receptor mRNA rather than the
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result of rapid receptor internalisation, since the half-time of TRH-induced TRH-R
down-regulation is approximately 12 hours (Oron et al, 1987). More recent studies
using GH3 cells which express endogenous TRH-Rs, show that TRH-R mRNA is
similarly reduced by both TRH and PMA (a PKC activator) and this reduction can be
blocked by H-7 (an inhibitor of protein kinases; Gershengorn, 1993). An increase in
intracellular calcium levels does not decrease TRH-R mRNA on its own, which taken
together with the effects of PKC activator/inhibitor data suggests that TRH-R down-
regulation by TRH is mediated by a PKC-linked mechanism. VIP, which stimulates
hormone secretion from anterior pituitary cells via the PKA system, is also able to
decrease the level of TRH-R mRNA in GH3 cells. This process is mimicked by
forskolin (which directly activates adenylyl cyclase to increase intracellular cAMP
levels), cholera toxin and a cAMP phosphodiesterase inhibitor, which when taken
together suggests that VIP down-regulation of TRH-R mRNA is mediated by cAMP.
When cells are treated with the cAMP increasing agents (VIP or forskolin) in addition
to the PKC increasing agents (TRH or PMA) the decrease in TRH-R mRNA is greater
than observed by stimulation of one intracellular system alone. These results indicate
that TRH and VIP down-regulate TRH-R mRNA by activating PKC and PKA
respectively, and that these affects are additive. In cell lines expressing exogenous
TRH-Rs under the control of the strong CMV promoter (Gershengorn, 1993), TRH-R
mRNA was likewise decreased by TRH, suggesting that the rate of transcription was
not likely to be responsible for the decrease in receptor mRNA, particularly in view of
the finding that TRH actually stimulated the rate of TRH-R transcription rather than
reducing it. However this is probably a non-specific increase as the TRH-R construct
used in these transfection studies did not carry any significant portion of upstream
gene regulatory elements upon which transcription factors could have any effect (Yan
et al, 1991). It was subsequently discovered that TRH caused an increase in the rate
of TRH-R mRNA turnover, decreasing the mRNA half-life from 3 hours in untreated
cells to 45 minutes in TRH treated cells.
2.7.4 Upstream and downstream regulatory elements of the
TRH-R gene
Truncation of the 3' untranslated region (UTR) of the mouse TRH-R such that 143
bases inclusive of the poly (A)+ tail is deleted, results in mRNA that is not down-
regulated or has a decreased half-life as is found with the full-length mRNA. This is
despite the fact that in general plasmid vector transcripts expressed in a transfected cell
will be polyadenylated by the presence of the bovine growth hormone polyadenylation
signal which is part of the vector. Therefore, there appears to be a sequence within the
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3' end of the TRH-R mRNA that is essential for TRH-induced regulation of TRH-R
mRNA which is not the poly (A)+ tail. The decrease in TRH-R mRNA in transfected
cells could therefore the result of decreased mRNA stability, possibly mediated by the
activity of an RNAse which has been shown to degrade the mRNA in TRH stimulated
GH3 cells (Narayanan et al, 1992). A similar mechanism may cause the same
decrease in TRH-induced TRH-R mRNA turnover in thyrotroph cells. No similar
effects on TRH-R mRNA stability/degradation have been shown in non-pituitary cells
or in AtT20 adrenocorticotroph cells (Gershengorn et al, 1994).
The rate of TRH-R transcription was not considered as important in the extensive
study reported above, however the 5' UTR of the mouse TRH-R gene should not be
ignored. After all, many other gene promoter regions contain transcription factor
binding sites which mediate effects required for cellular regulation. This is of
particular significance to the TRH-R as the rate of transcription has been shown to be
increased by dexamethasone (Yang and Tashjian, 1993) and oestradiol (Kimura et al,
1994). The effects of dexamethasone and oestradiol are not inhibited by
cyclohexamide (a protein synthesis inhibitor), suggesting that the protein(s) mediating
transcriptional regulation are present in unstimulated cells. Glucocorticoid and/or
steroid response elements may be present in the sequence of the TRH-R promoter
region.
The thyroid gland is located just below the larynx with its lateral lobes, which are
connected by a mass of tissue called the isthmus, lying to the left and right of the
trachea. When present, the pyramidal lobe extends upwards from the isthmus. The
thyroid gland is able to deliver high levels of hormones into the bloodstream in a short
period of time due to its rich blood supply.
Histologically the thyroid gland is composed of spherical sacs, or follicles,
encompassed by an epithelial layer. The colloid lumen is lined with follicular cells of
the epithelium, whereas the outer surface is adjacent to parafollicular, or C cells
(Figure 2.10) and capillaries located within the connective tissue of the gland. The
epithelial cells vary in shape in relation to their level of secretory activity. When
2.8 The thyroid gland
2.8.1 Structure and function
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inactive, they are squamous or cuboidal in shape, but attain a more columnar
appearance when actively secreting hormones. The follicular cells manufacture the
thyroid hormones (T3 and T4). As mentioned previously, although T4 is the major
secretory component, T3 is three to four times more potent, with conversion of T4 to
T3 taking place in several peripheral tissues including the liver and lungs. Despite these
factors it appears that both hormones are functionally similar. The parafollicular cells
produce calcitonin.
One of the thyroid's unique features is its ability to store hormones and release them in
a steady flow over an extended period of time. Essential to the synthesis of the thyroid
hormones is the uptake of dietary iodide ions. Inorganic iodide from the blood is
concentrated in the follicles by active transport across the cell membrane and rapid
translocation to the colloid lumen. Under normal conditions the follicular cells contain
a forty times higher concentration of iodide than is present in the blood, with this ratio
increasing up to 300 times during periods of maximal activity. Peroxidase within the
follicular cells oxidises the iodide to iodine which is then chemically bound to tyrosine
residues to form mono- and di-iodotyrosines (inactive metabolites MIT and DIT
respectively). Thyroglobulin (TGB), a large glycoprotein produced by the follicular
cells and secreted into the lumen binds MIT and DIT. The TGB-bound MIT and DIT
are then coupled by further enzymatic activity to form TGB-bound thyroid hormones.
The TGB-thyroid hormone complex is stored within the follicular lumen where it
constitutes the thyroid colloid. Droplets of colloid are pinocytosed by the follicular
cells in advance of hormone secretion. Within these small endocytotic vesicles colloid
is proteolysed by lysosomes resulting in uncoupling of the thyroid hormones. Thyroid
hormones secreted into the blood associate with plasma proteins, predominantly
thyroxine-binding globulin (TBG), with pre-albumin and to a lesser extent albumin.
Very little free circulating thyroid hormones are detected in blood samples although it
is this level which determines the individual's metabolic state and thyroid status. TBG
binding capacity is altered in many conditions. Pregnancy, myxoedema, use of oral
contraceptives, oestrogen levels, and genetic TBG excess cause increased TBG
capacity. Malnutrition, severe illness, thyrotoxicosis and drugs such as anabolic
steroids and phenytoin cause decreased TBG capacity. Hence the T4:TBG ratio or the
free thyroxine index (FTI) were often used to correct the effects of these differences in
TBG capacity. However, with the advent of more sensitive free T3 and T4 assays
these latter parameters are now used routinely in clinical practice.
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2.8.2 Functions of the thyroid hormones
The thyroid hormones have three principal effects on the body: 1) regulation of
organic metabolism and energy balance, 2) regulation of growth and development and
3) regulation of nervous system activity. Since the overall effect of the thyroid
hormones is to increase catabolism, they increase basic metabolic rate generating the
energy required to increase the rates of lipid and carbohydrate catabolism and protein
synthesis. The body produces heat during this energy production, a phenomenon
termed the calorigenic effect.
The thyroid hormones help to regulate tissue growth and development, especially in
children. In concert with hGH, body and nervous tissue growth is accelerated.
Deficiency of the thyroid hormones during foetal development can result in fewer and
smaller neurones, defective myelination of axons, and mental retardation (cretinism).
During early years of life, thyroid hormone deficiency leads to small stature and poor
development of certain organs such as the brain and reproductive structures.
The thyroid hormones increase reactivity of the nervous system, resulting in increased
heart rate, blood pressure, gastrointestinal motility and nervousness.
Figure 2.5 illustrates the control mechanisms involved in thyroid hormone secretion.
Essentially, chemical sensors in the hypothalamus detect changes in the levels of
circulating thyroid hormone. If this level drops below normal, the hypothalamus
responds by secreting TRH into the portal system. TRH stimulates the thyrotroph
cells of the anterior pituitary gland to secrete TSH, and hence thyroid hormones are
secreted by the thyroid gland until the blood levels are normalised. Conditions which
increase the body's energy requirements also trigger this negative feedback system and
increase thyroid hormone secretion (a cold environment, hypoglycaemia, high altitude
and pregnancy, for example).
The thyroid gland is regulated by the co-ordinate action of the hypothalamus and
pituitary (Figure 2.5). Therefore, thyroid dysfunction frequently occurs in subjects
with lesions of these organs.
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Epithelium
o1 follicle Thyroid follicle Thyrogfobulin (TGB)
Figure 2.10 Structure of thyroid tissue
Left; photomicrograph of thyroid follicles. Right; diagram showing the arrangement of follicular
structures, highlighting the cuboidal cells of the epithelium which secrete the factors which together
form the thyroid colloid, into the interior lumen of the follicle.
2.8.3 Hypothyroidism
The most common cause of hypothyroidism and goitre world-wide is iodine
deficiency. Where iodine levels are not deficient, autoimmune disease is the most
common cause of hypothyroidism, followed by hypothyroidism as a result of thyroid
resection or radio-iodine treatment of thyrotoxicosis. Hypothyroidism can be the
result of failure of the thyroid gland itself (primary hypothyroidism), can be due to
failure of the pituitary gland (secondary hypothyroidism), or can be the result of
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hypothalamic failure (tertiary hypothyroidism) (Table 2.4). Primary hypothyroidism
is the most common form of the disease and can be divided into congenital and
acquired types of disease. The congenital forms of hypothyroidism can result from
inherited conditions of lack of thyroid function, ectopic thyroid conditions or
disruptions of thyroid hormone synthesis. The acquired forms include those arising
from iodine deficiency, autoimmunity, thyroid tissue removal (by partial
thyroidectomy or radio-iodine treatment) or iodine excess. Primary hypothyroidism is
ten times more common in females than males. Secondary hypothyroidism can be
caused by pituitary tumours or other destructive lesions, both of which can interrupt
pituitary signalling to the thyroid gland. Hypothalamic lesions and isolated TRH
deficiency are causes of tertiary hypothyroidism.















Table 2.4 Summary of diagnostic test results in hypothyroidism
Cretinism, caused by insufficient foetal thyroid hormone exposure is an example of
primary congenital hypothyroidism. The disease is characterised by several
outstanding clinical symptoms: dwarfism, mental retardation, low body temperature
and heart rate, and general lethargy, for example. Dwarfism is caused by the failure of
the skeleton to grow and mature. hGH on its own is not sufficient for normal
development. Mental retardation occurs as a result of poor neuronal development as
discussed in Section 2.8.2. Cretins also show retarded sexual development and a
yellowish skin colour. The affected infant attains characteristic facial features due to
the formation of fat pads under the skin and the development of a large protruding
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tongue. Carbohydrates are stored rather than metabolised in this state of general
metabolic underactivity. Congenital hypothyroidism is not widely recognisable
clinically at birth. Measurement of TSH five days postnatally may reveal a persistent
elevation of this hormone reflecting hypothyroidism due to primary thyroid failure.
However, it will not detect the rare case of hypothyroidism secondary to pituitary-
hypothalamic disease (central hypothyroidism, which will be discussed at length in a
following section). If congenital hypothyroidism is diagnosed early, the symptoms
can be somewhat alleviated by thyroid hormone therapy.
Severe hypothyroidism in the adult, myxoedema, is most often the end result of
autoimmune destruction of the thyroid gland (Hashimoto's thyroiditis), although sub¬
clinical hypothyroidism can occur in which low levels of thyroid antibodies in the
circulation are associated with moderately elevated TSH, but normal T4.
Approximately 50% of patient with subclinical hypothyroidism progress to overt
hypothyroidism. For reasons identical to the infantile syndrome, the adult sufferer of
hypothyroidism exhibits decreased heart rate, low body temperature, sensitivity to
cold, muscular weakness, general lethargy, a tendency to gain weight easily along
with a characteristic puffiness of the face and thick, dry flaky skin. Since neurological
maturation has not been affected, the patient with myxoedema does not suffer from
mental retardation. However, in some cases neuronal reactivity may be dulled
resulting in a loss of mental alertness. Symptoms are alleviated by administration of
thyroid hormones. Circulating thyroid antibodies are more common in women than in
men at all ages but are most common in postmenopausal women.
Hypothyroidism is treated with replacement thyroxine therapy which should be
maintained for life, with regular follow-through testing.
2.8.4 Central hypothyroidism: an example of specific type of
hypothyroidism
Central hypothyroidism (and hyperthyroidism) is far less common than primary
thyroid disease. More than 95% of patients with hypothyroidism, have disease of the
thyroid gland. The remaining group who have normal thyroid associated with reduced
TSH secretion, normally as a result of either hypothalamic or pituitary disease, have
central hypothyroidism. Such hypothyroidism occurs most often in association with
GH-deficiency. Isolated central hypothyroidism is considered rare. Any lesion that
leads to insufficient TRH or TSH production, or interrupts anatomic connections
between the hypothalamus and pituitary can cause central hypothyroidism. The
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recognition of central hypothyroidism as a bona fide condition has implications which
are important in both the diagnosis and subsequent therapeutic regime used with
individual patients. Failure to recognise and treat central hypothyroidism can result in
poor growth and less than optimal state of health (Manasco et al, 1994; Samuels and
Ridgway, 1992).
By definition patients with central hypothyroidism have low circulating- and free-T4
levels. T3 levels are often low, but are less predictable than T4 levels. TSH levels are
generally lower in patients with pituitary lesions, compared with those with
hypothalamic lesions, who have been found to have normal or even elevated TSH
levels (Patel and Burger, 1973). Hypothyroidism in the presence of normal or
elevated TSH levels in central hypothyroidism may be a result of decreased TSH
bioactivity. Direct data from some patients with central hypothyroidism suggests that
their TSH has reduced activity in human thyroid membrane radioligand binding and
adenylyl cyclase activating assays, compared to the TSH from patients with primary
hypothyroidism (Beck-Peccoz et al, 1985; Faglia et al, 1983). In addition, lectin
chromatography of the sera from patients with central hypothyroidism has shown their
TSH to be differentially glycosylated in comparison to TSH from euthyroid or primary
hypothyroid patients (Miura et al, 1989). The bioactivity of TSH is impaired in this
pattern of glycosylation, which has effects on subunit combination and hormone
clearance (Magner, 1990), although another study by the same investigator found no
strict correlation between glycosylation patterns and bioactivity (Magner et al, 1992).
However, animal studies of central hypothyroidism and studies of the effects of
exogenous TRH on TSH glycosylation in humans (Magner, 1990) suggests that the
changes observed in central hypothyroidism may be due to TRH deficiency and
indeed, one group of investigators found that TSH bioactivity in central
hypothyroidism was enhanced (and even pushed into the normal range) by exogenous
TRH, either by acute injection or chronic oral administration (Beck-Peccoz et al,
1985). T4 also increased or was normalised in this and another study (Faglia et al,
1983), suggesting that at least in some patients, TRH deficiency is implicated in the
production of inactive TSH. Horimoto et al. (1995) deduced that TSH bioactivity was
reduced in patients with central hypothyroidism (as determined by a reduction in the
ratio of the T3 increment to mean TSH increment after TRH administration, as
compared to normal). However, even when using their novel serum TSH purification
method they were unable detect any TSH bioactivity reduction in vitro. Therefore, at
this time it is not possible to draw concrete conclusions as to the existence or function
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of differential TSH glycosylation in central hypothyroidism, and the role that TRH
deficiency might play in this process.
Cases of central hypothyroidism can be classified based on the pathophysiological
cause of the condition. These include:
• destructive hypothalamic hypothyroidism; caused by mass or infiltrative
lesions (see pituitary hypothyroidism below), congenital defects, degenerative
diseases, traumatic injury or iatrogenic effects
• idiopathic hypothalamic hypothyroidism
• tumorous pituitary hypothyroidism; mass lesions e.g. pituitary adenomas,
craniopharyngiomas, metastatic cancer, cysts and abscesses
• atrophic pituitary hypothyroidism; infiltrative lesions e.g. tuberculosis and
toxoplasmosis, pituitary atrophy
• idiopathic pituitary hypothyroidism
Each of these subgroups can be identified by differential diagnosis (Table 2.5).
Destructive Idiopathic Tumorous Atrophic Idiopathic
Hypothalamic Hypothalamic Pituitary Pituitary pituitary
Diabetes
insipidus Y N rare N N
Neurologic
defects







prolactinaemia N N N Y N
Anterior hypo¬
pituitarism Y Y Y Y N
TSH/PRL
response to
TRH Y/Y Y/Y Y/Y rare/N N/Y
Table 2.5 Differential diagnosis of central hypothyroidism.
Causes of central hypothyroidism can be diagnosed by combination of the symptoms and signs
observed as indicated. Annotations: Y= yes, N=no. Adapted from Emerson (1985).
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A less specific subdivision is that which categorises the causes of central
hypothyroidism into one group resulting from TSH deficiency (pituitary based) and a
second group which arises from TRH deficiency (hypothalamus based).
When the symptoms presented by a patient with central hypothyroidism cannot be
assigned to any of the above categories a diagnosis of idiopathic central
hypothyroidism is made. Idiopathic TRH deficiency is diagnosed in patients who
retain intact TSH responses to exogenous TRH, perhaps in association with isolated
TRH- or pluri-hypothalamic releasing hormone deficiencies, but in the absence of
anatomical abnormalities. The aetiology of idiopathic TRH deficiency remains
unknown, although a few cases have been found to be transient, with spontaneous
resolution of hypothyroidism (Gharib and Abboud, 1987).
Idiopathic TSH deficiency is diagnosed when a patient with central hypothyroidism
has low, or undetectable TSH levels, no TSH or PRL response to TRH, no evidence
of other pituitary hormone deficiencies, and no abnormalities on radiological
investigation. Idiopathic TSH deficiency may have several plausible aetiologies one of
which is the mutation of the TSH-(3 gene resulting in inactive, or no TSH.
Genetic analysis of five Japanese kindreds with isolated TSH deficiency has indicated
that the disease is inherited in an autosomal recessive pattern (Hayashizaki et al, 1990).
All of the affected individuals have severe growth failure and mental retardation,
accompanied by a failure to secrete active TSH in response to TRH administration,
despite the expected increase in free a-subunit. In three of the kindreds, a single
nucleotide substitution in the second exon of the TSH P-subunit was discovered. This
mutation resulted in an amino acid substitution (within exon 2, previously established
as a region critical for aP-dimer formation) which has been proposed to cause a
deleterious structural change in the p-subunit which prevents formation of biologically
active TSH. In a similar study of two related Greek families with three children
affected by congenital TSH deficiency, a different exon 2 mutation was found. In this
case the mutation resulted in a premature stop codon and the gene therefore encoded a
truncated P-subunit (Dacou-Voutetakis et al, 1990).
Acquired central hypothyroidism probably accounts for less than 5% of all cases of
hypothyroidism which makes this condition much rarer than primary hypothyroidism.
Pituitary tumours (functioning and non-functioning) are the most common cause of
acquired central hypothyroidism in adults. TSH deficiency usually occurs in
association with other pituitary hormone deficiencies which may arise due to the
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existence of a macroadenoma and very rarely of a microadenoma (Abboud, 1995), but
may also result from ablative surgery, radiotherapy or other organic causes.
Patients with primary hypothyroidism show an increased TSH pulse amplitude and a
blunting of the normal nocturnal TSH surge. Patients with central hypothyroidism
also exhibit atypical pulsatile TSH secretion. It has been shown that the normal
nocturnal TSH surge is absent or blunted in central hypothyroidism, giving rise to a
sensitive and specific test for identification of this condition (Rose et al, 1990).
Isolated central hypothyroidism has been identified in children previously diagnosed
with idiopathic short stature using this more accurate method (Rose, 1995). It is
interesting to note that a blunted nocturnal TSH surge has been identified in patients
suffering from seasonal defective disorder (SAD; (Coiro et al, 1994)). Although SAD
patients experienced psychiatric depression in the winter the blunted TSH secretory
pattern was consistent throughout the seasons. Normal subjects showed a significant
nocturnal TSH surge in the tests at all times. The authors of this report suggest that
patients with SAD exhibit symptoms of mild central hypothyroidism, i.e. low TSH
response to TRH in the presence of normal serum thyroid hormone levels and an
absent nocturnal TSH surge. Patients with SAD may be suffering from a TRH-linked
defect, perhaps located in the retina, since TRH has previously been detected in this
tissue (Schaeffer et al, 1977), where the hormone appears to be regulated by
environmental lighting, although the outcome of TRH activity in the retina is presently
unknown.
In three reports (Costom et al, 1971; Miyai, 1985; Miyai et al, 1988) patients with
central hypothyroidism had undetectable basal and TRH-stimulated TSH levels,
suggesting that these rare patients had thyrotroph insensitivity due to a receptor or
post-receptor defect or primary thyrotroph disease interfering with the synthesis and
secretion of TSH.
2.8.5 Hyperthyroidism
Hyperthyroidism is much less common than hypothyroidism although its symptoms
are those which are more often brought to mind when discussing thyroid disease.
Grave's disease (also more common in women than in men) is an example of a
hyperthyroid state caused by autoimmune destruction of thyroid tissue. One of the
primary symptoms is a vast enlargement of the thyroid tissue resulting from excessive
lymphocytic infiltration of the gland, the end result of which is goitre formation.
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Additional causes of hyperthyroidism include toxic multinodular goitre and toxic
adenoma formation. More rare causes are de Quervain's thyroiditis, 'silent' thyroiditis
and neonatal hyperthyroidism caused by transplacental passage of thyroid stimulating
antibodies into the foetal circulation.
In Grave's disease thyroid stimulating antibodies activate adenylyl cyclase by binding
to the surface TSH receptors on thyroid cells in much the same manner as TSH. The
TSH receptors are thereby switched on, promoting the secretion of excess levels of
thyroid hormones. In addition to goitre, thyroiditis is characterised by other overt
physical symptoms many of which are associated with periorbital swelling and include
exopthalmos and lid retraction. More occasionally localised myxoedema and vitiligo
are evident. The metabolic rate as could be expected is abnormally high, resulting in
symptoms of increased pulse, high blood pressure, high body temperature, heat
intolerance, flushed skin, irritability and possibly muscle tremors caused by increased
responsiveness of the nervous system.
Hyperthyroidism is usually treated by antithyroid drugs (e.g. carbimazole which is
metabolised to its active counterpart, methimazole), surgical removal of excess tissue
or radio-iodine treatment.
2.9 Pituitary tumours
Pituitary tumours account for approximately 10% of intracranial tumours. These
tumours are classified into two broad groups; those which are associated with
hormone secretion are termed functioning, whereas those showing no overt signs of
hormone output are classified as non-functioning. Hormonal stimulation of
hypothalamic source seems an unlikely primary cause of adenoma formation, although
these signals may have a secondary effect on adenoma growth and secretion. Pituitary
tumours are generally benign neoplasms which in the majority of cases are detected
only as a result of mass effects from tumour expansion, such as visual field defects,
hypopituitarism (due to compression of the pituitary stalk and blockade of the delivery
of hypothalamic hormones to the pituitary or compression of other secretory cells of
the normal gland) or hyperprolactinaemia (if dopamine delivery to the pituitary is
blocked by compression of the portal system). Pituitary tumours have been shown to
arise from the clonal expansion of a single, transformed progenitor cell (Herman et al,
i990) but little is known of the mechanisms which underlie oncogenic transformation
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in most pituitary adenomas. However, the gsp mutations (Section 2.4.1) have been
shown to be associated with the transformation of a subset of GH-secreting pituitary
adenomas and thyroid tumours.
Adenomas of the anterior pituitary gland may arise from any of the major cell types
making up this tissue. The hormone produced by the resulting lesions therefore
depends on the nature of the progenitor cell.
Lactotroph cell adenomas or prolactinomas are one of the most common anterior
pituitary tumours, accounting for approximately 60% of all identified pituitary
tumours.
Somatotroph cell adenomas which account for approximately 15% of pituitary
tumours are usually associated with gigantism (prior to epiphyseal fusion) or
acromegaly (after epiphyseal fusion). Indeed, over 98% of patients with acromegaly
have pituitary adenoma, 30% of whom also have hyperprolactinaemia due to the
incidence of tumours ofmammosomatotroph origin.
Corticotroph adenomas are the cause of Cushing's disease. These tumours tend
to be very small (microadenomas) lesions located in the centre of the pituitary gland.
Gonadotroph cell adenomas were until relatively recently believed to be rare with
an incidence of less than 1%. Recently, it has been shown that a large proportion of
non-functioning pituitary adenomas are of gonadotroph origin, indeed taking this
finding into account makes gonadotroph adenomas one of the largest groups of
pituitary tumours, accounting for 40 to 50% of all macroadenomas. Symptoms
associated with hormonal hypersecretion are the least common clinical presentation of
gonadotrophinoma. They usually come to recognition as a result of neurological
effects caused by growth and expansion of the tumour. Therefore, gonadotroph
adenomas are generally recognised only once they have attained macroadenoma
proportions. The reasons for the failure to recognise gonadotroph adenomas are two
fold; firstly, they secrete inefficiently, and secondly, the hormones which they secrete
(the gonadotrophins and their subunits) do not produce recognisable clinical
symptoms. In comparison with a prolactinoma of equivalent size, which can produce
a 100-1000-fold increase in normal serum prolactin levels, the gonadotroph adenoma
increases serum FSH to up to 10-fold and often levels are not elevated above the
normal range at all (Snyder, 1995). FSH is most commonly the secretory product of
gonadotrophinomas. LH hyper-secretion is less frequently observed. Additionally,
the secretion of intact gonadotrophins is rare. The hormone output usually includes a
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combination of intact FSH, FSH- and LH-(3 subunits and some a-subunit (Snyder,
1995), with the proportions of each secretory product being inconsistent amongst
adenomas. Hormonal output by these tumours appears to depend to a certain extent on
endogenous GnRH, since treatment with Nal-Glu-GnRH (a GnRH antagonist)
reduces elevated FSH levels in patients with gonadotroph adenomas to normal
(Daneshdoost et al, 1990). Patients with gonadotrophinomas often show a
paradoxical rise in gonadotrophins and/or their subunits in response to exogenous
TRH (Daneshdoost et al, 1993; Daneshdoost et al, 1991; Katznelson et al, 1992). The
incidence of truly non-functioning adenomas is approximately 20%.
The thyrotroph cell tumour, or thyrotrophinoma, is the most infrequently
encountered pituitary adenoma. Approximately 30% of patients with thyrotroph
adenomas show a rapid rise in serum TSH in response to TRH administration (Bevan
et al, 1989). The remainder show no response to TRH challenge. TRH binding sites
have been detected on the cells of some thyrotrophinomas (Chanson et al, 1988) but
not on others (Filetti et al, 1982). Patients with TSH-secreting adenomas often present
late, with large and usually invasive tumours.
2.10 Concluding remarks
The HPT axis has been extensively studied by many researchers using the tools of the
pharmacologist, the physiologist and most recently the molecular biologist. The
identification of many of the molecules involved in control of the HPT axis, and in
particular the cloning of cell surface receptors has allowed a hitherto unprecedented
level of investigation. The cloning of the TRH-R has allowed studies of the molecular
and cellular aspects of this receptor, including elucidation of its structure, function,
and regulation. However, there still exist many aspects of TRH-R structure and
activity that remain to be elucidated. Many questions as to the mechanisms of receptor
activation, ligand binding, desensitisation as well as to the mechanisms and roles of
down-regulation and the possible existence of TRH-R isoforms possibly binding the
TRH-like peptides in extra-hypothalamic tissues, still exist. Additionally, in view of
the already large number of GPCRs that have been linked with disease, is there a place
for the TRH-R on this list ? With the continual advancement of the molecular and
biological tools which are available, and in conjunction with high power computer
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modelling techniques, the pace of progress into the understanding of the TRH/TRH-R




The methods detailed in this chapter are general tools of molecular biology but are
discussed in relation to their use specifically as applied to the study of GPCRs. The
experimental chapters contain the detailed information pertaining to individual
experiments.
A detailed list of buffers and solutions used is included in Appendix I. Appendix II
details the suppliers of consumables and equipment used in the experiments.
3.2 The polymerase chain reaction (PCR)
The polymerase chain reaction which originated in the mid 1980s (Mullis and Faloona,
1987) is used to enzymatically amplify a stretch of DNA between two regions of
known sequence. Two amplimers, or PCR primers (short single strand
oligonucleotides), are synthesised to complement sequences which lie on each of the
complementary strands of the DNA and which flank the segment to be amplified.
These amplimers are added to a reaction mix which contains a molar excess of the
amplimers and the four deoxynucleoside triphosphates (dNTPs), buffer, a
thermostable DNA polymerase, and a source of template DNA. This mixture is
processed through a series of heating and cooling cycles which perform the following
functions;
a) Denaturation by heating to form the single strands of target DNA to which
the amplimers can anneal.
b) Annealing which allows the amplimer to bind to its complementary region
on the single-stranded DNA target generated in step a.
c) Extension by the DNA polymerase which recognises and binds only to the
double-stranded DNA formed in step c.
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The products of one round of amplification become the template for the next, resulting
in an exponential increase in the number of amplified molecules with each PCR cycle.
The major product of a PCR reaction is a fragment of DNA delineated by the 5' ends
of the amplimers and whose length is the distance between the amplimers.







denaturation 1 95 120
denaturation 95 45
annealing 20-30 50-60; depending
on primers
45
extension 72 30+;depending on
length of product
extension 1 72 300
Table 3.1 Outline of a basic PCR temperature cycling protocol
After the initial denaturation cycle, 20-30 cycles of amplification are performed (shaded section) with
the annealing temperature determined by the average melting temperature of the primers used.
A PCR reaction necessarily includes the following components: however, the final
volume of the reaction can be scaled to complement specific experimental requirements
Reaction components 5' amplimer, 0.5 pi (20pM)
3' amplimer, 0.5 pi (20pM)
dNTPs, l.Opl (lOmM)
Magnesium chloride, 5-10pl (25mM)
lOx reaction buffer, 5pi
DNA polymerase, 0.5pl (5U/pl)
template DNA, lpl (10-50ng)
dH20, to 49pl
The product of the PCR is analysed for length and integrity by agarose gel
electrophoresis (see section 3.6)
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3.3 Detection of single-strand conformational
polymorphisms in PCR products (PCR-SSCP)
PCR-SSCP is a method which is used to screen DNA sequences (usually of genomic
DNA or mRNA origin) for the presence of mutations or polymorphisms. Mutations
are detected as a shift in the migration pattern of the single strands of DNA PCR
amplified from the DNA under analysis. This method is based upon the hypothesis
that single-stranded DNA adopts a secondary structure which is determined by its
primary structure (or nucleotide sequence). If even a single nucleotide in a given
strand of DNA is altered then it is proposed that the secondary conformation of that
DNA will be different and may be detected as a shift in electrophoretic mobility under
non-denaturing conditions.
The first step in this method of analysis is PCR which is performed as in section 3.2.
A PCR product of 200-250 bp achieves the most accurate results. A larger PCR
product can be incubated with appropriate restriction endonuclease/s in order to
generate smaller fragments for PCR-SSCP analysis.
A final PCR reaction volume of 10|ll is used which requires the relative reduction of
all reaction components. Either pfu (Boehringer Mannheim) or ULTMA (Perkin
Elmer) DNA polymerase is utilised as these enzymes have proof-reading activity and
therefore exhibit higher fidelity (i.e. incorporate fewer erroneous nucleotides) than Taq
DNA polymerase. 32[P]-a-dCTP (Amersham) is added to the reaction in order that
the product can be detected by autoradiography.
2jil of the PCR product is heat denatured (5 minutes at 95°C) in 1 8jj,1 of SSCP sample
buffer (Appendix I). 10-20|ll of the denatured PCR product is then applied to the well
of a vertical non-denaturing 10% polyacrylamide/0.5x TBE gel and is electrophoresed
at 30 Watts overnight in 0.5x TBE electrophoresis buffer.
The gel may require to be run with external water-cooling or in a temperature
controlled cold-room to prevent over-heating which would destroy the secondary
structure of the single-stranded DNA as it migrates through the gel matrix. If the gel is
run slowly at a low power setting it may be possible to electrophorese at ambient
temperature. To enhance the resolution achieved by PCR-SSCP analysis a 5-10%
final volume of glycerol may be added to the polyacrylamide gel mixture but this may
necessitate a reduction in the electrophoresis rate or require cooling of the
electrophoresis set-up. Combinations of conditions must be tested in order to optimise
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this method for the specific PCR product and to enhance the possibility of detecting all
of the nucleotide substitutions which may be present.
Following electrophoresis the gel is transferred to filter paper, covered with cling-film
and exposed to photographic film for 4-16 hours at -70°C. On development of the
film discrete bands are visualised as a record of the migration patterns of the individual
single strands of the PCR DNA. If the sample PCR is electrophoresed with PCR from
a known wild-type template source the presence of a single nucleotide base difference
may be visible as a shift in the migration pattern as compared to wild-type. However,
SSCP analysis cannot detect all possible base changes since this screening method
only detects those which result in a conformational change.
3.4. TA cloning
This method allows the rapid and effective ligation of PCR-generated DNA fragments
into plasmid vectors which allow the propagation of the amplified DNA in E. coli for
post-PCR applications.
TA cloning is used extensively by molecular biologists. In the studies detailed in the
following experimental chapters, this method was used to clone PCR products for
several purposes. The products of the PCR step of PCR-SSCP analysis (unlabelled of
course) were cloned to check that no mutations were missed by this screening method.
In addition several PCR fragments of different origins (the mTRH-R 5' UTR and
genomic DNA extracted from pituitary adenomas for example) were cloned prior to
sequencing and/or subsequent subcloning into vectors with desired functions.
TA cloning utilises the fact that non-proof-reading DNA polymerases such as Taq add
single deoxyadenosine triphosphate residues to the 3' end of the PCR fragment in a
template-independent fashion. The construction of a linearised plasmid vector with
single deoxythymosine triphosphate overhangs allows annealing of the complementary
As and Ts, with the plasmid/PCR fragment junction being covalently linked by the use
of a DNA ligase enzyme. The circular construct thus generated can be transformed
into an appropriate strain of E. coli which permits amplification of the PCR fragment
in its plasmid carrier. The PCR fragment-containing plasmid can be extracted from
bacterial cell lysate by various methods. The TA vectors contain the lacZ gene which
when intact enables E. coli expressing this gene to metabolise X-gal which results in a
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blue coloration of arising colonies. When a PCR product is successfully inserted the
reading frame of lacZ may be disrupted and therefore colonies arising from vector +
insert plasmids are unable to metabolise X-gal and remain white. This is known as
blue/white screening and is a useful way of identifying positive colonies.
3.5 Automated fluorescent DNA cycle sequencing
Cycle sequencing is a rapid and convenient method for performing enzymatic
extension reactions for DNA sequencing. The strategy of chain termination by the
incorporation of radiolabeled deoxynucleoside triphosphates (dNTPs) in the presence
of unlabelled dideoxynucleoside triphosphates (ddNTPs) which was originally
described by Sanger et al. (1977) has recently been combined with fluorescent
technology.
The chemistries of the original radioisotopic method and the more recently developed
non-radioisotopic system are identical. Each method generates a population of labelled
oligonucleotides that begin from a fixed point and end randomly at a fixed residue.
Every base in the DNA has an equal chance of being the variable terminus which
results in a population of oligonucleotides which differ in length by one base. The
population of fragments are resolved by electrophoresis through a denaturing
polyacrylamide gel.
The Sanger method requires using four separate reaction tubes, each with only one of
the four nucleosides in the form of a radiolabeled ddNTP. Each of these four
reactions are electrophoresed in individual lanes of the resolving gel, with the sequence
determined by the pattern of bands observed on an autoradiogram of the resulting gel.
However, the modern chemistry utilises the incorporation of ddATP, ddGTP, ddCTP
and ddTTP conjugated to distinctive fluorophores which can all be added in a single
reaction tube. During the cycle sequencing reaction, the oligonucleotide chains
synthesised are terminated by a fluorescently labelled ddNTP. When electrophoresed
through a denaturing polyacrylamide gel these oligonucleotides are separated by size.
The automated DNA sequencing apparatus uses a laser source to excite the
fluorophores as they migrate past a detection point. Computer software subsequently
constructs a screen image of the gel with coloured bands representing each nucleotide
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base of the DNA chain. The actual DNA sequence is then automatically computed and
can be further analysed as required.
All DNA sequence analysis and manipulation was performed using the programmes
Gene Jockey and most recently, Gene Jockey II (Phil Taylor, Cambridge Biosoft)
3.6 Horizontal agarose electrophoresis of DNA
fragments
DNA may be size-separated by electrophoresis through an agarose gel matrix. The
percentage of agarose added to the gel mixture determines the size separation which
can be achieved and therefore the resolving power of the gel. For most general
purpose electrophoresis a 1% agarose (Boehringer Mannheim) gel was made using
0.5x TBE buffer (Appendix I), as this gives high resolution of DNA fragments
between 500 bp and 7 kb.
The agarose was melted in 0.5x TBE buffer, and when hand hot, 0.3|lg/ml ethidium
bromide was added. The gel was poured into a casting tray and allowed to solidify. A
10% volume of agarose gel loading dye (Appendix I) was added to the DNA samples
(50ng to lpg DNA) which was then diluted to the final loading volume in distilled
water. Once set, the gel was inserted into its electrophoresis tank and was submerged
in electrophoresis buffer (0.5x TBE). As DNA carries an overall negative charge the
samples are placed at the negative terminal of the electrophoresis tank and migrate
towards the positive terminal. Electrophoresis was carried out at a constant voltage of
5-10V/cm until the dye front reached the bottom of the gel. When electrophoresis was
complete the gel was placed on a UV transilluminator (Vilber Lourmat) and
photographed to provide a permanent record. The DNA appeared as bright, luminous
bands. Size markers (Hind III/Eco R1 and pGEM, both Promega) were run alongside
the sample DNA so that its size (in base pairs) could be estimated.
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3.7 DNA purification
3.7.1 Plasmid recovery
The plasmid to be amplified was transformed into E. coli cells by either a heat-shock
method or by electroporation as described in section 3.12.
Cells from a resulting single bacterial colony were used to inoculate 10ml of LB broth
(Appendix I) containing appropriate antibiotics (Table 3.2 indicates the bacterial strains
used for different vectors used throughout the experiments and indicates the selective
antibiotics used in their culture). The E.Coli culture was grown overnight with
shaking at 37°C and the DNA extracted using a Promega Wizard™ Mini-prep DNA
purification system as follows: Bacterial cells were pelleted by centrifugation at 12000
rpm for 5 minutes, resuspended, lysed and neutralised with 200|ll of resuspension,
lysis and neutralisation solutions respectively. Following further centrifugation at
12000 rpm for 5 minutes, the cleared supernatant was removed and added to 0.5ml of
Mini-prep DNA purification resin in a clean 2ml Eppendorf tube. The DNA/resin
mixture was subsequently filtered through Miniprep columns using a vacuum
manifold. Finally, the columns were washed with ethanol, dried, and the DNA eluted
with 50pl of TE buffer (Appendix I) or autoclaved water by centrifugation at 12000
rpm for 1 minute. Approximately 30(Xg of plasmid DNA was obtained from a 10ml
E.Coli bacterial culture. Larger scale plasmid DNA preparations were carried out
using a Promega Wizard™ Maxi-prep kit. Using this procedure, 0.5ml of a 10ml E.
Coli starter culture was used to inoculate 300ml of antibiotic-containing LB broth and
the DNA extracted using a similar but scaled up version of the Mini-prep procedure
described above. Approximately 500-1000p,g of DNA was obtained using this
method.
The extracted plasmid DNA was analysed by restriction digest and agarose gel
electrophoresis to check both its integrity and its identity.
3.7.2 Extraction of high molecular weight genomic DNA
The medium from which the DNA was to be extracted was homogenised in DNA
extraction buffer (150mM NaCl, lOmM Tris.HCl (pH 7.5), lOmM EDTA, 0.4%
SDS). Proteinase K was added to the homogenate to a final concentration of 5|J,g/ml.
The samples were then incubated at 55°C overnight. DNA was isolated by
phenokchloroform extraction followed by ethanol precipitation and pelleting by
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centrifugation at 10000 rpm for 10 minutes. The air-dried pellet was resuspended in
autoclaved, distilled water or TE buffer and quantified by UV spectrophotometry at
260nm. To confirm that DNA had not degraded during tissue storage and extraction
procedures, aliquots of the DNA were electrophoresed in 0.7% agarose gels
containing 0.5x TBE as described above.
3.7.3 Recovery of DNA from an agarose gel
It is often necessary to extract DNA of a certain size from a heterogeneous mixture.
One method of achieving this is to electrophorese the mixture of DNA fragments
through a low melting point agarose (Sea Plaque agarose, Flowgen) gel. This method
is similar to the protocol described above except that the 1% low melting point agarose
gels were set and run at 4°C. In addition, to prevent any damage to the DNA,
ethidium bromide staining was performed after completion of electrophoresis. The gel
was then viewed under UV light, the position of the required fragment(s) ascertained
and the correct DNA bands excised with a scalpel blade for further purification. DNA
recovery was achieved using a Qiagen gel purification kit. In essence this procedure
involves melting the DNA-containing gel slice in extraction buffer and then binding the
DNA to a matrix in a dedicated centrifuge spin column. The liquid portion of the
mixture is spun out of the column whilst the DNA is retained, bound to the matrix.
The DNA is then eluted by adding Tris-Cl buffer (lOmM, pH 8.0).
3.7.4 Phenohchloroform DNA extraction
Phenolxhloroform extraction separates nucleic acids from proteins, and is a widely
used technique for the removal/inactivation of enzymes or for the purification of DNA
from agarose gels. An equal volume of TE-saturated phenol was added to the DNA
containing sample and the sample vortexed for 1 minute followed by centrifugation at
10000 rpm for 1 minute. The upper aqueous phase was removed into a clean 1.5ml
Eppendorf tube and the vortexing and centrifugation procedure repeated, first with an
equal volume of phenohchloroform and finally with an equal volume of chloroform.
The DNA was extracted from the chloroform phase using a salt/ethanol precipitation
method (see section 3.8 below).
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3.8 Salt and ethanol precipitation of DNA
Nucleic acids may be concentrated by precipitation with ethanol, in the presence of
monovalent cations. Ammonium acetate (10M, pH 5.0) or sodium acetate (3M, pH
5.0) was added to a final concentration of 2.5M or 0.3M respectively, together with 2
volumes of 100% ethanol. The samples were precipitated at 4°C/on ice for 30 minutes
and centrifuged at 12000 rpm for 30 minutes at 4°C. The supernatant was then
removed, the DNA pellet washed in 70% ethanol and resuspended in TE buffer/water.
3.9 Spectrophotometric DNA quantitation
The concentration of a 1:100 dilution of a DNA sample was determined by measuring
the optical density (OD) at 260nm and 280nm in a Kontron Analytical
spectrophotometer. An OD26O reading equivalent of one corresponds to a solution
containing 50(ig/ml of double stranded DNA, 40|lg/ml of either single stranded DNA
or RNA or 20(lg/ml of single stranded oligonucleotides. Depending on the relative
base composition of the DNA an OD 260:280 ratio of between 1.5 and 2.3 indicates
good DNA sample purity.
3.10 Restriction endonuclease digestion of DNA
Restriction endonucleases are enzymes found naturally in bacterial cells. These
enzymes are highly specific in their activity, recognising short sequences (generally
palindromic in nature) in double-stranded DNA. On binding to their individual
recognition site the endonucleases cleave the DNA. Restriction endonucleases are
used extensively in molecular biology and are useful for several protocols. If the
sequence of a length of DNA is known, the restriction sites it contains can be
identified. On incubation with a given restriction endonuclease, fragments of expected
lengths are generated confirming the identity of the DNA. This is especially useful in
confirmation of the identity of plasmid DNA extracted from E. coli host strains.
Restriction endonucleases are also used in the transfer of stretches of DNA between
plasmid vectors, a method known as subcloning.
l-5|ig of purified DNA was digested with 10 units of restriction enzyme (sourced
from several suppliers), in lx enzyme buffer (supplied with the enzyme in lOx
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solution) at the optimum digestion temperature (generally 37°C) for 1 hour, and the
digestion products subsequently analysed by agarose gel electrophoresis.
3.11 DNA ligation
The cut ends of restriction endonuclease-treated DNA fragments can be rejoined with
the use of a DNA ligase enzyme. Bacteriophage T4 DNA ligase is most commonly
used as it gives efficient ligation of both blunt and sticky ended DNA. The ligase
enzyme regenerates the phosphodiester bond between the 3' terminal phosphate group
on one strand of the DNA fragments and the 5' hydroxyl group of the other DNA
fragment by transferring the phosphate group from ATP present in the ligation reaction
buffer.
It is often advantageous to dephosphorylate a linearised (cut with a restriction
endonuclease so that it is no longer circular) plasmid vector . If the plasmid into which
another stretch of DNA is to be ligated is dephosphorylated, the ligase only forms a
bond in one strand of the DNA at each end of the ligation. This results in unligated
strands containing "nicks". This enhances transformation as nicked DNA is more
effectively taken up and replicated by E. coli than is fully ligated DNA.
Dephosphorylation also inhibits recircularisation of the plasmid DNA during ligation
so more of the desired product is formed.
Ligation may be enhanced by the addition of condensing agents such as polyethylene
glycol or hexaminecobalt chloride. These agents condense the DNA into aggregates
which increases molecular proximity and subsequently increases the rate of the ligation
reaction.
The molar ratio of vector to insert DNA is of great importance for efficient ligation.
The insert DNA must be at least equimolar to the vector, but should preferentially be in
a 3 to 5-fold molar excess, particularly if a less efficient blunt end ligation is being
performed.
As with restriction endonuclease digestion of DNA, ligation requires the incubation of
the cut DNA fragments with the ligase enzyme of choice in a buffer which is usually
supplied with the enzyme. Optimal reaction conditions are dictated by the enzyme
being used.
Chapter 3 Materials andMethods 62
3.12 Transformation of plasmid DNA into E. coli
Plasmid vectors are circular stretches of DNA which carry various pieces of genetic
information; antibiotic resistance, mating factors, replication origins, promoter
sequences and enzymatic capability for example. It is possible to ligate a chosen
length of DNA, a GPCR cDNA for example, into a plasmid vector for further
analysis. The plasmid vector construct must be transformed into appropriate E. coli
strains so that large quantities of the desired DNA can be extracted from the resulting
bacterial cultures.
3.12.1 Chemically competent E. coli
E. coli cells are grown in 300ml of the appropriate medium until the cells reach mid log
phase (at an optical density of 0.5-0.6 at 600nm). Making sure that all solutions are
ice cold and that all processes are performed at 4°C, the cells are pelleted at 4000rpm
for 10 min and are then resuspended in 10ml of 0.1M CaCl2- This cell suspension is
centrifuged as described previously, resuspended in 10ml of the 0.1M CaCl2 and
dispensed into 200|ll aliquots which can be stored at -70°C until use.
To introduce exogenous plasmid DNA into chemically competent cells the following
protocol is followed. The cells are incubated with the DNA to be transformed on ice
for 30 minutes. The E. coli are then shocked at 42°C for 30-45 seconds which
provokes a transient permeability in the cell wall of the bacteria allowing the DNA to
pass into the cells. The cells are then placed on ice for 2 minutes during which time
the cell wall reintegrates. Finally the E. coli are incubated at 37°C for 60 minutes in
SOC medium (Appendix 1). This allows the selective antibiotic resistance carried in
the sequence of the plasmid vector to be expressed prior to the cells being plated onto
LB agar (Appendix 1) containing selective antibiotic/s. The LB agar plates are
incubated in an inverted position at 37°C overnight. Post-transformation, isolated
single colonies are selected and grown in liquid culture for the extraction of plasmid
DNA as previously described.
3.12.2 Electrocompetent E. coli
E. coli cells are prepared from a liquid culture such that they are suspended in a
medium with very low electrical conductance properties. This involves washing the
cells pelleted from a 300ml log phase bacterial culture twice with 20ml of ice cold
sterile water, and then once with 2ml of ice cold sterile 10% glycerol solution. The
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resulting cell pellet is resuspended in a small volume (approximately 800jil) of the
10% glycerol and 50jil aliquots stored at -70°C for up to six months.
The DNA to be transformed is mixed with the bacterial cells which are placed between
the metal contacts of a 2mm electroporation cuvette (Flowgen). A high voltage pulse
(2.5kV) is then discharged through the E. coldDNA mixture using a Gene Pulser II
apparatus (Bio-Rad). The electric shock permeabilises the bacterial cell wall allowing
DNA to diffuse into the cell interior where it is replicated alongside the bacterial
chromosomal DNA (episomal replication). The cells are incubated for 1 hour in SOC
buffer to allow antibiotic resistance to develop and then the bacteria are spread onto LB
agar + antibiotics plates. Following overnight incubation, isolated colonies are
selected for liquid culture and DNA isolation.
The amount of DNA isolated by both of the above methods depends on the inherent
copy number of the plasmid vector and the volume of bacterial culture extracted.
Plasmid vector E. coli strain Selective antibiotics
pcR2.1 (TA vector, Invitrogen) INVa F 50|lg/ml Amp or Kan
pT7-blue (TA vector, R&D) NovaBlue 50|ig/ml Amp or Kan
pcDNA-3 TOP 10 F 50(lg/ml Amp
pGL3-basic JM109 50|ig/ml Amp
pcDNA-3 CJ236 (dut/ung mutant) 50(ig/ml Amp
Table 3.2 Some of the plasmid vectors and their E. coli host strains used
The TA vectors can be selected on either Amp or Kan which allows for the destruction of any plasmid
template which may be carried over from the PCR reaction. For example, if the PCR template is in
an Amp resistant plasmid, the TA clones should be selected on Kan, and vice versa. CJ236 is the
dut/ung mutant strain which produces DNA containing uracils which is required for the site-directed
mutagenesis method described in Section 3.13 below.
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3.13 Site-directed mutagenesis
3.13.1 General methodology
DNA mutations were introduced into the TRH-R using a method adapted from Kunkel
(1985) and performed using a Muta-Gene™ phagemid in vitro mutagenesis kit (Bio-
Rad). The coding DNA of interest was cloned into an eukaryotic expression vector
and the DNA replicated within a dut/ung double mutant E. Coli bacterium. The dut
mutation inactivates dUTPase whereas the ung mutation inactivates the enzyme uracil-
N-glycosylase. Together these mutations result in the incorporation of uracils into the
DNA. This 'parental' DNA single-strand was then used as a template to anneal an
oligonucleotide containing the desired mutation. A complementary, non-uracil
containing DNA strand, identical except that it carried the mutation, was subsequently
synthesised. The double stranded DNA construct was transformed into cells
containing an efficient uracil-N-glycosylase enzyme system which resulted in the
inactivation of the parental DNA strand, thus permitting only the DNA strand carrying
the mutation to replicate.
3.13.2 Eukaryotic expression vectors
The plasmid pcDNA-3 (Invitrogen) is a 5.4 kb vector derived from pRc/CMV (Figure
3.1a). The vector contains a CMV promoter and enhancer, SV40 origin for transient
episomal replication of cells expressing the SV40 large T antigen, and a bovine growth
hormone polyadenylation signal. It also contains an fl origin for the rescue of single
stranded DNA, T7 and SP6 promoters for the production of sense/antisense RNA
transcripts, and a ColEl (from pUC 19) high copy number origin. The p-lactamase
gene confers Amp resistance in the E.Coli strain TOP 10F'. In addition, this vector
has the advantage of a neomycin resistance marker, expressed from the SV40 early
promoter, for the selection of stable transformants in the presence of G418 (a
neomycin analogue). A recombinant eukaryotic expression vector for the human
TRH-R was constructed by subcloning the hTRH-R cDNA into the Eco RI restriction
site of pcDNA-3 (Invitrogen, Figure 3.1b). The receptor cDNA was inserted
downstream of the sequence of the human CMV promoter which permits the
membrane expression of the receptor protein in the chosen mammalian host cells.




CMV promotor: bases 209-863
T7 promotor: bases 864-882
Polylinker: bases 889-994
Sp6 promotor: bases 999-1016
BGHpolyA: bases 1018-1249
SV40 promotor bases 1790-2115
SV40 origin of replication: bases 1984-2069
NeoHORF: bases 2151-2932
SV40po!yA: bases 3120-3250
pUC19 backbone: bases 3272-5446
AmpRORF: bases 4450-5310
Bsml
Figure 3.1 The hTRH-R/pcDNA-3 construct and pcDNA-3
Schematic representation of pcDNA-3 highlighting some of the control elements of this vector (a) and
the hTRH-R/pcDNA-3 expression construct (b) assembled by ligating the receptor cDNA into the Eco
RI site of the pcDNA-3 polylinker (or MCS).
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Single strand DNA was produced from wild-type hTRH-R/pcDNA-3 transformed into
CJ236 E. coli. This uracil-containing single strand DNA was subsequently used to
generate mutant receptor cDNA sequences as described in the method below. Mutant
hTRH-Rs were transfected into mammalian cells for expression and subsequent
functional studies.
3.13.3 Helper phage
M13K07 (Invitrogen) is a single-stranded interference resistance helper phage
carrying the mutant gene II. Phage infection of plasmids containing either an fl or
M13 origin (for the rescue of single stranded DNA) results in the preferential
replication, packaging and extrusion of single strand plasmid DNA. M13K07 had a
titre of 2.6xl010 plaque forming units (pfu)/ml and was added at a multiplicity of
infection of 20:1 (phage:cells) to a cell culture containing 1x10s colony forming units
(cfu)/ml. Kan was used to select for cells infected with helper phage.
3.13.4 Preparation of uracil-containing template
CJ236 cells were streaked onto LB agar plates containing 30|ig/ml chloramphenicol
(Chi) and single colonies selected for further use. Individual colonies were
subsequently grown in an appropriate antibiotic environment and electrocompetent
cells prepared. Electrocompetent CJ236 cells (50|ll) were electroporated (Section
3.12.2). The transformed cells were plated onto LB agar plates, containing Chi and
Amp, incubated overnight at 37°C and single colonies picked. The DNA plasmids
were then extracted and the presence of inserts checked by Eco R1 restriction digests.
3.13.5 Single-strand DNA preparation
Selected CJ236/pcDNA-3 colonies were grown in 2xYT broth, containing appropriate
concentrations of Chi, Amp until an OD reading (at 600 nm) of 0.3 was reached.
M13K07 helper phage was added, the incubation continued for 1 hour prior to the
addition of Kan (70pg/ml) and then continued overnight. The E. Coli cells were
pelleted by centrifugation and the supernatant treated with lOfig/ml RNase and
10|ig/ml DNase at 37°C for 10 minutes. One quarter of the total volume of 3.5M
ammonium acetate/20% polyethylene glycol was added, the solution precipitated on ice
for 10 minutes and the DNA pelleted by centrifugation at 12000 rpm for 20 minutes.
The DNA was resuspended in TE buffer and purified using a phenol/chloroform
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extraction method. The single-strand uracil-containing DNA was then used as a
template to anneal mutagenic oligonucleotides.
3.13.6 Oligonucleotide design
Mutagenic oligonucleotides, complementary to the receptor DNA except containing
internal base mismatches, were designed to the targeted area of the receptor and
synthesised on an Applied Biosystems PCR Mate synthesiser. The oligonucleotides
were deprotected in 1ml of ammonia solution at 55°C overnight, purified by
salt/ethanol precipitation, and subsequently phosphorylated using T4 polynucleotide
kinase. These phosphorylated oligonucleotides were then annealed to a uracil
containing template in a 25:1 primer to template ratio. A complementary strand of
DNA was synthesised using T7 DNA polymerase and the ends of this de novo DNA
strand ligated together with T4 DNA ligase generating covalently closed circular DNA
(cccDNA) which should carry the desired mutation(s).
3.13.7 Transformation of the cccDNA for plasmid recovery
1 or 2 pi of the cccDNA was electroporated into TOPIOF' E. coli (Section 3.12.2) and
resulting colonies grown in liquid culture for plasmid purification (Section 3.7.1).
The plasmid DNA was sequenced to confirm the presence of the desired mutation prior
to transfection experiments. In general, 40-70% of colonies selected would contain
the expected mutation.
3.14 Tissue culture
Tissue culture reagents were purchased from GlBCO-BRL. COS-1 cells (Monkey
kidney, SV40 transformed fibroblasts), HEK-293 cells (human embryonic kidney
epithelial cells), GH3 and GH4CI cells (mouse GH/PRL secreting cells of lactotroph
origin) and AtT20 cells (mouse corticotroph tumour cell line) were obtained from the
American Type Culture Collection. Alpha-T3-1 cells (immortalised anterior pituitary
cells of gonadotroph lineage) were a gift from Dr. Pamela Mellon (The Salk Institute,
La Jolla, CA, USA). Cells (except GH4C1 cells) were routinely maintained and
passaged in complete Dulbecco's modified Eagle's medium (complete DMEM, see
Appendix I) and incubated at 37°C in a humidified atmosphere of 5% (v/v) CO2 in air.
GH4C1 cells were maintained in Ham's F10 medium supplemented with 10% horse
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serum and antibiotics/glutamine as for complete DMEM. Incubation of GH4C1 cells
was identical to that of the other cell lines used.
3.15 Transfection of eukaryotic cells
All transfections whether transient or stable were performed using a liposome-
mediated transfection protocol (Transfectam™, Promega). The lipid molecules in the
transfection reagent form liposome structures or micelles which carry a positive
charge. This positive charge interacts with the overall negative charge of the DNA
resulting in the lipid coating of the DNA which can then be intercalated into the lipid
bilayer of the cell membrane allowing the DNA to enter the cell. On reaching the
nucleus the plasmid DNA is episomally transcribed into RNA and then translated into
the protein of interest.
The specific cell lines transfected, the density at which they were plated out, the
amount of DNA transfected, and the culture medium used, are all detailed in the
relevant chapters.
3.15.1 Transient transfection
Transient transfections were performed according to manufacturers instructions.
Briefly, on the afternoon prior to transfection the cells to be treated were trypsinised,
harvested, counted and plated out at the desired density in 60mm tissue culture grade
petri dishes in complete growth medium. On the morning of transfection the cells
were washed twice with serum-free medium and 0.5ml replaced into the dishes whilst
the DNA and Transfectam™ were mixed. The appropriate amount of DNA (usually
5|0.g/60mm dish) was mixed with 0.75ml serum-free medium. In a separate tube 10(ll
Transfectam™/60mm dish and 0.75ml of serum-free medium were mixed together by
vortexing. 0.75ml aliquots of diluted DNA and diluted Transfectam™ were mixed
together and the resulting 1.5ml of DNA/liposome were added dropwise to the cells in
the petri dishes. Cells were incubated at 37°C in 5% CO2 in a humidified incubator
for 6 hours after which time the DNA/liposome-containing medium was removed and
replaced with complete culture medium.
Using this method, the DNA is not incorporated into the genome of the host cells and
therefore daughter cells generated by cellular division do not contain the receptor DNA
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or express the receptor protein. Functional assays were performed 48-72 hours post-
transfection.
3.15.2 Stable transfections
HEK-293 cells were generally used for stable transfections. To generate a clonally
derived stably expressing cell line, the protocol as described above was followed
except that the transfected DNA was restriction digested (linearised) at a site in the
multiple cloning site of the vector downstream of the receptor sequence. 48 hours
post-transfection the cells were trypsinised from the 60mm petri dish and seeded into a
125cm2 tissue culture flask. On reaching approximately 50% confluency the cells
were seeded into a 175cm2 tissue culture flask and allowed to grow to 60%
confluency. At this point the Geneticin™ analogue, G418 (Sigma), was added to the
culture medium at a final concentration of 800p.g/ml. Over the next 10-14 days those
cells not expressing the resistance gene died, leaving isolated colonies which had
expanded from a single G418-resistant progenitor cell. The culture flask was cut open
and the colonies were trypsinised in cloning rings and removed to the chambers of a
24 well tissue culture plate. The cells were maintained in G418-containing complete
culture medium and were seeded into larger volume vessels as required, until the cell
lines had been expanded to provide adequate numbers of cells for receptor function
assays.
3.16 Total inositol phosphate (IP) production assay
3.16.1 Methodology
24 hours post transient transfection cells were trypsinised and transferred to 24-well
tissue culture plates (2x 60mm plates per 24 wells). The cells were labelled to isotopic
equilibrium with 1 (iCi/ml myo-3[H]-inositol (Amersham) in inositol-free DMEM
(GIBCO-BRL).
48 hours later this medium was removed and the cells washed once with 250(il of
Buffer A (Appendix I). A further 500|il Buffer A containing LiCl (lOmM) was
replaced into the wells and the plates incubated at 37°C for 30 minutes. 55jiLl of ligand
agonist of increasing concentrations (0-10~5M) was added into the wells in triplicate
and the plates returned to the incubator for a further 45 minutes.
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The drug-containing medium was aspirated and the reaction stopped by adding 500|il
of PCA stop solution (0.5M PCA/5mM EDTA), followed by the addition of 50|il
phytic acid (1.8mg/ml) and incubation at 4°C for 10 minutes. The total reaction
mixture was removed to numbered test tubes and neutralised with 0.5mM potassium
hydroxide/60mM HEPES containing Universal pH indicator, producing a 'mid-green'
colour.
The neutralised solutions were transferred to a second set of numbered test tubes
containing 500fll of Dowex anion exchange resin (Analytical grade anion AG® 1-X8
resin, 100-200 mesh, Bio-Rad), vortexed briefly, allowed to settle and the supernatant
aspirated. Inositol, glyceroinositol phosphates and total inositol phosphates were
eluted from the resin by washing sequentially with 1ml dH20, 1ml 60mM ammonium
formate/5mM sodium tetraborate and 1ml 1M ammonium formate/0.1M formic acid
respectively. 800jil aliquots of the total IP-containing fractions were individually
transferred to scintillation vials and 4ml Optiphase HP (Pharmacia) liquid scintillant
was added. Radioactivity was measured in an LKB Rackbeta liquid scintillation
counter.
Total cell radioactivity was measured to compensate for interwell variations in cell
numbers. Wells were washed twice with 250|il PCA/EDTA stop solution and the cells
solubilised with 500jil 0.1M NaOH solution. Each well was neutralised with the
required volume of 0.66% acetic acid. The resultant solution was transferred to
individual scintillation vials and radioactivity measured as above.
3.16.2 Expression of results
Results are expressed as dpm/105 Total Counts (Tc) with assay points representing the
mean of triplicate samples. Assays were carried out on at least three independent
occasions unless otherwise stated. The ED50 was estimated by fitting a sigmoid curve
of the dose response data using the program SigmaPlot on Macintosh computers.
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3.17 Calcium imaging
3.17.1 Intracellular calcium measurements
Before intracellular calcium ([Ca2+];) measurements could be determined, cells first
had to be loaded with the fluorescent calcium dye fura-2 AM. Trypsinised and
dispersed cells were plated on to sterile glass coverslips. After 2 days attached cells
were washed (X2) with Buffer A (Appendix I). Cells were loaded with fura-2 AM
ester (4|iM final concentration in Buffer A) for 30min at 37°C in a 5% CO2 humidified
incubator. Unincorporated dye was removed by washing (X3) with Buffer A.
Coverslips were then transferred to the heated stage (37°C) of an inverted
epifluorescence microscope (see below).
3.17.2 Stimulation of cells with TRH and [Ca2+]j imaging
Dynamic video imaging was carried out using the MagiCal hardware and Tardis
software provided by Joyce Loebl Ltd. A Nikon Diaphot microscope with a X40
quartz oil immersion objective, operated in epifluorescence mode, was used to image
the cells.
Fluorescent images were obtained by exposing cells to 340nm and 380nm light,
alternated under computer control, at a speed of approximately 0.6Hz. The images,
viewed at wavelengths of 510nm (with a 40nm wide band filter), were focused on to
the face of an intensified charge-coupled device camera (Photonic Sciences, UK)
interfaced in turn, to an analogue hardware averager and 8-bit analogue-to-digital
converter, both operating at video frame rate. Typically, eight images were averaged
at each wavelength. A similar number were collected for background images which
were subsequently subtracted on a pixel-by-pixel basis from the image samples.
These images were held in dynamic random access memory for subsequent processing
and analysis.
Fluorescence excitation shifts occur when fura-2 binds calcium, i.e. the excitation
efficiency increases at 340nm and 380nm. Ratios of values obtained at 340/380nm
represent changes in [Ca2+]j. The 340/380nm ratio was calculated from averaged
video frames on a pixel-by-pixel basis, and was proportional to the [Ca2+]j.
Calibration was performed on cells loaded with dye which had been made permeable
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to extracellular Ca2+ using l(iM ionomycin. Exposure of cells to solutions containing
either lOmM Ca2+ or lOmM EGTA provided an estimate of the minimal and maximal
fluorescence at 340nm and 380nm. A dissociation constant of 225nM for fura-2 and
Ca2+ at 37°C was used. Possible errors in [Ca2+]j determination were estimated to be
5% from frame to frame, and were measured by collecting data from known standards
of Ca2+/EGTA buffers, containing 50-100|iM fura-2 free acid. Within a single frame,
the maximal pixel-to-pixel standard error (spatial variation) was less than 3% in
concentration for an average of 4 frames, and this fell to under 2% for an average of 8
frames.
3.17.3 Data analysis and presentation
Software-based image analysis using MagiCal allowed quantitation of ionised Ca2+ in
whole cells versus time. This was accomplished by the use of a light pen accessed
into dynamic memory to define a pixel data-set on a given image frame and the
software then automatically constructed a graphical presentation of Ca2+ concentration
with time. ASCI files of quantitative data could also be derived, and these were used
to derive plots of [Ca2+]j versus time for either single cells, or the averages of several
cells.
3.18 Radioligand receptor binding assay
3.18.1 Cell membrane preparation
48-72 hours post transient transfection the 60mm dishes of monolayer cells were
washed twice with phosphate buffered saline (PBS, Sigma) and the cells harvested by
scraping in a further 2ml of PBS. Whole cells were pelleted by centrifuging at 2500
rpm for 5 minutes at 4°C. The cell pellets were resuspended and lysed in 4ml of
hypotonic ice-cold lx radioligand binding assay (RBA) buffer (Appendix I) for 10
minutes. The disrupted cells were homogenised with coarse and then fine pestles in a
glass homogeniser. Homogenates were transferred to 2ml Eppendorf tubes and
centrifuged at 1 lOOOrpm for 30 minutes at 4°C. The supernatant was aspirated and the
membrane preparations stored at -70°C until use.
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3.18.2 Radioligand receptor binding assay (dose displacement)
Freshly made or stored membrane pellets were kept on ice and diluted in the required
volume of lx RBA buffer. An even suspension was obtained by aspirating the
membranes through a 19 gauge needle. TRH binding assays were performed using
the tritiated TRH agonist [3H](3-Me-His2)TRH (NEN-Du Pont). The radiolabel was
diluted to 2000 counts/pl in lx RBA buffer and 50jll added to each one of a set of
glass tubes (approximately 105 counts/tube). Unlabelled peptide (3-Me-His2)TRH
(50|il, Peninsula) was added at varying concentrations (0-10~10M) in triplicate.
Finally, 400(il of the diluted membrane preparation was added to each tube and the
reaction allowed to reach equilibrium over 2 hours at 4°C. Maximal binding (B0) was
measured when no cold peptide was added, non-specific binding (NSB) measured by
adding a saturating dose (10'6M) of [3-Me-His2]TRH and blank values from tubes
with no membranes.
Membranes were filtered through GF/B filter papers (Whatman) soaked in lx RBA
buffer containing 0.5% polyethylenimine (Sigma) using a Brandel cell harvester
(SEMAT). The filters were washed quickly 3 times with lx RBA buffer to remove
free ligand, leaving receptor-ligand complexes bound to the filter paper discs. Filter
paper discs were transferred to individual scintillation vials to which 4ml of Ecoscint
(National Diagnostics) liquid scintillation fluid was added. Radioactivity was
measured as previously described.
3.18.3 Determination of protein concentration of membrane
preparations
The protein concentration of the membrane preparations was determined
colorimetrically using Bio-Rad assay reagent in a 96 well microtitre plate format. 50|ll
protein standard (bovine serum albumin, BSA) or test sample, lOOfil 0.2M NaOH,
150p.l dH20 and 50|ll assay reagent were added to each well and the results measured
using a Labsystems plate reader set at an absorbance wavelength of 620nm. Results
were analysed using the computer programme Assay Zap (Phil Taylor, Cambridge
Biosoft) run on Apple Macintosh computers. Protein concentration was corrected for
intersample variations allowing the estimation of the concentration of receptors/|ig of
total protein (Bmax).
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3.18.4 Data analysis
Receptor dissociation constant (Kd) and receptor number (Bmax) were calculated from
the results arising from Scatchard analysis or Cheng and Prussoff analysis (Cheng and
Prusoff, 1973) of assay data using SigmaPlot. When the same ligand is used as the
hot and cold competitors in a displacement experiment an adaptation of the Cheng and
Prusoff equation (DeBlasi et al, 1989) can be used to calculate receptor number.
Cheng and Prussoff analysis involves the calculation of Kd from measurements of the
concentration of unlabelled ligand required to displace half the specific binding (ED50
values). This analysis is only appropriate when the same compound is used as both
the radioligand and competitor. The proof of this equation is shown below:









= Kd + (L.Kd)/ Kd
= Kd + L
= IC50- L
Kc = Kd of cold ligand








= B0 (Kd + L)/ L, substituting Kd = IC50 - L
= B0 (IC50 - L + L)/ L
= (B0. IC50 )/ L
Alternatively Scatchard analysis may be used which is a method based on the
calculation of the amount of radioactivity bound (B) to cell membranes versus the
amount of free radioactivity (F). A Scatchard plot involves the plotting of B/F versus
B. A linear relationship indicates a single affinity binding site with a Kd value
calculated from the slope of this line and a Bmax value from the point at which the line
intercepts the x-axis.
Assays were carried out on a minimum of three independent occasions, unless
otherwise specified, with individual assay points representing the mean of triplicate
samples.
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3.19 In-Vitro translation
In-vitro translation is a method whereby the polypeptide encoded by any stretch of
cDNA can be produced in a cell-free system. Using the Coupled Rabbit Reticulocyte
System (Promega) both the transcription and translation reactions can be performed in
a single reaction tube. The only requirements with regards to the DNA sequence are 1)
that it is cloned downstream of an RNA polymerase promoter sequence (T7, SP6 or
T3 for example), 2) that the DNA is linearised downstream of the sequence of interest
and 3) that the sequence contains an ATG translation initiation signal. The reaction is
set up to include the RNA polymerase of choice, purified rabbit reticulocyte
preparation, reaction buffer, amino acids (minus methionine ) and radio-labelled
methionine (35[S]-Met, Amersham). Reactions are incubated at 30°C for 90 minutes
and then an aliquot is loaded onto a SDS-PAGE gel and analysed to ascertain the
relative molecular weight of the protein product. The SDS-PAGE gel is dried and
exposed to photographic film (at -70°C) with dark bands indicating the position of
35[S]-Met-labelled reaction products. Figure 3.2 shows a schematic representation of
the in-vitro translation method.
Chapter 3 Materials andMethods 76
linearise plasmid DNA by
digestion with a restriction
endonuclease
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Figure 3.2 Cartoon representation of Promega's Coupled Rabbit Reticulocyte
in-vitro Translation System.
Plasmid vector containing the DNA sequence encoding a protein of interest is first linearised by
restriction digest and is then included in the reaction mix which transcribes RNA initiated from the
RNA polymerase promoter and subsequently translates this RNA into protein. The inclusion of radio-
labelled methionine in the amino acid (aa) mixture allows autoradiographic detection of the protein
products following SDS-PAGE analysis.
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3.20 Polyacrylamide gel electrophoresis in the
presence of sodium dodecyl sulphate (SDS-PAGE)
This method allows the estimation of the molecular weight of proteins as they are
electrophoresed in a denatured state in which structure and native charge bear no
influence. The proteins are denatured using a reducing agent such as (3-
mercaptoethanol, and the chaotropic detergent SDS which essentially forms a
negatively charged 'cage' around the protein. This results in an electrophoretic
migration pattern which is influenced only by the molecular weight of the protein.
Therefore, the size of proteins can be estimated by co-electrophoresis with proteins of
pre-determined sizes. SDS-PAGE can be used in the first stage of Western blot
analysis or simply as a method of analysis of protein products. The PAGE gel can be
fixed and stained by several different methods, or radio-labelled proteins can be used
to produce an autoradiographic record of migration patterns.
3.21 Rapid amplification of 5' cDNA ends (5' RACE)
Obtaining a full-length cDNA is of critical importance for structural and expression
studies. For analysis of promoter regions of genes it is essential to ascertain the exact
site of transcriptional initiation. This requires detecting the 5' (or upstream) sequence
of RNA which is required for efficient transcription. 5' RACE allows the
amplification of unknown sequences at the 5' end of the messenger RNA (mRNA).
The methodology of 5' RACE is outlined in Figure 3.3, and is based on the protocol
of the Boehringer Mannheim 573' RACE Kit.















PCR product ready for analysis by gel
electrophoresis, hybridisation or cloning
synthesis of first strand
cDNA with primer SP 1
degradation of the mRNA by
RNaseH activity of AMV
reverse transcriptase
tailing of the cDNA with
dATP and TdT
PCR amplification of the
tailed cDNA using the oligo
dT-anchor primer and a
nested SP 2 primer
second PCR with the PCR
primer anchor primer and a
nested SP 3 primer
Figure 3.3 Overview of 5' RACE
First strand cDNA is synthesised from total or poly(A)+ RNA using a sequence specific primer, SP 1,
using AMV reverse transcriptase and dNTP mix. The first strand cDNA is purified from
unincorporated nucleotides and primers, and a homopolymeric-adenosine tail is added to its 3' end
using the terminal transferase enzyme. A-tailed cDNA is then PCR amplified using a second sequence
specific primer, SP 2, and the oligo dT-anchor primer. The use of a second primer increases the
specificity of the reaction products, eliminating amplification of products arising from mispriming.
The obtained DNA is further amplified by a second PCR using a nested specific primer, SP 3 and the
PCR anchor primer. The 5' RACE products can be TA cloned for subsequent sequencing and
characterisation.
The size of the PCR band produced by 5' RACE should correspond to the length of
the sequence which exists in the mature RNA transcript, giving the exact position of
the transcriptional start site.
Chapter 3 Materials andMethods 79
3.22 Quantitation of promoter activity
In order to ascertain the regions of a promoter which have intrinsic
stimulatory/inhibitory affects on the levels of transcription within cells, methods using
reporter genes have been developed. The principle underlying all of these methods is
the same. Essentially, the sequence of interest is cloned in front of a reporter gene
within a plasmid vector which, unlike other mammalian expression vectors, has no
intrinsic promoter activity. The resulting plasmid construct is transfected and
expressed in host cells. The cells will only transcribe RNA from the reporter gene if
the cloned sequence contains transcription factor binding sites. The level of
transcription initiated by the experimental sequence is extrapolated from the level of
reporter activity by assay of reporter gene products.
One of the most sensitive and simple methods utilises the gene for luciferase as the
reporter. Promoter activity is measured as a function of the light emitted from
transfected cell extracts on addition of luciferin, the enzyme substrate.
3.22.1 Luciferase assay
The DNA sequences to be tested were cloned into the pGL3-Basic vector (Promega)
upstream of the luciferase gene. Cells were transiently transfected as previously
described, using 3|ig of DNA/60mm dish. 48 hours post-transfection cells were lysed
for 15 minutes in 400|ll of lx Reporter Lysis Buffer (Promega) and scraped from the
plates. The cell debris was pelleted by centrifugation in 1.5ml Eppendorf tubes. 20|il
of the supernatant was added to lOOpil of luciferase assay reagent (Promega) and the
light emission measured in a luminometer with an integration time of 60 seconds.
3.22.2 p-galactosidase assay
p-gal was used to correct for transfection efficiency when co-transfected with
luciferase vector constructs. Transfection with pSVP-gal, a vector which contains the
p-gal gene under the control of the SV40 promoter, allows for correction of inter-plate
variations in cell numbers. 3|ig of pSVp-gal was co-transfected with the pGL3
constructs in the promoter experiments. The luciferase cell lysis samples (50|il) were
used to assess |3-gal activity which is measured by adding 50jll of P-gal assay reagent
in a 96 well plate format (Promega) and measuring absorption at 540nm (OD540).
Luciferase activity was subsequently expressed as a function of P-galactosidase levels.
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3.23 Statistical analysis of experimental results
Where necessary, data was analysed for statistical significance using Student's t test in
the statistics programme Statview on an Apple Macintosh computer. Results were
deemed significant when p < 0.05.
The following chapters describe and discuss the results obtained using the
methodologies which have been described in this chapter. These techniques were
applied to the study of the hTRH-R in endocrine disease and in site-directed
mutagenesis experiments, and to the characterisation of the 5'-flanking and
untranslated region (UTR) of the mTRH-R gene.
Chapter 4
Structure of the TRH-R in human pituitary
adenomas
4.1 Introduction
Under physiological conditions hypothalamic thyrotrophin-releasing hormone (TRH)
stimulates the release of thyrotrophin (TSH) and prolactin (PRL) from pituitary
thyrotrophs and lactotrophs respectively (Kaplan et al, 1972). TRH exerts its effects
by binding to specific high-affinity receptors located on the surface membrane of target
cells. After the initial isolation of the murine cDNA for the TRH-R (Straub et al,
1990), the human TRH-R has recently been cloned (Duthie et al, 1993a; Hinuma et al,
1994; Yamada et al, 1993), confirming it to be a G-protein coupled receptor (GPCR),
and its gene mapped to chromosome 8q23 of the human genome (Morrison et al,
1994). The human TRH-R protein is encoded by a gene which has two exons,
separated by a single intron longer than lkb, which is found within the region of the
DNA sequence encoding the third cytoplasmic loop (Hinuma et al, 1994). The TRH-
R couples principally to the inositol phosphate second messenger pathway, and the
regulatory G-proteins associated with TRH-R signal transduction have been identified
as Gq and Gj j (Aragay et al, 1992; Hsieh and Martin, 1992)
TRH binding sites have previously been detected by classical radioligand-binding
techniques on PRL- and GH-secreting adenomas (Le Dafniet et al, 1985a; Le Dafniet
et al, 1985b) and non-functioning tumours (Le Dafniet et al, 1987). In approximately
half of patients with acromegaly TRH induces the release of GH (Irie and Tsutsima,
1972). This discordant GH response to TRH does not occur in healthy normal
individuals. Over 50% of patients with an apparently non-functional tumour secrete
LH(3 subunit in response to TRH (Daneshdoost et al, 1990). PRL responses to TRH
administration in patients with prolactinomas can vary (Snyder et al, 1974; Yovos et
al, 1981). Administration of TRH to patients with TSH-secreting adenomas causes
brisk TSH release in about one third of patients, the remainder are unresponsive
(Bevan et al, 1989). Therefore, a variety of abnormal hormone responses to TRH
have been described in patients with pituitary adenomas. However, controversy
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surrounds the existence of TRH binding sites in TSH-secreting adenoma cells.
Radioligand-binding techniques could not detect TRH-Rs from the cells of two TSH-
secreting tumours which were shown to be unresponsive to TRH (Chanson et al,
1988). Other reports however, describe a normal response to TRH by cultured
thyrotroph adenoma cells (Filetti et al, 1982), implying normal TRH-R function.
Figure 4.1 shows a schematic representation of the pathways involved in TRH-
induced responses from cells of the anterior pituitary gland. Figure 4.2 illustrates





Figure 4.1 Responses of thyrotrophs, lactotrophs and somatotrophs of the
anterior pituitary gland to TRH.
Thyrotrophs and lactotrophs respond to TRH under normal conditions whereas TRH induces
paradoxical GH secretion from somatotrophs in acromegalic states.
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Figure 4.2 PRL, TSH and GH responses to exogenous TRH in normal subjects
and in patients with pituitary adenomas/acromegaly.
(a) Patients with prolactinoma generally show no response to TRH. (b) Patients with GH-secreting
adenomas and resulting acromegaly exhibit a paradoxical TSH response after TRH challenge, (c)
Patients with TSH-secreting adenomas produce varying responses ranging from complete lack of
TRH-induced stimulation of TSH secretion to exaggerated TSH response.
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Despite the high incidence of pituitary tumours, the molecular mechanisms underlying
both cellular transformation and clonal expansion (Herman et al, 1990) in the majority
of these adenomas are poorly understood. Mutagenesis studies of various GPCRs
have shown that single amino acid substitutions and deletions can alter ligand binding
and signal transduction. Recent studies have identified mutations in human GPCR
genes as the causative factors in several diseases (Hirata et al, 1994; Pollack et al,
1994). These mutations invariably lead to either constitutive receptor activation or
receptor inactivation. No naturally occurring mutations have yet been ascribed to the
TRH-R, although an artificial mouse TRH-R construct with a truncated carboxy
terminal tail has resulted in a TRH-R which is constitutively active in both Xenopus
oocytes and AtT20 mammalian cells (Matus-Leibovitch et al, 1995)
The ability of TRH to stimulate the secretion of PRL and TSH from different pituitary
cell types under normal physiological conditions makes the pituitary TRH-R a
candidate for potential GPCR mutations associated with disease states. Thus,
oncogenic mutations of this receptor might be important in the aetiology of
prolactinomas and the less common TSH-secreting tumours. Additionally, the
paradoxical stimulatory effect of TRH on GH secretion in acromegaly and
glycoprotein subunits in non-functioning adenomas, makes the TRH-R a candidate for
involvement in the pathogenesis of these tumours. A mutant TRH-R could cause
excessive hormone output from dysregulated cells in vivo and may therefore be
involved in the unrestrained hormone secretion exhibited by certain types of pituitary
tumours.
Functional pituitary tumours expressing TSH, PRL or GH may respond to TRH by
either enhanced, blunted or paradoxical hormone release. Little however is understood
of the mechanisms regulating hormone release in these tumours. To assess whether
the TRH-R is involved in aberrant hormone secretion, the entire coding region of the
TRH-R gene from pituitary adenoma tissues was screened for somatic mutations. In
this study the objective was to determine the TRH-R structure in TSH-, PRL- and
GH-secreting adenomas as well as in non-functioning pituitary adenomas. Tissue
from fifty patients with pituitary adenomas (11 TSH-secreting, 15 PRL-secreting, 17
GH-secreting, and 7 non-functioning tumours) was screened using SSCP analysis of
PCR amplified TRH-R gene fragments from extracted genomic DNA. The PCR
products from tumour DNA were analysed in parallel with DNA derived from
matching lymphocytes.
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4.2 Materials and methods
4.2.1 Patients
Pituitary adenoma tissue samples were obtained at surgery from 50 patients with
pituitary adenoma (17 acromegaly, 15 prolactinoma, 11 TSH-secreting and 7 non¬
functioning adenoma) along with blood samples to provide lymphocyte DNA as
control sequence. Pituitary adenoma tissue samples were freshly obtained from 50
patients at surgery and subsequently stored at -70°C. In 45 of the 50 cases, patient's
peripheral blood samples (20ml) were collected in ethylenediaminetetraacetic acid
(EDTA)-coated tubes for subsequent lymphocyte separation. Genomic DNA was
extracted from adenoma (5-20mg) and lymphocyte samples (1.5ml) as described in
Section 3.7.2
All 50 tumours were diagnosed by standard clinical, imaging, immunocytochemical
and biochemical criteria. Details for the tumours used in this study are shown in Table
4.1.
Table 4.1 Details of the 50 patient tumours used in this study (following
page)
AC 1-17 - GH-secreting adenomas, TSH 1-11 - TSH-secreting adenomas, PRL 1-15 - prolactinomas,
NF 1-7 - non-functioning adenomas (NFPA). Immunohistochemical staining was scored on a relative
scale; +++, ++ and + representing high, medium and low levels of positive staining respectively; n.d.
- not done.
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Tumour No Sex Diagnosis Immunohistochemistry
ACl F Acromegaly GH+
AC2 F Acromegaly GH+/PRL+
AC3 F Acromegaly GH+
AC4 M Acromegaly GH+
AC5 F Acromegaly GH+
AC6 F Acromegaly GH+
AC7 M Acromegaly GH+
AC8 M Acromegaly GH+
AC9 F Acromegaly GH+
AC10 F Acromegaly GH+
ACl 1 F Acromegaly GH+
AC 12 F Acromegaly GH+
ACl 3 F Acromegaly GH+
AC 14 F Acromegaly GH+
AC 15 F Acromegaly GH+
AC16 M Acromegaly GH++/PRL+
AC 17 M Acromegaly GH+++
PRL1 M PRL-oma PRL+
PRL2 F PRL-oma PRL+
PRL3 F PRL-oma PRL+++
PRL4 F PRL-oma PRL++
PRL5 F PRL-oma PRL+
PRL6 F PRL-oma PRL+
PRL7 F PRL-oma PRL++
PRL8 F PRL-oma PRL+
PRL9 F PRL-oma PRL+++
PRL10 F PRL-oma PRL+
PRL11 F PRL-oma PRL+
PRL12 F PRL-oma PRL+
PRL13 F PRL-oma PRL+
PRL14 F PRL-oma >50% PRL+/>50% GH
PRL15 M PRL-oma PRL+
TSH1 F TSH-oma TSH+/GH+
TSH2 M TSH/GH-oma Thyrotrophs +++/GH minor
TSH3 F Thyrotoxic TSH++/GH+
TSH4 M Thyrotoxic TSH++/GH+
TSH5 F Thyrotoxic TSH++/GH+
TSH6 F TSH-oma TSH++
TSH7 F TSH-oma TSH+
TSH8 F TSH-oma TSH+
TSH9 M TSH-oma TSH++
TSH10 M TSH/GH-oma TSH+
TSH11 M TSH-oma TSH++
NF1 M NFPA gonadotrophic
NF2 F NFPA gonadotrophic
NF3 M NFPA gonadotrophic
NF4 M NFPA gonadotrophic
NF5 F NFPA nd
NF6 M NFPA nd
NF7 M NFPA nd
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4.2.2 Oligonucleotide PCR primer design and synthesis
The primers for PCR reactions were synthesised on a PCR MATE Model 391 DNA
Synthesiser (Applied Biosystems). Primer sequences (Table 4.2) were derived from
published receptor sequences (Duthie et al, 1993a; Hinuma et al, 1994), and were used
to amplify exon sequence from the flanking intron where necessary. The regions of
the hTRH-R amplified by each primer pair are represented in the schematic diagram of
the receptor gene structure shown in Figure 4.3.
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Table 4.2 Primers used to PCR amplify the coding region of the hTRH-R
Sequence of primer pairs 1-5 are given in the 5' to 3' orientation, those shown in upper case anneal to
the hTRH-R cDNA sequence (Duthie et al, 1993a). Primer sequences shown in lower case anneal to
intronic sequence (Matre, unpublished data). The lengths of the PCR bands produced by each of the
primer pairs is given in the right-most column.
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Figure 4.3 Regions of the hTRH-R amplified for PCR-SSCP analysis
Exons 1 and 2 and the single coding region intron of the hTRH-R are shown in relation to the deduced
transmembrane regions (I-VII) of the receptor structure. The sections of the hTRH-R gene amplified
using the primer pairs given in Table 4.2 are indicated by the numbered bars below the exon/intron
representation. The hTRH-R is encoded by two exons separated by a single intron (believed to be
>1000bp) in il 3 at amino acid position Val 264 (Figure 2.8).
4.2.3 PCR-SSCP analysis of TRH-R mutants generated by site-
directed mutagenesis
Mutations were generated in the rat TRH-R cDNA by the method of Kunkel (1985).
In one mutant (SSR260AAW), three bases were substituted from T to G, T to G and
A to T, and in two others single bases were substituted (R262W, A to C; K263N, G
to C). The region of the receptor containing the mutations was amplified with TRH-R
specific primers (upstream primer anneals at position 546-568,
5'GATCTCCAGGAATTACTACTCAC3'; downstream primer anneals at position
851-876, 5'CTCTAGTGGTTGTCAACTCATTTCTC3'; results in a 330bp PCR
fragment) and analysed by PCR-SSCP alongside wild type PCR products similarly
amplified. PCR-SSCP analysis of the cloned wild-type and mutant rat TRH-Rs was
performed to confirm the ability of this method to detect the subtle mobility shifts
caused by single base alterations in PCR fragments of a size comparable to those
analysed from patient-derived genomic DNA.
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4.2.4 PCR-SSCP analysis of TRH-R from genomic DNA
samples
PCR amplification was performed with 50ng of genomic DNA in a final volume of
10|il containing 2pmol of each 5' and 3' primer, lpl Taq buffer (GIBCO-BRL), O.lpl
of Taq DNA polymerase (GiBCO-BRL), 0.2 |il of lOmM dNTPs, MgCl2 to
concentration specified by primers, and 0. ljll a-32[P]-dCTP (Amersham). PCR
amplification was performed using an Omnigene Thermal Cycler (Hybaid) applying
the following parameters: an initial denaturation step at 94°C for 2 min, followed by
35 cycles of 94°C for 1 min, 52-60°C for 45 s, 72°C for 45 s, and then a final
extension cycle at 72°C for 5 min.
lpl of the labelled PCR product was diluted in 19pl of SSCP sample buffer (Appendix
I), heated for 3 min at 94°C and rapidly cooled on ice. 3-5pl of the denatured sample
was analysed by electrophoresis on 5% neutral polyacrylamide gels containing 10%
glycerol and 0.5x TBE. Gels were electrophoresed in 0.5x TBE at 250V overnight at
room temperature and then exposed to X-ray film (Kodak X-OMAT AR) at -70°C for
12-24 hours.
4.2.5 Cloning of PCR fragments and DNA sequencing
To confirm the results obtained by PCR-SSCP analysis, genomic DNA was PCR
amplified and subjected to DNA sequencing. In brief, unlabelled PCR reactions
(50(il) were run using the same ratios of components as for PCR-SSCP above. The
amplified product was then cloned into the pT7-Blue vector (Novagen) following the
manufacturer's protocol. Plasmid-containing clones were identified and grown up for
DNA isolation using Wizard™ miniprep purification system (Promega) according to
the manufacturer's instructions. Plasmid DNA was then cycle sequenced using
fluorescent dideoxy terminator chemistry as described in section 3.5. Sequence
analysis was performed using GeneJockey II DNA analysis software (Biosoft).
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4.3 Results
Table 4.2 shows the oligonucleotides used in this study. These sequences were
derived from the structure of the hTRH-R gene depicted in Figure 4.3. The hTRH-R
gene comprises at least two exons with the coding region of the receptor interrupted by
a single intron in the third cytoplasmic loop. Typical donor and acceptor consensus
sequences flank the splice site which is found in the codon for valine 264 at base pair
790 (Hinuma et al, 1994; Matre et al, 1993). PCR primer pairs 1 to 5 (Table 4.2)
were used to amplify the entire coding region of the hTRH-R. These primer pairs
PCR-amplified successfully from all genomic DNA samples, as shown by the
resolution of a single PCR band of the correct size on 1 % agarose gel electrophoresis
(not shown).
Figure 4.4 shows an autoradiograph of PCR-SSCP analysis of wild type TRH-R and
three mutant TRH-Rs generated by site-directed mutagenesis. The 330bp band
amplified from the plasmids containing the cDNA for the triple mutant (SSR260AAW)
and both of the single mutants (R262W and K263N) were detected by this method,
visualised as an electrophoretic shift in position of the bands when compared to wild
type sequence. This control experiment confirms that PCR-SSCP analysis is
sufficiently sensitive to detect single base alterations in PCR fragments at the
maximum end of the size range examined in this study.
Figure 4.4 PCR-SSCP analysis of rat TRH-R wild-type and mutant sequences
(following page)
Autoradiograph of SSCP-PCR analysis of cDNA from wild type rTRH-Rs and rTRH-Rs with point
mutations introduced by site-directed mutagenesis. Lanes 1 and 2 are wild-type sequence, lane 3 is
triple mutant SSR260AAW and lanes 4 and 5 are two different mutants with single base changes,
R262W and K263N, respectively. For base changes refer to Materials and Methods (this Chapter).
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As pituitary tumours are generally clonal in origin, disease related mutations would be
expected to be confined to the tumour tissue. PCR-SSCP analysis of the entire hTRH-
R coding region derived from the tumour DNA samples from 50 patients exhibited no
electrophoretic shifts as shown in the representative examples illustrated in Figure 4.5.
In 45 of the 50 patients, respective matched lymphocyte DNA samples were available.
This lymphocyte DNA served as normal controls and exhibited identical migration
patterns to the tumour DNA samples. This indicates that the TRH-R is structurally
normal in TSH-, PRL- and GH-secreting pituitary adenomas, and in non-functional
pituitary tumours.
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Figure 4.5 Representative examples of PCR-SSCP analysis of pituitary
adenoma DNA samples
Representative examples of PCR-SSCP analysis of tumour (T) and matching lymphocyte (L) DNA
derived from separate patients. TSH, GH, PRL and NFPA represent TSH-secreting, GH-secreting,
PRL-secreting and non-functioning pituitary adenomas respectively. The numbers in parentheses
indicate the set of primers used for PCR (see Table 4.2).
The PCR-SSCP results were confirmed by sequencing of the PCR fragments
amplified from 10 randomly selected tumours. Alignment of these DNA sequences
with the wild type human TRH-R sequence showed that there were no nucleotide
substitutions in any of the samples amplified from patient DNA (data not shown).
Sequencing of these DNA fragments confirmed the absence of a second intron in the
coding region which had been postulated to exist at nucleotide position 1177 in the
carboxy tail of the human TRH-R (Matre et al, 1993)
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4.5 Discussion
Compelling evidence suggests that pituitary adenomas arise from intrinsic pituitary cell
defects caused by spontaneous or induced somatic mutations (Faglia, 1993; Melmed,
1994) with the resulting neoplastic mass consisting of a body of clonally derived cells
(Herman et al, 1990). TRH has known stimulatory effects on lactotrophs, thyrotrophs
and under certain circumstances somatotrophs. In patients with pituitary adenomas
which secrete excessive amounts of either PRL, TSH or GH, a somatic mutation of
the TRH-R could be implicated in the pathogenesis of the disease. In this study of 50
different human pituitary tumours, the coding region of the TRH-R was found to be
unaltered, indicating that the TRH-R protein is likely to retain its normal structure in
the majority of these tumours. One possible explanation for the lack of observed
mutations could be that the PCR-SSCP method is not sufficiently sensitive. However,
the sensitivity of the PCR-SSCP analysis used in control experiments with known
TRH-R mutants was sufficient to detect single point mutations. Furthermore, DNA
sequencing confirmed the results obtained by PCR-SSCP. Another possibility is that
a defect might exist in non-coding portions of the receptor gene i.e. in the promoter
region, or in other regulatory intronic sequences, which have not yet been analysed.
Mutations in intronic sequence have been reported in isolated cases of hereditary
diseases (Cooper, 1992; Naylor et al, 1992) but have not yet been associated with
endocrine tumour formation. Increasing evidence does indicate though that most
disease-causing mutations associated with GPCRs occur in the coding region or at the
splice sites of receptor genes.
Several pathogenetic activating mutations in human GPCRs have been reported (Hirata
et al, 1994; Pollack et al, 1994; Rao et al, 1994). Activating mutations frequently
appear in the carboxy terminal region of il 3 of the GPCRs, an area that is believed to
be important for G-protein coupling. This is coincidentally the location of the single
intron in the coding region of the human TRH-R. This region of the TRH-R therefore
becomes increasingly important as a candidate site for receptor mutations. In the
present study it was therefore essential that the primers used to PCR the TRH-R splice
junction should amplify from within the intron so that none of the receptor sequence be
masked by primer sequence. The splice sites at both ends of this intron were therefore
extensively analysed in all tumour types, but were found to be unaltered.
In the presence of an apparently normal TRH-R, another possible explanation for
aberrant pituitary cell function is a post-receptor signal-transducing defect.
Mutation(s) could occur in the G-protein (Gq/Gi \ in the case of the TRH-R; Aragay et
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al, 1992; Hsieh and Martin, 1992) or other participants in the second messenger
signalling pathway. Somatic G-protein gene mutations have so far only been
identified in GH-secreting adenomas of somatotroph origin. There have been several
reports of activating mutations in the a-subunit of the adenylyl cyclase linked G-
protein, Gs. Known as gsp mutations, these are believed to occur in approximately
40% of GH-secreting pituitary adenomas (Landis et al, 1989; Spada et al, 1994). A
study by Dong and colleagues (1996) found no evidence of mutations in Gaq, Gaj i or
Gas from nine TSH-secreting tumours. This recent study also confirms the lack of
TRH-R mutations in TSH-secreting adenomas as described here. It is also possible
that chronic desensitisation and down-regulation of the TRH-R and/or its associated
G-proteins could be responsible for the lack of TRH responsiveness exhibited by
some TSH- and PRL-secreting tumours. Anderson et al. (1995) have shown that the
human TRH-R can be desensitised by TRH stimulation and in addition it has been
shown that the levels of Gq/Gi i are downregulated in the presence of TRH (Kim et al,
1994) both of which may be partly responsible for the reduced or absent response to
TRH exhibited by certain pituitary adenomas.
Despite the presence of high affinity binding sites for TRH, non-functioning pituitary
tumours show no TSH or PRL immunoreactivity. However, most of these tumours
have a few LH/FSH/ a-subunit positive cells and may respond to TRH (Daneshdoost
et al, 1990; Katznelson et al, 1993). These findings suggest that the TRH-R is not
stimulating the same intracellular response in non-functioning pituitary tumour cells as
it does in thyrotrophs. This could perhaps be the result of a TRH-R mutation allowing
the receptor to couple to an inappropriate intracellular signalling system. In this study
genomic DNA extracted from a series of non-secreting pituitary adenomas and
analysed by PCR-SSCP analysis did not show any abnormalities in the TRH-R from
non-functioning pituitary adenomas.
The dopamine type 2 (D2) receptor inhibits pituitary hormone secretion so it is feasible
that a loss of function mutation of this receptor could release pituitary tumour cells
from tonic inhibition resulting in a secretory pattern similar to that expected of an
activating mutation of a stimulatory GPCR. However, it has been shown that the D2
receptor retains normal structure in a range of pituitary adenomas including those
secreting PRL, TSH and GH (Friedman et al, 1994).
In conclusion, the TRH-R examined in a large number of human pituitary tumours
was found to possess an intact DNA coding sequence, indicating that this receptor is
not likely involved in the pathogenic transformation of anterior pituitary cells. Future
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studies to elucidate the role of possible defects in pituitary tumour signal transduction
pathways should probably be directed both at proteins involved in post-receptor events
as well as at the regulatory elements of these proteins.
Chapter 5
Naturally occurring inactivating mutations of the
human TRH-R
5.1 Introduction
Hypothyroidism is the result of functional failure at one of several points on the
hypothalamo-pituitary-thyroid axis (Fig 2.5). Deficiency of the thyroid gland itself
(primary hypothyroidism) is more common than both pituitary failure (secondary
hypothyroidism) and hypothalamic failure (tertiary hypothyroidism). Central
hypothyroidism is a very rare disorder, occurring in approximately 0.005% of the
general population (Martino et al, 1996) and resembles secondary hypothyroidism in
that there is no TSH response to exogenous TRH. However, central hypothyroidism
can be due either to pituitary diseases, leading to TSH deficiency, or to hypothalamic
diseases, leading to TRH deficiency (Emerson, 1985). Such problems result in
characteristic symptoms of insufficient bioactive TSH secretion and resultant
insufficiency of thyroid hormones. Central hypothyroidism is rarely isolated, being
most usually associated with other pituitary hormone abnormalities. Deficiencies
causing central hypothyroidism are known to result from tumours or infiltrative
diseases of the hypothalamo-pituitary area or to pituitary atrophy (Emerson, 1985). In
a few kindreds with isolated central hypothyroidism, inactivating mutations in the
TSH|3-subunit gene have been described (Dacou-Voutetakis et al, 1990; Hayashizaki
et al, 1990). Inactivating mutations of pituitary receptors for hypothalamic hormones
also are a plausible cause of hypopituitarism. Indeed, such mutations have recently
been reported for the growth hormone-releasing hormone receptor (Wajnrajch et al,
1996). It is possible therefore that inactivating mutation(s) of the TRH-R which
would result in blunted TSH (and PRL) response to TRH challenge may be involved
in the aetiology of this disease in some cases. To determine the role of the TRH-R in
central hypothyroidism we analysed the TRH-R gene from two patients with
conditions diagnosed as having isolated central hypothyroidism.
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5.2 Materials and methods
5.2.1 Patient 1
Patient 1, the first of two similarly affected male siblings of two unaffected parents,
was a 37 week gestation 71b 9oz baby of an unremarkable pregnancy, but suffered
from prolonged post-partum indirect hyperbilirubinaemia. Newborn screening
revealed an abnormally low T4 level of 30nmoles/litre which was still low in a repeat
test (36nmoles/litre). At this time TSH was measured at 14 mU/1 with a T3-
radioligand uptake (T3RU) of 35% (normal range 30-40%) but showed no other signs
of marked hypothyroidism. A TRH stimulation test revealed absent TSH and PRL
responses, whilst FSH and LH were within normal limits. A cranial CT scan did not
reveal any abnormalities. Thyroid hormone replacement (thyroxine) therapy (50
fig/day increasing to 62.5 pg/day) was initiated 8 days post-partum. T4 therapy
rapidly corrected hormone levels but at age 2 years thyroxine therapy was discontinued
which resulted in rapid fall in T4, TSH and T3RU values. Therapy was re-established
and maintained for a further 5 years after which time the mother withdrew thyroxine.
Within 2 months T4 had dropped to 60nmoles/litre, TSH was 6.9 mU/1, and T3 was
192nmoles/litre (normal 145-370nmoles/litre). Thyroxine therapy was again restarted
at 100 pg/day. When assessed at 10 years of age and whilst still taking thyroxine,
Patient l's T4 level was normal at 104nmoles/litre. At age 11 years (June 1995)
Patient 1 is clinically in early puberty with 5 cubic centimetre testes and Tanner II
pubic hair, suggesting no problem with gonadotrophin secretion. Until 10.5 years of
age Patient l's growth rate was within the 75 percentile, but at 12.5 years had dropped
into the 50 percentile. His weight has always been at or above, and is currently within
the 95 percentile. Patient 1 is doing well at school. Clinically there has been a long
term problem with constipation but Patient 1 does not suffer from any other chronic
complaints.
A younger sibling of Patient 1 also suffered from prolonged hyperbilirubinaemia after
birth and when tested was found to have low T4 (73nmoles/litre), inappropriately low
TSH (2.65 mU/1) and normal T3RU (31.2%) levels. At 24 days old thyroxine therapy
was initiated at 37.5 pg/day. Ten days later a TRH stimulation test failed to elicit any
TSH or PRL response. Magnetic resonance imaging of the head revealed no
abnormalities. FSH, LH and testosterone levels were normal (15 mU/ml, 9.1 mU/ml
and 127 ng/ml respectively). This sibling is a large child with length within the 75-90
percentile, but with a very high weight of 20 kg and a large head circumference of
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53.5 cm at 26 months of age. Development of speech and walking has been slow in
this infant, the latter most likely attributable to the obesity. Most recent thyroid tests
(whilst on 50(lg/day thyroxine) show T4 at 152nmoles/litre and a free T4 of
0.03nmoles/litre, both of which are at the high end of the normal range. Subsequent
assessment may indicate that the daily thyroxine dose be reduced in order to normalise
thyroid hormone levels.
5.2.2 Patient 2
Patient 2, the second of three sons born to nonconsanguineous Caucasian parents, was
referred for evaluation of short stature at 8.9 years of age. His clinical history was
unremarkable except for poor school performance. On examination, his height was
115.2 cm (-2.6 SD), his weight was 23.0 kg (-0.4 SD), and his heart rate was 64
beats per minute without others signs of hypothyroidism. The bone age was 4 years (-
4.1 SD). Plasma thyroxine (T4) was 52 nmoles per liter (normal, 60-150 nmoles/litre)
and TSH was 1.3 mU/1 (normal, 0.1-5.0; Table 5.1). Peak plasma growth hormone
response to clonidine and levodopa were 31.8 and 15.6 (ig per liter, respectively
(normal, >8). Baseline plasma prolactin was 6.2 fig per liter (normal, <15) and
intravenous TRH failed to induce a rise in either TSH or prolactin levels. On a
computerised tomographic scan, the pituitary volume was normal at 175 cubic mm
(Huot et al, 1989); on films of the abdomen, taken after the scan, a stippled right
femoral epiphysis was noted. A diagnosis of central hypothyroidism of unknown
cause was made. The patient was started on T4 at a daily dose of 50|lg.
Normalisation of plasma T4 levels (Table 5.1) was associated with an increase in heart
rate (to 100 beats per minute) and a slight and transient increase in height velocity
(from 4.8 to 7.3 cm per year). At 10.9 years, height velocity decreased again to 2.7
cm per year and the dose of T4 was increased to 75 fig per day. At 12.3 years, after
one month of T4 withdrawal, plasma T4 was 43nmoles/litre and TSH was 2.2 mU/1;
intravenous TRH failed again to release TSH and prolactin (Figure 5.1). At 11.9
years, his overall intellectual quotient (IQ) was evaluated with the Wechsler
Intelligence Scale for Children - Revised (Wechsler, 1974) at 92 (Verbal 79,
Performance 109). The testicular volume started to increase at 12.5 years, with
normal pubertal progression thereafter. The two brothers and the parents had no signs
or symptoms of hypothyroidism. The overall IQ of the elder brother at age 16 years
was 76 (Verbal 74, Performance 81), and that of the younger brother, at age 11 years,
was 89 (Verbal 86, Performance 93). After obtaining the consent of the parents and
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the assent of the brothers, basal thyroid function studies and a TRH test were
performed and gave normal results (Figure 5.3).
Plasma T4, triiodothyronine (T3) and TSH were measured on the AutoDelfia by time-
resolved immunofluorometric assays (Wallac). Thyroxine binding globulin (TBG)
and prolactin were measured by radioimmunoassays. The free T4 index was
calculated as the ratio of plasma T4 to TBG times 100. The TRH test was performed
as previously reported (Collu, 1977; Collu et al, 1977) using 7 jig per kilogram
(maximum 200 jig) of Relefact™.
5.2.3 Screening TRH-R genes for mutations
Genomic DNA was isolated from the peripheral blood of both patients as described in
section 3.7.2.
Patient 1 DNA was PCR-amplified and analysed by SSCP analysis as described in
Chapter 4.
For Patient 2 the entire coding region of the TRH-R was amplified by the polymerase
chain reaction and sequenced directly. Mutations were identified by sequence
alignment with wild type hTRH-R cDNA. New restriction sites created by each of the
two mutations was used to confirm the presence of the mutations and to identify family
members as carriers of the mutated alleles. PCR was performed under the same
conditions as previously described (Tang et al, 1995), except for the addition of
a32[P]-dATP. After amplification of genomic DNA of each family member, the PCR
products were digested with the appropriate enzymes and electrophoresed on a
polyaery lamide gel. The gel was dried and exposed overnight to an X-ray film. The
appearance of additional digested fragments indicated the presence of a mutation in one
of the two alleles.
5.2.4 Construction of wild-type and mutant TRH-R cDNA
expression vectors
Mutant TRH-Rs (maternally-derived, designated M-STOP and paternally-derived,
designated F-TM3) were constructed by removing Bgl II/Hind III fragments of the
mutant hTRH-R clones and ligating them into similarly digested wild-type hTRH-
R/pcDNA-3 expression construct. The entire sequence of the cloned receptors was
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verified and found to be identical to that of the published hTRH-R (Duthie et al, 1993a;
Yamada et al, 1993) except for the expected mutations in the mutant clones.
5.2.5 Functional studies of mutant TRH-Rs in a transient
expression system
HEK-293 and COS-1 cells were maintained as described in Section 3.14. Monolayer
cultures of either HEK-293 or COS-1 cells (1.2X106 cells per 60mm dish) were
transiently transfected with either the wild-type or the mutant human TRH-R cDNAs
(5pg per 60mm dish) using Transfectam™ (Promega) as described in Section 3.15.1.
Radioligand binding assays were performed with cell membranes as described in
Chapter 3. Sigmoid displacement curves were generated using Sigmaplot. All values
are means of triplicate determinations and the experiments were performed on at least
three independent occasions.
Total inositol phosphate accumulation assays were performed and results analysed as
described in Chapter 3.
5.2.6 In vitro translation
Receptor cDNA samples (lOpg) were linearised by digestion with Xba I, followed by
heat inactivation of the restriction endonuclease at 85°C for 15 min. 2(tg of the
linearised DNA was added to the translation reaction as described in Section 3.19 and
was transcribed by the addition of T7 RNA polymerase which transcribes from the T7
promoter site of pcDNA-3 and through the receptor coding sequence (Figure 3.1).
Following incubation 5(il of the translation reaction was added to 20pil of SDS sample
buffer (Appendix I) and run on a 12.5% SDS-PAGE gel at 100V overnight. The
resulting gel was treated as described in Section 3.19 and an autoradiographic image of
the gel produced using X-Omat AR film (Kodak) for 2-5 days at -70°C.
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5.3 Results
5.3.1 Tests of thyroid function (Patient 2)
The results of thyroid function tests of all Patient 2 family members are shown in
Table 5.1. Patient 2 was the only family member to have abnormally low plasma T4
and free T4 index values, but normal TSH levels when evaluated at age 8.9 years.
Retrospective verification of T4 and TSH values obtained at neonatal screening of two
days of age revealed that these anomalies were present since birth: T4 was 64 nmoles
per liter at neonatal screening (normal, > 88nmoles/litre), but the baby was not recalled
because his TSH concentration was 13 mU per liter (normal, <50). Treatment with T4
at 8.9 years of age resulted in normalisation of plasma T4 and free T4 index values;
these values returned to abnormally low levels one month after interruption of the
therapy. The intravenous administration of TRH failed to induce any rise in plasma
TSH and prolactin levels when the patient was tested after one month of T4 withdrawal
at 12.3 years of age (Figure 5.1). Similar results had been obtained before initiating
T4 treatment at 8.9 years of age, and also at 10.3 years of age one month after
stopping T4. Plasma TSH and prolactin levels rose after TRH administration in all the
other family members (Figure 5.1).
Table 5.1 Hormone levels of patient 2 and his family (following page)
Hormone levels for Patient 2 were measured before, during and after treatment. As comparison his
parents' and brothers' hormone levels were measured. The normal ranges for the measurements are
included for reference.
















8.9 None 52 1.8 9.1 1.3
9.1 50|i,g/day 121 3.2 17.1 0.3
11.6 75|0.g/day 116 2.4 16 <0.1
12.3 None for 1
month
43 1.2 6.7 2.2
Brother 1 15 None 96 1.8 0.9
Brother 3 10 None 96 2.0 0.9
Mother 37 None 133 2.3 0.4
Father 46 None 96 1.5 1.9
Normal Range 60-150 0.9-2.9 15-23 0.1-0.5
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Figure 5.1 TRH-induced responses of TSH and PRL of all Patient 2 family
members
Plasma TSH and PRL measurements after TRH injection at time zero minutes. All family members
except the affected son (Patient 2) exhibited normal TSH and PRL responses after administration of
200|ig TRH i.v. Patient 2= brother 2
Chapter 5 Naturally occurring inactivating mutations of the hTRH-R 104
5.3.2 DNA sequence analysis
Patient 1 DNA was found to carry normal TRH-R sequence suggesting that this
receptor is not involved in the aetiology of this case of central hypothyroidism. Figure
5.2 shows the PCR-SSCP results from Patient 1.
— •£ — — > s. ^
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Figure 5.2 PCR-SSCP analysis of the TRH-R from Patient 1
There were no apparent mobility shifts in the TRH-R fragments amplified from the DNA of Patient 1
(P) as compared to those amplified from the DNA from an unaffected individual (WT). The numbers
below the figures indicate the primer pairs used to amplify the individual segments of the hTRH-R
(Table 4.2)
In contrast Patient 2 was found to be a compound heterozygote, having inherited a
different mutated allele from each of the parents. Several germline mutations were
found in the patient's TRH-R-encoding DNA. Sequencing of 10 clones indicated that
the mutations were in different alleles. In one allele, a cytosine-to-thymosine (C to T)
mutation at nucleotide position 49 resulted in arginine (CGA) being substituted by a
premature stop codon (TGA) at amino acid position 17. In the other allele, a deletion
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of nine nucleotides from position 343 to 351, plus a mutation of guanine-to-adenine
(G to A) at position 352 were found. The deletion resulted in the loss of three amino
acid residues (Serll5, lie 116, Thrll7) at the cytoplasmic end of the third
transmembrane domain of the receptor. The mutation at position 352 resulted in the
replacement of alanine (GCC) by threonine (ACC) at amino acid position 118 (Figure
5.4). The presence of different mutations in each of the patient's alleles indicates that
he is a compound heterozygote. The mutation at position 349 generated a new
restriction site for the enzyme Nla III while the deletion plus mutation at positions 343-
352 created a new restriction site for the enzyme Rsa I. Family studies applying
restriction site enzymatic digestion to the respective parts of the gene traced each of the
mutant alleles to either one of the parents and provided evidence that the elder brother
of the proband had also inherited the mother's mutant allele (Figure 5.3). The
heterozygous state of each parent and of the elder brother was confirmed by the
presence of one normal allele. These results indicate that the patient and his elder
brother had inherited germline mutations. The location of the mutations in the
predicted topographical structure of the hTRH-R is shown in Figure 5.4. Mutation M-
STOP (maternal) was located within the extracellular amino tail and mutation F-TM3
(paternal) was located in TM III (Figure 5.4). No other mutations were found by
direct sequencing of the remainder of Patient 2's TRH-R DNA.
■>rO
Figure 5.3 Inheritance pattern of mutated alleles
Patient 2 (2*), one of 3 sons, inherited one defective allele from each parent. One son carried a WT
allele from his father and a mutant allele from his mother (1) and the third had inherited two wild type
(WT) alleles (3). Only possession of two defective genes results in symptomatic manifestation.
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Figure 5.4 Location of the inactivating hTRH-R mutations identified from
Patient 2
Amino acids are shown in the one letter code. The putative locations of the seven transmembrane
helix bundles are indicated as is the predicted disulphide-bridge between el 1 and el 3. The location of
the mutations identified are highlighted; M-STOP, maternal mutation; F-TM3, paternal mutation.
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5.3.3 Functional studies
The biological activity of the receptor constructs was examined by evaluating binding
of labelled TRH analogue and stimulation by TRH of total inositol phosphate
accumulation in transfected cells. Mutated TRH-R cDNAs were transfected into HEK-
293 cells for binding assays and into COS-1 cells for total inositol phosphate
accumulation assays. Radioligand displacement curves with (3Me-His2)-TRH and
membranes prepared from HEK-293 cells expressing wild-type and mutant TRH-Rs
M-STOP and F-TM3 are represented in Figure 5.5. The wild-type receptor exhibited
high affinity binding with an affinity constant (Kd) of approximately 1.6 nM (± 0.09
SEM), similar to that previously reported (Duthie et al, 1993a). In contrast, the
maternally-derived mutant (M-STOP) showed no measurable binding, while the
paternally-derived mutant (F-TM3) showed a very small amount of binding.
Untransfected HEK-293 cells did not demonstrate any binding (results not shown).
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Figure 5.5 Radioligand displacement assay results
Representative curves of displacement of ^H-[3Me-His2]-TRH binding by [3Me-His2]-TRH in
membrane preparations from HEK-293 cells transiently expressing wild type and mutant hTRH-Rs
(maternally-derived mutant M-STOP and paternally-derived mutant F-TM3). Data points represent the
mean (± SEM) of triplicate samples. Assays were performed on at least three independent occasions.
In accord with the binding assay results mutated receptors were as expected unable to
activate total inositol phosphate accumulation when transfected into COS-1 cells,
indicating that both of the mutated forms of the TRH-R are functionally inactive
(Figure 5.6). The EC50 value of total inositol phosphate stimulation by TRH for
COS-1 cells expressing the wild-type receptor was 2.4 nM (± 0.12 SEM). Sham
transfected COS-1 cells demonstrated no inositol phosphate response at any of the
TRH doses used.
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Figure 5.6 Total inositol phosphate production
TRH-induced total inositol phosphate accumulation in COS-1 cells transiently expressing wild type
and mutant hTRH-Rs (maternally-derived mutant M-STOP and paternally-derived mutant F-TM3).
Sham transfected COS-1 cells were used as a negative control. Data points represent the mean (± SD)
of duplicate samples. Assays were performed on at least three independent occasions.
In vitro translation was performed to ascertain the possibility of translation of a
truncated hTRH-R from the second methionine in the receptor sequence, Met75 (in
TM I), even from the DNA encoding M-STOP (Figure 5.4). Figure 5.7 shows an
autoradiograph of an in vitro translation experiment. In Figure 5.7 the protein
products appear as dark bands on the gel. The predicted molecular weight of the
unglycosylated, full length hTRH-R is 45kDa, which is reduced to 40kDa if translated
from Met75 instead of the initiation codon for Met 1. The 40kDa band is visible in all
three lanes but the full length hTRH-R only appears in the lanes representing
translation products from cDNAs without a premature stop codon (namely WT and F-
TM3). The smaller molecular weight band is the only specific protein translated from
the M-STOP construct. There were no translation products in the reaction which was
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performed with no added DNA (not shown), indicating the specificity of the
production of the bands which are visible.
Figure 5.7 In-vitro translation of WT, M-STOP and F-TM3 receptor cDNAs
(following page)
Protein products arising from in vitro translation of WT hTRH-R (WT lane), M-STOP and F-TM3
DNA appear as dark bands on the autoradiograph. The 45kDa full length product is only produced
from WT and F-TM3 cDNAs, whereas the shorter 40kDa band translated from Met 75 is visible in all
three lanes.
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5.4 Discussion
The TRH-R is a member of the large family of G protein-coupled, seven
transmembrane domain receptors (Straub et al, 1990). The hTRH-R has recently been
cloned and its structure and functionality have been found to be similar to that of the rat
and mouse receptors (Duthie et al, 1993a; Hinuma et al, 1994; Yamada et al, 1993).
Receptor-mediated stimulation of the synthesis and release of TSH and PRL is exerted
through activation of the inositol phosphate-calcium-protein kinase C signal
transduction pathway (Gershengorn, 1989). The third transmembrane helix is an
essential constituent of the TRH-R binding pocket (Perlman et al, 1994b). In this
study of two patients with outwardly similar clinical symptoms, one (Patient 2) was
found to confirm the hypothesis that inactivating mutation of the TRH-R could be
responsible for human disease whereas Patient 1 carried apparently normal TRH-R
genes (at least within the coding region). Although Patient l's TRH-R genes were
normal, Patient 2 was found to be a compound heterozygote, having inherited a
different mutation in the TRH-R gene from each parent. The presence of a stop codon
at amino acid position 17 in the mutated maternal allele (M-STOP) presumably results
in a truncated protein, missing all seven transmembrane domains. On the other hand,
deletion of three amino acids and substitution of alanine by threonine in the mutated
paternal allele (F-TM3) may result in alteration of the tertiary structure of the third
transmembrane helix, so disrupting normal receptor function. Both mutated receptors,
when expressed in eukaryotic cells, resulted in severely reduced or absent TRH
binding and TRH-induced inositol phosphate accumulation confirming the role of the
mutant TRH-Rs in the pathophysiology of this patient's central hypothyroidism. The
results suggest that the mutant TRH-Rs have essentially absent biological activity
which explains the observed failure of this patient to elicit a rise in either TSH or PRL
following the administration of TRH. The mutations are recessive and therefore, both
mutations must be present for symptoms to be observed, as both parents had normal
thyroid function, as did the sibling who also carried the mutated maternal allele. This
case provides an opportunity to study the effect of isolated TRH insensitivity in the
brain and elsewhere in the absence of compounding effects arising from deficiencies of
other hypothalamic or pituitary hormones which often accompany central
hypothyroidism. It would be interesting to assess both the glycosylation status of the
TSH present in Patient 2's serum, and the profile of any TSH secretion with regards to
the presence/absence of the nocturnal TSH surge observed in euthyroid subjects.
However, the ethics of performing such studies, which are not clinically indicated,
particularly in this patient who is at present only 15 years old, must be considered.
Chapter 5 Naturally occurring inactivating mutations of the hTRH-R 113
Although naturally occurring activating or inactivating mutations of G protein-coupled
receptors linked to other intracellular signalling systems have been reported (Pearce
and Trump, 1995) to the author's knowledge this is the first description of naturally
occurring inactivating mutations of a GPCR linked to the PLC second messenger
pathway. This is also only the second report of a defect in a pituitary gland receptor.
In addition, identification of the receptor mutations from Patient 2 expands the range of
molecular defects within the thyroid axis, which already includes defects in TSH(3, the
TSH-R, thyroid hormone synthesis and thyroid hormone insensitivity, to include
defects in the TRH-R. Central hypothyroidism, defined as low plasma total and free
T4 concentrations in the presence of normal TSH values, is rare. It may result from
either hypothalamic or pituitary lesions and usually occurs in association with other
pituitary hormone deficiencies (Emerson, 1985). The clinical manifestations of central
hypothyroidism are usually mild, especially when it is isolated (Martino et al, 1996).
Indeed, in Patient 2, the only presenting symptoms were short stature with markedly
delayed bone maturation, which shows the exquisite sensitivity of these markers of
hypothyroidism in children (Rose, 1995). Substitution therapy with T4 did increase
height velocity and there was a catch-up in bone maturation; however, the growth
acceleration during treatment was modest and temporary. Furthermore, although the
patient had cognitive deficiencies, his two unaffected brothers had similar learning
difficulties and low IQs. Extrapituitary expression of the TRH-R has been reported,
suggesting that TRH may have non-endocrine functions (Collu et al, 1980). The
reasons as to why the TRH-R mutations do not appear to cause dysfunction in any of
the extrahypothalamic systems believed to be influenced by TRH (Section 2.2.7)
remain unclear at this time. This patient appears to represent a naturally occurring
TRH-R knock-out, the result of which was previously predicted to be lethal in utero as
a consequence of the possible widespread functions of TRH outside of the pituitary
gland. If TRH is indeed involved in foetal development it would appear that the almost
negligible binding of mutant F-TM3, whilst insufficient to maintain mature thyroid
function, may be adequate to permit normal foetal development. In addition the in vitro
translation experiment seems to indicate that low levels of a truncated receptor may be
translated from the alternative Met75 in TM I. Whether this peptide would express as
a functional receptor is unknown. Interestingly, it has recently been shown that a
TRH-R missing the entire amino tail binds ligand with wild type characteristics (Han
and Tashjian, 1995). It is therefore conceivable that an amino terminally truncated
receptor could be responsible for the non-lethality of this apparent TRH-R knockout,
providing enough receptor activity to allow almost normal TRH function. The
prevalence and phenotypic spectrum of TRH-R mutations in isolated central
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hypothyroidism as well as in other related diseases remain to be established. In light
of the recent description of the hTRH-R promoter region (Iwasaki et al, 1996) it would
be informative to screen this region of the receptor in Patient 1 for mutations which
may interfere with either the initiation or control of transcription as non-expression of
the TRH-R could explain the lack of responsiveness to TRH in this patient.
In order to investigate the effects of TRH-R knock-out it would be useful to establish a
transgenic mouse line with targeted receptor ablation. In preparation for this project it
will be necessary to identify and characterise the promoter elements of the mTRH-R
gene. The approaches and experimental design of such an undertaking are described
in Chapter 7 of this thesis.
Chapter 6
Site-directed mutagenesis and expression studies
of the hTRH-R
6.1 Introduction
The intracellular domains of GPCRs contain regions which on ligand binding are
believed to undergo conformational changes permitting G-protein coupling, and which
may be phosphorylated conferring receptor regulation. Unlike the transmembrane
domains of GPCRs, there is no model of 3-dimensional structure for the cytoplasmic
regions, so predictions concerning structure-function relationships are more difficult to
make. The most useful tool is comparison of different GPCRs in an attempt to
identify conserved amino acids as these are likely to be of functional significance.
Based on such comparisons it is possible to carry out site-specific mutagenesis of any
given amino acid or group of amino acids of a GPCR and to examine the effects of
mutation(s) on in vitro receptor function. The results of such experiments allow the
extrapolation of predicted relationships between specific amino acids and receptor
function. Several regions of the internal, or intracellular domains of GPCRs have
been identified as being involved in coupling to G-proteins, receptor phosphorylation,
regulation and internalisation.
A conserved region at the junction between TM III and il 2, known as the AspArgTyr
or DRY motif, has been linked with mediation of receptor activation. Several GPCRs
have a conserved substitution of Glu at the Asp position of the DRY motif. Spectral
studies of rhodopsin show that movements in this region of the molecule occur upon
photoactivation (Farahbakhsh et al, 1995). Indeed Glul34, of the DRY motif of
rhodopsin appears to undergo proton uptake immediately upon retinal isomerisation
(Amis et al, 1994). Substitution of Glu 134 for Gin results in low level constitutive
activity and enhanced light-dependent responses (Amis et al, 1994; Cohen et al,
1993). Scheer and co-workers (1996) suggest that protonation of the equivalent
residue of the aiB-adrenergic receptor, Asp 142, alters the equilibrium between the
inactive and active receptor states and replacement of this residue with Ala leads to
high constitutive receptor activity. In addition, this study finds that disruption of the
molecular interactions between Argl43 and nearby residues displaces Argl43 from its
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'polar pocket' thereby activating the photoreceptor. Both the Asp (or Glu) and the Arg
of this conserved motif appear to be fundamental for mediating receptor activation.
The TRH-R has Glu instead of Asp at this intracellular location.
Site-directed mutagenesis studies of several GPCRs have indicated that coupling to
specific G-proteins seems to be predominantly mediated by sequences within il 3, in
particular, those regions at the membrane interface. Mutation of Ala293 (in il 3) of the
ocib-AR, which lies 3 amino acids from the cell membrane, to any other amino acid,
results in agonist-independent, or constitutive, receptor activity (Kjelsberg et al,
1992).
In this study the functional roles of two specific amino acids of the hTRH-R were
studied by measuring ligand binding and effector activation in cells transfected with
mutant hTRH-Rs. Two specific residues were chosen for study:
1. Thr265 (in il 3) was highlighted for two reasons. Firstly, the analogous Thr
residue (Thr373) in the (^-adrenergic receptor when mutated results in
constitutive activity (Ren et al, 1993) and secondly, Thr265 is a potential
phosphorylation site which may be involved in receptor
activation/desensitisation.
2. Glu 122 was studied as it is part of the DRY motif which has previously been
implicated in GPCR function.
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Figure 6.1 Primary structure of the hTRH-R
This diagram shows the primary sequence of the hTRH-R and the proposed arrangement of the seven
transmembrane helices and the extra- and intracellular domains. Amino acids are shown in the single
letter code. The mutated residues are highlighted in blue (Glul22) and magenta (Thr265), and the
substitutions are indicated by the letters at the ends of the arrows.
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6.2 Materials and methods
Site-directed mutagenesis was carried out as described in Section 3.13.
Oligonucleotides were synthesised using a PCR MATE Model 391 DNA Synthesiser
(Applied Biosystems) based on the wild type sequence of the hTRH-R. Single
nucleotide base changes resulted in amino acid substitutions generating the receptor
constructs outlined in Table 6.1. The sequences of the oligonucleotides used to
generate these mutant TRH-Rs are also shown in Table 6.1.
Thr265 was mutated to one of three different amino acids; Ser (conservative change
which retains the hydroxyl side chain), Ala (moderate change) and Asn (large change
of side chain charge). Glul22 was substituted for one of two amino acids; Asp
(reverts receptor to DRY consensus sequence) or Leu (large alteration in side chain).
Receptor expression in mammalian cells, radioligand binding assays and total inositol
phosphate accumulation assays, were performed as described in Chapter 3.
Table 6.1 Oligonucleotides used to generate site-specific mutant hTRH-Rs
(following page)
Mutant hTRH-R constructs generated by site-directed mutagenesis using the oligonucleotides described
to alter specific amino acids within the receptor peptide. Thr265 lies at the membrane proximal
region of the carboxy end of the third intracellular loop (the oligonucleotide spans from 801 to 825).
Glul22 is located at the amino end of the second intracellular loop and is found within the DRY motif
(the oligonucleotide spans from 372 to 396). As the single-strand DNA isolated from pcDNA-3 is
synthesised in the forward orientation, the sequences shown were inverted for oligonucleotide synthesis
to allow annealing of the oligonucleotide primer to the single-strand DNA.
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Construct Oligonucleotide Sequence Amino acid change
Wild Type 801ggaagcaggtcaccaaaatgctggc825 none
T265A ggaagcaggtcgccaagatgctggc Thr265 to Ala
T265S ggaagcaggtctccaagatgctggc Thr265 to Ser










The rTRH-R was used as a positive control in the transfection experiments.
Throughout the expression experiments it became obvious that the hTRH-R expressed
at a much lower level in comparison with the rTRH-R. In order to carry out
experiments comparing expression levels, different TRH-R constructs were generated.
The coding regions (i.e. from ATG start codon to AGT stop codon) of the rat and
human TRH-Rs were PCR amplified, ligated into the TA vector pcR2.1, and then
subcloned into the Eco RI site of the pcDNA-3 polylinker. These 'start-stop' (s-s)
clones were expressed in COS-1 cells for comparison of function with the WT cDNA
clones which were expressed with intact 5' and 3' UTRs.
Additionally, a stable cell line was established in which the hTRH-R was expressed in
HEK-293 cells as described in Section 3.15.2. Resulting stable cell lines were
assayed for TRH-induced changes in the concentration of intracellular calcium
([Ca2+]j) using calcium imaging (Section 3.17). The newly established hTRH-R-
expressing cell line was compared with the 293-E2 cell line which is a stable line
expressing the rTRH-R (established by Dr Jelka Zabavnik; (Kim et al, 1994)).
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6.3 Results
6.3.1 Thr265 mutants compared to WT hTRH-R
Substitution of Thr265 with either one of the three amino acids chosen here (Ala, Thr
or Asn) results in increased hTRH-R expression levels. Radioligand binding
measurements were carried out using the same amount of membranes of WT and
mutant expressing cells, however the level of binding was approximately three to six
times greater in the mutants. The Bmax value was O.lpmol/mg protein for the WT
hTRH-R and was significantly increased to 0.66 (p<0.05, n=3), 0.34 (p<0.02, n=3)
and 0.32 (p<0.02, n=3) pmol/mg protein for mutants T265A, T265S and T265N
respectively (Table 6.2). These three mutant TRH-Rs had increased affinity for ligand
as compared to that of the WT hTRH-R. The dissociation constant (Kd) was 5.43nM
(± 0.6 SEM) for the WT hTRH-R and 1.38 (± 0.15 SEM), 2.17 (± 0.05 SEM), and
1.98nM (± 0.07 SEM) for mutant receptors T265A, T265S and T265N respectively
(Figure 6.2a and Table 6.2). The reduced Kd values for the mutant hTRH-Rs were
significantly lower than the Kd of the WT receptor with p<0.02 from 3 separate
experiments. Similarly, in the IP assays, although basal levels of second messenger
turnover were not significantly altered by these mutant receptors, maximum
stimulation was higher compared to WT (Figure 6.2b). The EC50 of total inositol
phosphate stimulation was reduced from 4.0nM (± 0.45 SEM) for the WT hTRH-R to
l.OnM (± 0.02 SEM) for each of the Thr265 mutant receptors (significant with
p<0.05, n=3), indicating that these receptors can be activated at a lower ligand
concentration compared to wild type hTRH-R. COS-1 cells alone showed no
measurable level of ligand binding or inositol phosphate stimulation.
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Figure 6.2 Functional determinations of Thr265 mutations of the hTRH-R
(following page)
Thr265 was substituted with one of three different amino acids (Ala, Ser or Asn) producing the
constructs T265A, T265S and T265N. Each of these mutant receptors was transiently expressed in
COS-1 cells along side WT hTRH-R. Cells from a single transfection were used for both radioligand
displacement assays and total inositol phosphate accumulation assays, a) Scatchard displacement plots
(which plot bound ligand versus bound/free ligand) were derived from a competition radioligand
binding displacement experiment using [3H](3Me-His2-TRH) tracer. Data points are the mean of
triplicate samples ±SEM, and are representative of at least three independent experiments, b) shows
the TRH-induced total inositol phosphate production in cells from the same transfection as used in the
binding assay above. Results are shown as the mean of triplicate determinations +SEM.
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6.3.2 Glul22 mutants compared to WT hTRH-R
The mutant receptor carrying the Glul22 to Asp substitution (E122D) exhibited a
reduced EC50 value (0.5nM ± 0.03) as compared to TRH-induced total IP stimulation
by the WT TRH-R (4.0nM ± 0.45 SEM; p<0.05, n=3). Mutant E122D also showed a
reduced dissociation constant (calculated using the adapted Cheng and Prusoff
equation described in Section 3.18.4) compared to the WT hTRH-R (WT hTRH-R
Kd=5.43nM compared to 0.46nM for mutant E122D; p<0.05, n=3), indicating a
relative increase in ligand affinity for mutant E122D. Substitution ofGlul22 with Leu
(E122L) totally abolished binding and was therefore unable to stimulate IP
accumulation (Figure 6.3). Radioligand binding and IP assay results for Glul22
mutants are summarised in Table 6.2.
Figure 6.3 Functional analysis of Glul22 mutants of the hTRH-R (following
page)
a) shows the results of a radioligand displacement binding experiment using [3H](3Me-His2-TRH) and
membranes prepared from COS-1 cells transiently expressing WT and mutant hTRH-Rs (E122D and
E122L). The data points represent the mean of triplicate samples and the graph is representative of at
least three separate experiments, b) shows the total inositol phosphate accumulation induced by
varying concentrations of TRH in COS-1 cells from the same transfection as those used for the
radioligand binding assay above.
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6.3.3 Comparison of rat and human TRH-R expression
In order to establish an hypothesis regarding the difference in expression levels
between the rat and human TRH-Rs, several receptor constructs were generated.
Essentially, the receptors were expressed either from full length constructs for WT
determinations, that is with 5' and 3' untranslated regions (UTR) intact, or were
expressed from clones without any UTR (designated 'start-stop' or s-s clones). The
WT TRH-Rs-s forms of the rat and human TRH-Rs expressed at lower levels than did
their respective full length clones with untranslated regions intact as measured by
accumulation of TRH-induced total inositol phosphate. However, rTRH-Rs-s still
expressed much more highly than both the intact and s-s hTRH-R cDNAs. In fact,
there was a convincing gradation of IP stimulation with intact rTRH-R producing the
highest IP response, with rTRH-Rs-s next, the intact hTRH-R next, and the hTRH-
Rs-s having the lowest IP stimulatory effect of all four constructs (Figure 6.4).
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Figure 6.4 Comparison of total TRH-induced inositol phosphate production in
COS-1 cells transiently transfected with WT and start-stop versions
of the rat and human TRH-Rs
COS-1 cells transiently expressing the full length WT cDNAs for the rTRH-R and hTRH-R
containing intact 3' and 5' UTRs were assayed alongside cells expressing the 'start-stop' (s-s) forms of
the receptor constructs. The results are the mean of samples performed in triplicate (+SEM). The
upper inset graph shows the full length and s-s hTRH-Rs separately to indicate that these constructs
when expressed in COS-1 cells retain TRH-induced dose dependent total inositol phosphate
production.
Table 6.2 summarises the functional parameters of each of the mutant TRH-R
constructs discussed above.
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WT hTRH-R 5.43 ± 0.6 0.1 ± 0.05 4.0 ± 0.45
T265A 1.38 ± 0.15 0.66 ± 0.02 1.0 ± 0.02
T265S 2.17 ± 0.05 0.34 ± 0.05 1.0 ± 0.01
T265N 1.98 ± 0.07 0.32 ± 0.05 1.0 ± 0.01
E122L no binding not detected no stimulation
E122D 0.46 ± 0.03 0.30± 0.03a 0.5 ± 0.03
WT hTRH-R s-s n.d. n.d. 3.5 ± 0.3
WT rTRH-R 2.73 ± 0.68§ n.d. 0.6 ± 0.04
WT rTRH-R s-s n.d. n.d. 3.0 ± 0.2
Table 6.2 Functional measurements of each TRH-R construct.
K(j values were determined either from Scatchard analysis or from the Cheng and Prusoff equation
(DeBlasi et at, 1989). § previously determined (Cook et al, 1996). a was calculated using Cheng and
Prusoff analysis (see Section 3.18.4). n.d.= not done.
6.3.4 Calcium imaging of rat and human TRH-R stable cell lines
Single cells expressing the rat and hTRH-Rs were assessed using the technique of
calcium imaging which allows visualisation of ligand-induced changes in intracellular
calcium ([Ca2+]i) as it is released from intracellular stores. Figure 6.5 shows traces of
changes in [Ca2+]i levels in human (293-hlO, 6a) and rat (293-E2, 6b) TRH-R stable
cell lines. TRH (l|lM) induces a rapid increase in [Ca2+]i levels. A second pulse of
TRH has no effect on [Ca2+]j. Bradykinin (BK) acts through a specific receptor (BK-
R) to mobilise intracellular calcium. The BK-R is endogenously expressed in kidney
derived HEK-293 cells (Van Zoelen et al, 1994) and was used in comparison with the
TRH-R to assess the characteristics of homologous versus heterologous
desensitisation of the two receptors. However, BK was a poor stimulator of calcium
changes in these cells, and the spikes observed following addition of BK were often
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small. High-dose TRH desensitised both subsequent Ca2+ responses to TRH and
BK, whereas pre-treatment with BK desensitised only the BK-induced Ca2+ response.
The mobilisation of intracellular Ca2+ may negatively control PLC activity
(Stauderman and Pruss, 1990), and therefore, the lack of BK-induced Ca2+ response
following TRH pretreatment may be attributable to this negative feedback control at the
level of PLC activity, especially in view of the high level of intracellular Ca2 +
mobilised in the rat or human TRH-R stable cell lines. Although the hTRH-R has
shown lower expression levels as compared to the rTRH-R in the transient expression
experiments, the level of TRH-induced Ca2+ responses were not statistically different
between the stable cell lines 293-hlO and 293-E2 (p<0.04, n=6).
These experiments were carried out at early passage stages of clone 293-hlO (passage
4-6). Unfortunately, by passage 8-10 hTRH-R expression was lost, despite
maintenance of the cell line in Geneticin™ containing medium. All clones which were
isolated and characterised showed similar loss of TRH-R function whilst surviving in
the selective growth medium.
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Figure 6.5 Calcium imaging of 293-hlO and 293-E2 stable cell lines
Stably expressing cells were plated onto glass coverslips and were imaged as described in Section
3.17. TRH (lpM) and BK were added to the incubation buffer at the times indicated by the arrows,
a) represents the results obtained from 293-hlO cells and b) represents the results from 293-E2 cells.
The results are the average of at least six individual cells from one field of imaged cells.
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6.4 Discussion
On the basis of previous studies of the (3-adrenergic receptor it was hypothesised that
mutation of Thr265 of the hTRH-R would result in constitutive activity of the receptor.
The Bmax values showed that all three of the Thr265 mutants expressed at a much
higher level than the WT receptor (Table 6.2), between three and six times greater than
WT in fact. The basal levels of IP turnover were not increased as is often
characteristic of constitutively active receptors, although these mutants reached half
maximum stimulation at a lower TRH concentration than the wild type, indicating that
the EC50 was reduced. The EC50 for IP stimulation in the Thr265 mutant TRH-Rs
was reduced 5-fold in comparison to the WT hTRH-R. The binding affinity of each of
the Thr265 mutants was increased in comparison to the wild type binding affinity,
which is a phenomenon also observed in other cases of constitutively active GPCRs
(Lefkowitz et al, 1993). The result of increased affinity in the presence of increased
ability to stimulate phosphoinositide hydrolysis is probably a result of the increased
number of mutant receptors expressed at the cell membrane, rather than being due to
ligand-independent, or constitutive activation. Why such mutations result in increased
expression is not known, however this is an interesting finding deserving further
investigation.
Substitution of Glul22 for Asp resulted in a mutant TRH-R with increased binding
affinity, and reduced EC50 of total IP stimulation as compared to the wild type hTRH-
R. This alteration in apparent receptor function may be due either to a change in the
expression level of the mutant receptor or to altered receptor function. Substitution of
Glu by Asp is a relatively conservative change and probably allows the receptor to
retain near normal structure thereby not altering function to any great extent. In
contrast substituting this same Glu residue with Leu produces a mutant receptor which
shows no ligand binding or agonist-induced IP accumulation. It is often possible to
detect low level cell surface expression of GPCRs by increasing the concentration of
ligand used in IP stimulation assays into the pM range. If there are any receptors
present they should bind ligand and elicit a measurable IP response. Indeed, in a
study of the role of disulphide bond formation between cysteine residues of the rTRH-
R it was found that a mutant receptor which was not stimulated by this IP 'push'
method also showed no expression by Western blotting of epitope-tagged mutant
receptor, whereas other non-binding mutants responded to high level TRH doses and
were demonstrable in the cell membrane (Cook et al, 1996). It is unlikely therefore,
that mutant E122L is expressed at the cell membrane as no IP production was
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measurable even at very high (lOOpM) TRH concentrations. Construction of an
epitope-tagged version of this mutant receptor would enable the cell surface
expression, or lack thereof, to be measured. Personal communication with Professor
G Milligan (Department of Pharmacology, University of Glasgow, UK) suggested
that the E122L substitution would result in constitutive receptor activity, in analogy to
a D to L substitution in another GPCR with a conserved DRY motif. The loss of
function of mutant E122L whilst unexpected is not totally inexplicable. The change
from Glu to Leu is a relatively drastic one, with Leu being very much more
hydrophobic than Glu. However, this type of substitution is not without precedent as
substitution of a single residue in the a2-adrenergic receptor with any other amino acid
resulted in constitutively active receptors and there was no apparent correlation
between the change in side group and the degree of ligand independent activity (Ren et
al, 1993). Substitution of Glu 122 for Leu could potentially alter the 3-dimensional
structure of the receptor in this region, thereby destroying either normal membrane
insertion or receptor functionality.
The combined results of the site-directed mutagenesis of the hTRH-R highlight both
the sensitivity of certain regions of GPCRs to mutation and the effects that the choice
of substitution can have. Although Thr265 was substituted with a very dissimilar
amino acid, Asn, the effects were indistinguishable to those caused by only slight
alteration in the amino acid (i.e. T265S), assuming that the hydroxyl group is involved
in phosphorylation of this residue of the receptor. This site of the receptor is therefore
sensitive to any change. As this region may be involved in the processes of either
desensitisation and/or receptor internalisation this is not a surprising finding as the
alterations occurring during these processes (e.g. phosphorylation) are highly specific
and are also likely to be relatively subtle. Future studies would include investigation
of the pattern of desensitisation of this mutant, again using an epitope-tagged construct
so that receptor endocytosis (including agonist-induced receptor internalisation and
receptor recycling) could be monitored.
Our experience of hTRH-R expression studies indicated that this receptor has a
variable expression level which is consistently lower than that seen with the rTRH-R.
Other groups have experienced difficulty in expressing their hTRH-R clones (personal
communication with Dr R Collu). Using the rTRH-R as a positive control for
confirmation of receptor expression throughout the experiments highlighted this
phenomenon. When comparing receptor sequences at the DNA level, the major
difference between the rat and human TRH-R clones is in the amount of untranslated
region (UTR), with the rTRH-R clone (Sellar et al, 1993) having substantially more
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UTR sequence than the hTRH-R clone (Duthie et al, 1993a) and changes in the 3'
region encoding the carboxy tails of these related receptors. The hTRH-R cDNA clone
has only 19 bp of 5' UTR, whereas the rat has 340 bp of 5' UTR. At the 3' end of the
human clone there are 130 bp of UTR and the rat has 1800 bp UTR. The rat 3' UTR
contains a polyA+ tail, whereas in the hTRH-R clone this RNA stability region is
absent from the 3' UTR . The absence of a polyA+ tail should not affect expression
levels as the expression vector pcDNA-3 encodes the bovine polyadenylation signal
and therefore adds this sequence to transcripts synthesised from the expression vector.
It has been suggested that there are often AU rich elements (AREs) within the 3' UTR
which confer RNA instability. The mRNA molecules containing the AREs are
believed to be targeted for rapid and selective degradation, in particular, systematic
removal of the polyA+ tail. The rTRH-R 3' UTR contains single AUUUA sequences
at 1747-1751 and 1974-1978 and a double AUUUAUUUA between bases 2613 and
2621. The latter likely represents a more significant ARE as these regions are usually
composed of multiple copies of the sequence. The hTRH-R 3' UTR does not contain
any ARE consensus sequences. This would suggest that if anything the rTRH-R
mRNA should be less stable than that of the hTRH-R, and would therefore be
expected to express less efficiently. In reality the opposite is true. It would therefore
appear that there is some intrinsic element of the actual coding region which may
regulate expression, as even when expressed without any UTR sequence the rTRH-
Rs-s still expresses to a much higher level than the human isoform of the TRH-R.
However, the difference may not lie at the RNA level, the rat and human TRH-R
peptides may not be processed and targeted to the cell membrane equivalently. Future
studies lie in the direction of assessing expression of epitope-tagged WT and mutant
hTRH-Rs as a function of receptor mRNA.
The loss of hTRH-R expression in the HEK-293 stable cells lines was very
unexpected, especially as the rat TRH-R (293-E2) cell line has maintained expression
over a period of almost five years. Personal communication with Dr S Sealfon
indicates that similar difficulties have been experienced in expression of the human
gonadotrophin-releasing hormone receptor (hGnRH-R). No reason for this
phenomenon has yet been determined. Different approaches have been taken to
improve levels of expression of several GPCRs. Davidson et al. (1996) have shown
that incorporation of an additional glycosylation site in the hGnRH-R increases cell
surface receptor expression 1.8-fold. However, the expression levels reported, even
with the addition of an extra glycosylation site are still low and do not reach the levels
of GnRH-R expression attained in the rat GnRH-R (293-A2, established by Dr JVF
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Cook) stable cell line. Another group has inserted the hGnRH-R into an expression
vector containing the sequence for an internal ribosomal entry site (IRES) which has
led to the successful generation of an over-expressing hGnRH-R stable cell line
(Beckers et al, 1995). In addition it has been reported that there exists a consensus
sequence flanking the AUG translation initiation codon which creates an optimal site of
initiation for the 40S ribosomal subunit on the mRNA (Kozak, 1984; Kozak, 1981).
The original consensus sequence, known as a Kozak initiation sequence, takes the
nucleotide form CC(A/G)CCAUGG (AUG initiation codon shown in bold type), but
it has subsequently been shown that the optimal sequence for initiation by eukaryotic
ribosomes is ACCAUGG (Kozak, 1986). Neither the rat nor the human TRH
receptors have this consensus sequence flanking their initiation codons, but both
contain an A at position -3 and a G at position +4 which have been shown to be
important nucleotides for ribosomal translation initiation (Kozak, 1981) (Figure 6.6).
Creation of TRH-Rs containing a Kozak initiation sequence or the addition of extra







Figure 6.6 Flanking regions of the rat and human TRH-R translation initiation
codons
There is no Kozak consensus sequence in either the rat or the human TRH-R cDNA sequences,
although the -3 and +4 positions have the A and G nucleotides implicated by Kozak in efficient
eukaryotic ribosomal function (Kozak, 1981).
Although removal of the 3' and 5' UTRs of the rat and human TRH-Rs reduces levels
of receptor expression, some intrinsic sequence remains within the coding region of
the receptors which appears to mediate expression, since the rTRH-R retains its
superior expression in the absence of UTR sequences. The other significant difference
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there exists a point of sequence divergence (at amino acid 392), with each species
having a different receptor carboxy tail which exhibits no comparative sequence
homology. The rTRH-R has the longest tail, 19 amino acids after position 392, the
human has 5 amino acids after this same position and the mouse has the shortest tail
with only one amino acid following 392. The carboxy tail of GPCRs has been
implicated in receptor desensitisation (Hausdorff et al, 1991) and receptor
internalisation (Nussenzveig et al, 1993), and may also be involved in directing
receptor peptides to the cell membrane, although expression of a mTRH-R with a
truncated carboxy tail is still targeted to the cell membrane (Yeaman et al, 1996).
There are other more subtle amino acid differences between the rat and human TRH-
Rs which may create the molecular signals which direct receptor expression to the cell
surface. There are more than ten sites at which the hTRH-R has unique amino acids as
compared to the rat and mouse isoforms. Whether these differences are functionally
significant has not been determined to date.
In conclusion, the residues targeted by sequence analogy to the results obtained from
other mutant GPCRs do not produce the same results in the hTRH-R, indicating that
the function of amino acid residues is dictated by the context in which that residue
exists, and not only the characteristics of that particular amino acid. The increased
expression of mutant hTRH-Rs was an unexpected but interesting finding, the
cause(s) of which remain(s) to be determined. The reasons for decreased hTRH-R
expression level compared to the rTRH-R also remain elusive. In order to study the
hTRH-R further it will be necessary to increase and stabilise its expression, either by
introducing enhancing elements such as a Kozak sequence, or by using an IRES
expression vector. Stable hTRH-R cell lines would be highly useful for the study of
this receptor in pituitary and in extra-pituitary cells in the absence of available human
tissue samples or appropriate animal models, especially for screening novel drugs.
The murine TRH-R has been successfully expressed in a variety of cell types using
recombinant, replication-defective adenovirus vectors (Falck-Pedersen et al, 1994;
Wolff et al, 1996; Yeaman et al, 1996). This method of gene transfer allows more
accurate manipulation of the number of expressed receptors (as compared to plasmid
vector transfection) as this parameter is directly proportional to the multiplicity of viral
particle infection. It should also be possible to co-infect with different adenovirus
constructs in order to express multiple peptides in the same cell, such as other GPCRs
or components of intracellular effector systems not normally produced by the chosen
cell type.
Chapter 7
Isolation and characterisation of the 5'-flanking
region of the mTRH-R gene
7.1 Introduction
Thyrotrophin-releasing hormone (TRH) plays an important role in the control of the
hypothalamic-pituitary-thyroid axis. It stimulates both synthesis and release of TSH
from the thyrotrophs of the anterior pituitary. In addition TRH causes increased
synthesis and release of prolactin from the lactotrophs, although the physiological
significance of this is unclear. TRH has also been implicated in both affective
disorders and motor neurone diseases (Munsat et al, 1989; Nemeroff and Evans,
1989). TRH exerts its actions by binding to specific high affinity GPCRs on its target
cells. Binding studies have shown that the TRH-R is expressed in a tissue specific
manner. High affinity binding sites have been demonstrated in specific cells of the
anterior pituitary, i.e. lactotrophs and thyrotrophs (Hinkle, 1989), various regions of
the brain, in particular the amygdala, and in the anterior horn cells of the spinal cord
(Satoh et al, 1993b).
The mouse TRH-R (mTRH-R) was cloned from a TtT97 mouse thyrotrophic tumour
cDNA library (Straub et al, 1990), and this was quickly followed by the isolation of
TRH-R cDNAs from rat (de la Pena et al, 1992a; Sellar et al, 1993; Zhao et al, 1992)
and human (Duthie et al, 1993a) tissues. These cDNAs have been used to further
investigate the expression and regulation of the TRH-R, in particular to demonstrate a
more detailed pattern of expression of the TRH-R in the brain (Zabavnik et al, 1993)
and spinal cord, and in other tissues (Satoh et al, 1993b).
In pituitary cells, both homologous and heterologous hormonal regulation of TRH-R
concentration, as measured by [3H]-TRH binding, has been demonstrated (de Lean et
al, 1977b; Gershengorn, 1978; Gershengorn et al, 1979; Hinkle and Tashjian, 1975;
Perrone and Hinkle, 1978). The ability to modulate gene expression in response to
extracellular signals is a basic property of all living cells. The mechanisms whereby
specific genes are expressed in a temporal or tissue-specific manner or are activated in
response to extracellular inducers have been studied extensively by molecular
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biologists. It has been discovered that cis-acting DNA sequences are required for
eukaryotic gene regulation. The DNA sequences involved in transcriptional control are
short stretches of nucleotides or modular recognition elements which interact with
specific transcription factors (trans-acting elements). Positive and negative regulatory
elements which function in a cell-specific manner or in response to extracellular
inducers have been identified. In addition, pre-existing transcription factors may be
covalently or allosterically modified presenting a further level at which gene regulation
may be modified.
Additional studies have shown that the TRH-R is regulated in pituitary cells at the pre-
translational level by oestrogens (Kimura et al, 1994), glucocorticoids (Yang and
Tashijian, 1993) and thyroid hormones (Yamada et al, 1992), and that for the steroid
hormones, this regulation occurs at the level of transcription (Kimura et al, 1994; Yang
and Tashijian, 1993). The mechanism by which TRH decreases TRH-R mRNA levels
appears to be mainly post-transcriptional (Fujimoto et al, 1992; Narayanan et al,
1992), though there is some evidence of transcriptional regulation (Yang and
Tashijian, 1993). Both TRH itself and thyroid hormones down-regulate TRH-R
number in pituitary cells (Gershengorn, 1978), whereas oestrogens and
glucocorticoids increase receptor number (Gershengorn et al, 1979; Yang and
Tashijian, 1993).
In order to study the factors involved in the tissue specific expression and
transcriptional regulation of the mTRH-R gene, a 6.5kb genomic fragment containing
sequences upstream of the translation initiation codon has been isolated and
sequenced. This has been the preliminary step in identification of the sequences
necessary for expression and regulation of the TRH-R gene in pituitary cells. In
addition to the identification of the elements of the TRH-R promoter which regulate
receptor expression, the information regarding the TRH-R gene structure is essential
for designing transgenic and receptor knock-out animal studies. The technique of
homologous recombination in embryonic stem cells can be used to generate a mouse
lacking the TRH-R gene. This mutant mouse model will enable the determination of
the exact role that TRH input via the TRH-R plays in the control of the hypothalamo-
pituitary-thyroid axis and also its role in PRL secretion and lactation. TRH and its
receptor are also found in many extra-pituitary locations including the pancreas, the
prostate, the testis and the CNS, in particular the amygdala and spinal cord. TRH has
been shown to have effects on cognition, motor function and recovery after spinal
injury in both experimental models and in clinical trials. The TRH-R deficient mice
will advance our understanding of the role TRH plays in the development and function
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of the CNS. The effects of this knockout mutation will also provide information on
the role of TRH in other extra-pituitary locations as mentioned above.
7.2 Materials and methods
7.2.1 Isolation of the upstream 5'-flanking region of the mTRH-
R gene
A mouse genomic library constructed in EMBL3 (Clontech) was screened with a
[32P]-dCTP labelled 2.5 kb fragment of the rTRH-R cDNA (Sellar et al, 1993).
Hybridisation was performed at 42°C in hybridisation buffer containing 50%
formamide according to standard procedures. Five positive clones were isolated from
a total of 6 x 105 screened (Duthie et al, 1993b). Phage DNA from isolated clones
was purified and digested with restriction endonucleases. Southern blots of digested
genomic DNA clones were probed with [32P] labelled oligonucleotides corresponding
to different regions of the mouse TRH receptor. Clone 9, hybridising to an
oligonucleotide representing nucleotides-155 to -138 of the mTRH-R sequence was
approximately 19kb. This clone was digested with Bgl II and a 6.5kb fragment, also
hybridising to a probe in the same region (-156 to -181) was subcloned into the Bam
HI site of pBluescript II (Stratagene). Sequencing was carried out on as described in
Section 3.5.
7.2.2 5' RACE analysis
Normal mouse pituitary RNA was used as template for 5' RACE as described in
Section 3.21. As described, three gene specific primers (SP1, SP2 and SP3) were
designed to anneal regions within the 5'-flanking region of the mTRH-R gene (Duthie
et al, 1993b) . Primer sequences were as follows: SP1 was oligo 382 (Table 7.1)
which anneals at a position spanning the translation start site (-22 to +27), SP2 was
5'GACAGAAAGGTGAAGGCTG3' (-68 to -50) and SP3 was
5'CAGGCAGCGTGACAGAGTG3' (-119 to -101). The SP1 primer was used to
transcribe the first strand cDNA from the RNA template and SP2 and SP3 were used
as nested primers to increase amplification and specificity of the PCR reactions. The
resulting PCR products were separated on a 10-20% polyacrylamide precast minigel
(Bio-Rad) and stained with ethidium bromide following electrophoresis.
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7.2.3 Construction of pGL-3 constructs for functional study of
promoter activity
Figure 7.1 shows the relative positions of PCR primers used to amplify different
length fragments of the genomic mTRH-R gene upstream region. Table 7.1 gives the





























Figure 7.1 The mTRH-R 5' flanking promoter containing region
The 5' flanking region of the mTRH-R gene is numbered with 1 at the A of the ATG translation start
site. The genomic DNA sequences amplified and subcloned into the luc reporter vector are shown by
the double-ended arrows at the bottom of the figure (not to scale). Primer PX2 (annealing at -182 to
-157) was used as an anchor primer with primers 450, 750 and 1000. These 5' primers anneal to the
sequence at -609 to -640, -902 to -619 and -1154 to -1177 respectively. Primers 382 ( -22 to +27)
and 2000 (-2050 to -2030) resulted in production of a large PCR fragment (2700 bp) as it included the
intronic sequence (645 bp intron at position -95/-96) which was shortened by restriction digest with
the enzymes Kpn I and Xho I to just 1045 bp. All four of the fragments generated were inserted into
the cloning site of the promotorless luc reporter vector pGL3. The position of the most likely
CAATT and TATAA sequences are shown. The DNR spans a total of 74 bp from -396 to -470.
Chapter 7 Isolation and characterisation of the mTRH-R 5'-flanking region 139
Primer Primer sequence (5'-3') Size (bp)
PX2 < CCAATCCTGCAGAAGAAATCTTGTCC
450 > ATTTCAGAGCAGCTCAGGCACAAGAGTTTCTG 452
750 > CCCTTCTGACTCCTGACC 763





Table 7.1 Sequences of the primers used to amplify segments of the mTRH-R
promoter region.
The sequences are shown in the 5-3' direction. < indicates priming at the 3' end of the sequence and >
indicates the 5' primers. PX2 was used as the 3' primer in separate PCR reactions with 450, 750 and
1000. Primer 382/SP1 was used with primer 2000 in another PCR reaction. The sizes of the PCR
bands produced using these primers are given in bp in the last column of the table and are illustrated in
Figure 7.1 above.
PX2 was used as an anchor primer with primers 450, 750 and 1000 giving 3 different
PCR bands whose sizes (in bp) are shown in the last column of Table 7.1. The PCR
products were TA cloned and then subcloned into the Kpn I/Xho I sites of the
polylinker of the pGL3 luciferase (luc) reporter vector. Primers 382/SP1 and 2000
were used together to generate a PCR band of 2.0kb which contained an endogenous
Kpn I site at -1045 of the promoter sequence. This large PCR product (as shown in
Figure 7.1) was restriction digested from its TA clone with Kpn I (which cuts within
the promoter sequence) and Xho I (cutting within the multiple cloning site of the TA
vector sequence). The resulting fragment (1045bp) was subcloned into pGL3-basic as
described above. The luc expression constructs were sequenced to confirm the
presence and orientation of the promoter fragments. The resulting constructs were
now referred to as -450TRH-R-luc, -750TRH-R-luc, -lOOOTRH-R-luc and
-1045TRH-R-luc.
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7.2.4 Transient transfections
5(ig of each TRH-R-luc construct was transfected into GL^ GH4C1 and COS-1 cells,
along with 2|J,g of pSVP-gal construct, used to control for transfection efficiency. 5(ag
of the pGL3-basic and pGL3-control luciferase vectors, again along with the pSV(3-gal
vector were transfected into replicate dishes as negative and positive controls
respectively. The cells were transfected in 60mm tissue culture plates using 5(il
Transfectam™/well or were electroporated as described in Chapter 3. Cells were
harvested 48 hours after transfection into 400|il of Reporter Lysis Buffer (Promega)
and luciferase activity of the cell extracts determined using the Luciferase Assay
System (Promega). (3-gal activity was measured using the p-galactosidase Assay
System (Promega). Total proteins were determined using the BioRad protein assay
method. Relative luciferase activity was determined (light units/p-gal/mg protein) and
results for each construct were compared using the Students t-test (*p<0.05).
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7.3 Results
7.3.1 Sequencing of the 5'-flanking region of the mTRH-R gene.
Figure 7.2 shows the nucleotide sequence of the first 2251 nucleotides of the mTRH-
R gene upstream from the ATG translation initiation codon. Sequence analysis reveals
a long dinucleotide repeat (DNR), d(TG)i6d(AG)2i upstream of position -396 and an
intron at -951-96 with respect to the initiation codon as previously described (Duthie et
al, 1993b). There are consensus CAATT and TATAA motifs at -780/-775 and -756/-
752 respectively, at -1562/-1557 and -1468/-1464 respectively and a TATAA motif at
-2186/-2182 (highlighted in Figure 7.2) However, none of these sites are within an
appropriate distance from the position of the possible transcriptional start site around
-348 as indicated by alignment of the human1 and mouse 5'-flanking sequences
(Figure 7.5). There are other putative consensus motif sequences which may be the
binding sites for several regulatory elements/transcription factors (Figure 7.2 and
summary in Table 7.2).
•a paper by Iwasaki et al describing the promoter of the hTRH-R has recently been published (during
the course of this work) (Iwasaki et al„ 1996).
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agatcccttt agctccttgg gtactttctc tagctcctcc
-2011 attgggagcc tccattagct gactgtgggc atccacttct gtgtttgcta
-1951 ggccccggca tagtctcaca agagacagct acatctgggt cctttcgata aaatcttgct
-1891 agtgtatgca atggtgtcag cgtttggatg ctgattatgg ggtggatccc tggataaggc
-1831 agtctctaca tggtccatcc tttcatctca gctccaaact ttgtctctgt aactccttcc
-1771 aagggtgttt tgttcccact tctaaggatg gggcttattt gattttctgg agtccacctt
-1711 cttgagttct ttatatatgt tggatattat tcccctatct gatttaggat atgtaaatat
-1651 cctttcccaa tctgttggtg gccgtttttt cttattgaca gtgtcttttg ccttacagaa
-1591 gctttggagt ttcatgaggt cccatttgtc aattctcgat cttacagcac aatccattgc




-1471 ctctataaga ttcagtgtct gtggagttcc ttgatccact aagatttgac










-1231 ttcaggctgg cttgtgcttt ttctaaaacg acattgagtc cgtaacacat
-1171 tttatctcaa gccctgggga ctgcagtgac tcttggctag aatttcatta gataactgtc
TRE




aggvccttgg agcactacaa gtttccacag gtggattttg
-991 ataatcttat tctttgtttg cttgtttgtt catgacacaa ggtcttgata
-931 tatagcccaa actggtttca aattcacagc ccttctgact cctgaccact gcgattgcag
-871 tatatacccc
tcagaagctc
tgctccaagt cttcaagtca ttttttaaaa ataaaatttt tatatgagcc
-811 acagtaaaaa tggtttgaaa tcaattttaa ctcatttttc attcatataa

















agctcggctg cttccagatc cttttatctg tgatcaggca
-511 tccacactga agccacatgt ttaaaagtaa attcaacaga agattctgaa
-451 tcagtcagga ttgactagca cttctgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagag
-391 agagagagag agagagagag agagagagag agagagagct ctcattaagg gacgatctat
-331 ggtttgacag cctcggtgct gcgcctgctg ctgcttcagt tactgcggct gtgtggtctg
-271 tcatgagttg aaaagggatg tgagggttta gaggaactgc cgctctgaag actgagcctc
-211 tgctaagtga tcttcctgcc agacagactg gacaagattt cttctgcagg attggaaact




-91 aagaactact gcaaaaacaa acagacagaa tqgaaagatg ttttagagtc
-31 cccgtgtcag agaagcttca agccactgaa gatg
Met
Figure 7.2 Nucleotide sequence of the mTRH-R gene 5'-flanking region
Sequences of interest as summarised in table 7.2 are highlighted above. Consensus sites are
underlined and labelled accordingly. Only one of the E-box (Yoon and Chikaraishi, 1992) sites is
shown (indicated by an asterisk in Table 7.2) and none of the PEA-3 (Wasylyk et al, 1990) sites are
shown as they are too numerous. Only the perfect match Sp-1 (Schmidt et al, 1989) site is shown.
The positions of CAATT and TATAA boxes are indicated in bold and bold/underlined text respectively
and the location of the 3' splice site intron junction is shown as bold GG at position -95Z-96. The
numbering is relative to the ATG translation initiation site in which the adenosine is numbered +1.
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Table 7.2 Putative transcription factor binding sites of the mTRH-R 5'-
flanking region (following page)
Sequence analysis of approximately 2kb of the mTRH-R 5'-flanking region sequenced reveals the
locations of putative cis-active binding sites for several regulatory trans-acting factors, including Pit-1
(Kapiloff et al, 1991), AP-1 (Angel et at, 1987), AP-2 (Imagawa et al, 1987), AP-3 (Mitchell et al,
1987), GRE (glucocorticoid response element; (Forman and Samuels, 1990)), ER (oestrogen receptor
binding site; (de Verneuil and Metzger, 1990; Forman and Samuels, 1990)), E-box (Yoon and
Chikaraishi, 1992), PEA-3 (Wasylyk et al, 1990), TRE (thyroid hormone response element) (Forman
and Samuels, 1990; Forrest et al, 1991) and Spl (Schmidt et al, 1989). * indicates a site where the
central NN nucleotides are GG in the indicated binding location, a motif which often appears in this
cis-active site.
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Site Consensus sequence (5'-3') Position Match
Pit-i (A/T)TAT(C/T)CAT -1998/-1991 7/8
AP-l TGA(C/G)T(C/A)A -2110/-2104 6/7
AP-2 CCC(A/C)N(G/C)3 -2251/-2244 7/8
AP-3 TGTGG(A/T)3 -1452/-1445 7/8








ER AGGTCAN3TCACCT -569/-555 12/15
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It is not known how much of the sequenced 5'-flanking region appears in the mRNA
for the mTRH-R. It is feasible that some of this sequence may be spliced out of the
primary transcript prior to nuclear export to the ribosomes for translation. Analysis of
the sequence of the mTRH-R 5'-flanking region reveals several sites which adhere to
the consensus sequences for 5' splice donor and 3' splice acceptor sites (Senapathy et























Table 7.3 Positions of putative splice sites
Sequence analysis of the mTRH-R 5'-flanking region reveals several potential splice donor/acceptor
sites. The consensus sequences for these sites are given in the top row. The sequences located at the
given positions are shown with mismatches shown in bold type. Y= C or T, R= A or G, M= A or C
and N= any nucleotide.
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7.3.2 5' RACE analysis of mouse pituitary RNA
Figure 7.3 shows a photographic representation of the PCR bands produced by 5'
RACE analysis. The upper panel shows the products of the first PCR reaction using
SP2 and the d(T) PCR primer supplied by the kit manufacturer, Boehringer
Mannheim. This reaction produced a band of approximately 270bp as compared to the
size standards. The 234bp band was produced by the kit control to indicate that the
reverse transcriptase step had produced amplifiable cDNA. The lower panel shows
that the 270bp band was reduced to approximately 220bp following nested PCR with
SP3 (which anneals to the 5'-flanking sequence 50bp upstream of SP2) and the PCR
anchor primer (again supplied as a kit component). SP3 anneals at a position 101 bp
upstream from the ATG transcription start site so this would give a position of -321
for the transcription start site. However, the d(T) PCR primer adds 39bp onto the
length of the PCR product, so subtracting this from the initial position of -321 results
in a possible transcription start site at -282.
Figure 7.3 5' RACE analysis of the mTRH-R 5'-flanking region (following
page)
The upper panel shows the results of PCR amplification of reverse transcriptase derived cDNA from
both the control RNA supplied in the 573' RACE kit (Boehringer Mannheim) and mouse total
pituitary RNA. The control sample cDNA was amplified in the same reaction tube as the sample
cDNA and gave a band of 234bp as expected (when compared to the DNA size markers electrophoresed
in the lane labelled pGem markers). The sample cDNA gave a band of 270bp when amplified with the
d(T) PCR primer (supplied with the kit) and SP2. This sample band was reduced to 220bp on a
second amplification with the PCR anchor primer (supplied with kit) and SP3. The control
amplification again gave the expected sized band (157bp) as shown in the lower panel. Negative
control samples were performed at each step. In the upper panel (first PCR) RNA was added to the
PCR reaction components to discount the possibility of DNA contamination of the RNA samples
(labelled 'no RT'). In the second PCR reaction all components except first round PCR DNA was
added (labelled '-ve control') to eliminate the possibility of DNA contamination of reaction
components.
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no RT mouse pGeni
pit RNA markers
mouse -ve pGem
pit RNA control markers
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7.3.3 Expression of -1045TRH-R-luc in pituitary and non-
pituitary cells
-1045TRH-R-luc induced a 3.85-fold increase in luciferase activity in GH3 cells
compared to the pGL3 vector alone, and when this same construct was transfected into
COS-1 cells, which are derived from monkey kidney and do not normally express the
TRH-R, no increase in luciferase activity was seen (Figure 7.4). These findings
indicate that this fragment of the 5'-flanking region contains sequences necessary for

































pGL3 Basic -1045TRH-R-luc pGL3 Control
Figure 7.4 Expression of -1045TRH-R-Iuc in pituitary and non-pituitary cells
GH3 and COS-1 cells were co-transfected with -1045TRH-R-luc and pSV(3-gal. Luciferase and b-gal
levels were measured 48 hours later using the appropriate assay system (Promega). Luc activity was
corrected for p-gal activity (to control for transfection efficiency) and total protein content (to control
for cell number). pGL3 (without insert/promoter) transfected cells were used as a negative control and
the pGL3 control vector (in which luciferase transcription is controlled by the SV40 promoter) was
used as a positive control. Assay points are the mean of triplicate samples (± SEM), n=3).
Significance was determined when p< 0.05 and is indicated by asterisks.
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3.4 Discussion
The mTRH-R cDNA (Straub et al, 1990) contains 265bp of true 5' UTR which
indicates that the mRNA must be greater or equal in length to this sequence. The
rTRH-R cDNA (Sellar et al, 1993) has 340bp of 5' UTR indicating that this is
contained in the mature mRNA and that the transcription start site must be further 5' of
this location. Alignment of the mouse and rat 5' UTR regions reveals a high level of
sequence homology. Analysis of the sequence of the mTRH-R 5'-flanking region
reveals two perfect CAATT and TATAA pairs at positions -780 and -756, and -1562
and -1458, along with a further TATAA motif at -2186 (shown in Figure 7.2).
Although the CAATT/TATAA pairs are spaced at appropriate distances from each
other, none of these are at the correct distance from the translation initiation start site.
The TATA box is usually centred at -28 relative to the transcription initiation site and
the CAATT box is most often found between -50 and -129 (Bucher and Tifonov,
1986). The absence of typical TATAA and CAATT consensus sequences is
characteristic of other G-protein-coupled receptors such as those for GnRH
(Albarracin et al, 1994), TSH (Ikuyama et al, 1992), LH (Huhtaniemi et al, 1992;
Tsai-Morris et al, 1993) and FSH (Heckert et al, 1992) as well as the melatonin la
receptor (Roca et al, 1996), and instead possibly use other elements such as the GATA
motif. The GPCR genes may therefore be regulated by a common yet alternate
mechanism. Initial results using normal mouse pituitary total RNA in 5' RACE
analysis suggests the existence of a transcription start site in the region of -282 with
respect to the translation initiation codon. The precise position of this site requires the
cloning and sequencing of the PCR product which implicates this site. The analogous
upstream region of the hTRH-R has been recently cloned (Iwasaki et al, 1996), and
alignment of this sequence with the equivalent mouse sequence shows a remarkable
level of homology (Figure 7.5). The transcription initiation site of the human
sequence is at the adenosine base at -344 (marked by an asterisk in Figure 7.5),
directly adjacent to the 3' end of the DNR which appears in similar positions in both
species. Alignment of the analogous human sequence indicates that the transcription
start sites for both of these TRH-R genes are likely to be in close proximity, around
-344 which is the transcription start site for the hTRH-R mRNA. The analogous
position is -348 in the mTRH-R gene so it is therefore feasible that the transcriptional
initiation site of both of these genes will be found to lie at homologous positions with
respect to the ATG translation start site as this area of both promoter regions is almost
identical. The nucleotide homology continues beyond -650, to at least -800. It may be
possible to determine whether the mTRH-R mRNA extends beyond the -282 position
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by performing RT-PCR using an upstream primer based on the sequence alignment
shown in Figure 7.5. Choosing sequence spanning -348 to synthesise a PCR primer
should allow detection of this longer RNA transcript if it exists in cDNA reverse
transcribed from mouse pituitary RNA extracts. However, the presence of the
transcription site in such close proximity to the DNR may interfere with PCR based
techniques as such a sequence is both difficult to amplify and PCR primers cannot be
made to this type of repeat element as they will form primer-dimer complexes.
Table 7.2 outlines the putative transcription factor consensus binding sites identified in
the mTRH-R gene upstream region. TRH-R expression in the pituitary, in lactotrophs
and thyrotrophs (Hinkle, 1989), is restricted to cell types that are known to express
and translate the pituitary specific transcription factor, Pit-1. Therefore, it might be
expected that the regulatory region of the TRH-R gene would contain binding sites for
Pit-1, as is the case for the growth hormone and prolactin genes. Because TRH-R
mRNA has been identified in PRL- and GH-producing pituitary tumours (Kaji et al,
1995), Pit-1 may be involved in the regulation of anterior pituitary TRH-Rs through
activation of the TRH-R gene. Sequence analysis indicates the existence of a possible
Pit-1 binding site at -1998/-1991 on the coding strand of the TRH-R promoter region.
There are several consensus binding site matches for the transcription factor Sp-1 (-
1324/-1316, -1742/-1734, -1865/-1857 and -1853/-1845) which is thought to be
involved in modulating the activity of essential genes. There are putative binding sites
for the activator protein factors AP-1 (-2110/-2104), AP-2 (-2251/-2244) and AP-3 (-
1452/-1445) and these may be involved in the down-regulation of TRH-R mRNA
levels by phorbol esters (Fujimoto et al, 1991). A consensus motif known as the E-
box (an enhancer box recognition site for helix-loop-helix regulatory proteins) may
also be involved in the regulatory effects of phorbol esters upon TRH-R transcription.
There are approximately twenty putative PEA-3 binding sites, which may be targets
for transcriptional control via signal transduction-linked mechanisms (see Table 7.2).
TRH-R transcription may be regulated by oestrogen to a certain extent (Kimura et al,
1994).and might be mediated via the putative oestrogen receptor binding site located at
-569/-555.
Initial transfection studies suggest that -1045TRH-R-luc is sufficient to promote
luciferase activity in a pituitary cell specific manner. Given that these experiments
were performed in rat GH3 cells, this indicates that cross-species transcriptional
control is possible at least in vitro. In addition, the hTRH-R promoter was also active
in rat GH4C1 cells. It is note-worthy that the untranslated region of the rTRH-R
cDNA is also highly homologous to the mouse and human 5'-flanking regions. It
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would be interesting to investigate the cellular specificity of TRH-R expression, to
ascertain whether pituitary cells of non-thyrotrophic origin (a-T3-l gonadotroph cells
or AtT20 corticotroph cells, for example) will express this gene. There is evidence
which indicates that the AtT20 cell line (an adrenocorticotroph tumour cell line)
expresses cell surface TRH-Rs (Gershengorn et al, 1980), and may therefore possess
the machinery required for transcriptional initiation of this receptor gene.
Several different approaches are available to determine whether any of these putative
sites are involved in the control of TRH-R transcription. One method involves
mutation or deletion of consensus sites followed by measurement of the resulting
effects on promoter-induced luciferase activity as previously described for the
-1045TRH-R-luc construct. Luciferase activity would be expected to be lost when
regulatory sites in the RNA are mutated/deleted and can therefore no longer bind trans-
activating protein factors. Alternately, antisense oligonucleotides which bind to the
RNA and therefore block protein-RNA interactions could be tested in similar
protocols. Blocking regulatory sites in this way would result in a loss of luciferase
expression. It is possible to determine the presence of nuclear proteins which bind to
DNA molecules using a method which detects DNA-protein interactions as a function
of electrophoretic gel-shifts. In essence, this assay involves the radio-labelling of an
oligonucleotide probe which mimics a consensus transcription factor binding site, and
mixing of this probe with nuclear proteins extracted from tissues or cell lines which are
known to express the gene of interest. A DNA-protein complex will form if any
transcription factors are present which recognise and bind to the probe . When
electrophoresed through a polyacrylamide gel alongside the native probe the DNA-
protein complex should be retarded in its migration and should produce a higher band
on the resulting autoradiographic image. This is known as a gel shift. Specific
antibodies to many transcription factors are available and if added to an appropriate
DNA-protein complex and electrophoresed alongside the samples described above
should result in a 'super shift', or further migratory retardation, confirming the identity
of the protein which has bound the oligonucleotide probe.
The DNR element (d(TG)i6.d(AG)2i) of the 5' flanking sequence may be involved in
modulation of gene replication, transcription and recombination. It has been suggested
that an alternating purine-pyrimidine sequence such as the TG repeat may allow the
DNA to assume its lowest energy state, Z-DNA (Rich et al, 1984). Z-DNA adopts a
left-handed helical conformation as opposed to the more characteristic B-DNA which
forms right-handed helices. Z-DNA is often found in controlling regions of genes
(Schroth et al, 1992) where supercoiling of the DNA permits switching between B-
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and Z-DNA which is perhaps responsible for the activity of such regions as enhancers
or promoters for example (Liu and Wang, 1987). The rat prolactin gene 5' UTR
(Naylor and Clark, 1990) and the rat ceruloplasmin gene 5' UTR (Fleming and Gitlin,
1992)) both contain similar DNR sequences which have been shown to exert negative
effects on gene transcription. The gene encoding the substance P receptor, a GPCR,
encodes a d(GT)n sequence in its 5' UTR and a d(CT)n.d(CA)n sequence in its 3'
UTR, although the function of these regions is not known. Expression of the
comparable region from the mTRH-R gene in a reporter vector may allow
determination of the function of this region in the control of gene transcription.
Alternately, the DNR may be spliced out of the mature mRNA as splice donor and
acceptor consensus sequences have been identified in the 5'-flanking region of the
mTRH-R gene, and the DNR may therefore play no significant role in transcriptional
regulation of this receptor.
Figure 7.5 Alignment of the nucleotide sequences of the mouse and human
upstream regions (following page)
The first 650 bp of the 5'-flanking region of the mouse and human TRH-R genes are aligned to show
areas of sequence homology (indicated by dots between the lines of nucleotides), excluding the intronic
sequences which were removed at the positions of the arrows (between -96/-95 in the mouse and -89/-
88 in the human). The sequences are numbered with +1 being the adenosine of the translation
initiation ATG/Met codon (shown in shaded box). The upper lines show the mouse sequence and the
lower lines represent the equivalent region of the human sequence. The position of the exact
transcription start site for the human TRH-R promoter is marked by an asterisk (adenosine at -344).
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-650 -640 -630 -620 -610 -600 -590 -580
I I 1 I I I I I
mouse ttttgctatctcctaaaatcccatcaagcaagaagtaaaaatttatttcagagcagctcaggcacaagagtttctgc
human atttgctaac-cccaaagtcctatcaagcaaggagtgtaaatgtatttcagagcagctcaggtactagagtttctgc
I I I I I I I
-640 -630 -620 -610 -600 -590 -580
-570 -560 -550 -540 -530 -520 -510
I I I I I 1 i
mouse ggaacttagagcatctttacctacaagctcggctgcttccagatccttttatctgtgat--caggcatccacactga
human agaacttagatgataagcaacgacaaagccagctgcttctaga-cccctggcttatgatttcagctttccaaattaa
I I I I I I I I
-570 -560 -550 -540 -530 -520 -510 -500
-500 -490 -480 -470 -460 -450 -440
I I I I III
mouse gcactatgtcagccacatgtttaaaagtaaattc aacagaagattctgaatcagtcaggattgactagcac
human agactgtctcatcagcacatttaatagtaaatcctccaagagcagaagactctgaatcagtgaggactgactggcat
I I I I I I I
-490 -480 -470 -460 -450 -440 -430
-430 -420 -410 -400 -390 -380 -370 -360
I I I I I I I I
mouse ttctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgagagagagagagagagagagagagagagagagagagagagag
human ctgtgagtgtgtgtgaatgtatctgtgtgtgtgtgtgtgtgtctctgtgtgtgagagagcgagcgtgt atg
I I I I I I I I
-420 -410 -400 -390 -380 -370 -360 -350
-350 -340 -330 -320 -310 -300 -290
I I I I II I
mouse ctctcattaagggacgatctatggtttgacagcctc ggtgctgcgcctgctgctgcttcagtt actgcggc
human ttctcattaggggacgatctatgatttgacagcctcactgctgctgctcctgctgctgcttctgcttctgccgcggc
* I I I I I I I
-340 -330 -320 -310 -300 -290 -280
-280 -270 -260 -250 -240 -230 -220 -210
I I I I I I I I
mouse tgtgtggtctgtcatgagttgaaaagggatgtgagggtttagaggaactgccgctctgaagactgagcctctgctaa
human tgtatggtttgtcattagttggaaagggctgtgagggtttggagaaactgcagttttaaagactgagca-ctgctaa
I I I I I I I I
-270 -260 -250 -240 -230 -220 -210 -200
-200 -190 -180 -170 -160 -150 -140 -130
I I I I I I I I
mouse gtgatcttcctgccagacagactggacaagatttcttctgcaggattggaaacttggacctattagcacttcatcta
human gtggtctccctctcaaatagagtagacaagatt--ttctgcaagattagaaacttggaactattaccacttcatcta
III I I I I
-190 -180 -170 -160 -150 -140 -130
-120 -110 -100
, -90 -80 -70 -60
I I III I I I
mouse cc-agagaaacaggcagcgtgacagagtgaagaggggaaagaactactgcaaaaacaaacagacagaaaggtgaagg
human cccagaaaatcaggcagcgctacagaggataagggggatggaactgctgcaataa-aggtgggc gctggaaa
I I I I 4 I I I
-120 -110 -100 -90 -80 -70 -60
-50 -40 -30 -20 -10
I I I I I I .
mouse ctggaaagatgttttagagtccccgtgtcagagaagcttcaagccactgaagatg
human - -gaagatgttttgagaagtcagtgtttccgagaaactttaagcttctaaagatg
I I I I I I Met
-50 -40 -30 -20 -10
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In conclusion, we have isolated a 6.5kb genomic fragment of the mTRH-R gene, of
which almost 2.3kb of the 5'-flanking region (upstream of the translation initiation
codon) has been sequenced. Several putative transcription factor binding sites for
factors known to affect TRH-R transcription can be identified in the sequence although
many of these are not perfect matches to the consensus sequences. However, the
contribution of these sites to control of TRH-R expression should not be discounted
until further studies have been performed. Resection or mutation of the promoter
region should provide more accurate information as to the role of regulatory protein
binding sites in both the functional and tissue-specific control of TRH-R transcription.
Although the transcription start site for the mTRH-R has not been conclusively
identified it is possible that the site identified at -282 is one of multiple transcription
start sites. Several other GPCR genes have been found to be transcribed from multiple
positions within their promoters (Roca et al, 1996). It is note-worthy that no
appropriately located TATA or CAATT boxes are to be found in the mTRH-R gene as
this is appearing as a common feature of GPCRs, suggesting that these proteins share
an as yet unidentified, but common mechanism of transcriptional initiation. However,
given that the exact location of the transcriptional start site of the mTRH-R gene
remains elusive, and that the existence and use of possible intron splice sites (shown in
Table 7.3) remain to be determined, these identified sites may yet be found to be
involved in transcriptional activation. However, none of the putative splice
donor/acceptor pairs identified here would bring the CAATT and TATAA pairs closer
to the site potential transcriptional initiation site at -282. Precise characterisation of the
mTRH-R gene promoter region is essential if it is to be utilised in gene targeting and
transgenic studies.
Chapter 8
Summary of results and concluding remarks
8.1 Concluding remarks
Cells are constantly bombarded by a multitude of external signals. Many of these
signals bind to cell surface receptors to initiate a flow of information to the cell interior,
rather than entering the cell directly. A group of membrane receptors which, despite
sharing structural and sequence homologies, transmit signals as diverse as hormones,
neurotransmitters, biogenic amines, odourants and light (see (Dohlman et al„ 1991)
for review) are coupled to a group of guanine-nucleotide binding proteins (G-
proteins). These G-protein coupled receptors (GPCRs) regulate a variety of effector
enzymes and ion channels. The cellular response to any given signal depends on the
second messenger system affected by activation of the receptor concerned. The role of
GPCRs in disease is now well established for many human conditions, as is the role
of abnormally functioning G-proteins. The main aim of the work carried out for this
thesis was to determine whether the TRH-R may also be a causative factor in human
endocrine disease, including pituitary adenomas and central hypothyroidism.
The hTRH-R was found to retain normal structure in a sample of 50 various human
pituitary adenoma tissues suggesting that TRH-R dysfunction is not responsible for
the discordant and/or paradoxical effects of TRH in these patients. However, in an
additional study, one patient (out of two studied) was found to carry two separate
mutations in his genes for the TRH-R (M-STOP, which has a premature stop codon in
the extracellular amino tail and F-TM3 which has a deletion and substitution in TM
III). Both of these mutations result in inactive receptors with no measurable TRH
binding. Whether this patient represents a TRH-R knockout remains to be determined,
as there may be some residual receptor activity from the mutant F-TM3. Additionally,
in vitro translation experiments show that there is a low level of translation from
Met75, the next ATG in the reading frame of the hTRH-R cDNA. It is not known
whether this second translation initiation site will be utilised in vivo, and whether it
would bind ligand restoring TRH-induced cellular activity.
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Site-directed mutational analysis of two amino acid residues in regions of GPCRs
which are important for structure/function was performed with the aim of determining
the significance of these residues in TRH-R function. Mutation of Thr265 resulted in
mutant receptors which had characteristics of constitutive activity, although there was
no significant increase in basal second messenger activity under the conditions used in
these experiments.
The mTRH-R 5'-flanking region was isolated and sequenced in preparation for the
generation of a transgenic mouse line. The location of the transcriptional initiation site
was investigated using 5' RACE analysis and was found to reside potentially at a
location 282bp upstream of the translational start site (ATG). It is interesting to note
that the GnRH receptor RNA transcript may be initiated from one of several positions
within the 5'-flanking region of this receptor (personal communication with Dr S
Kakar, Department of Physiology and Biophysics, University of Alabama, USA).
Sequence analysis of the 5'-flanking region of the mTRH-R identifies several putative
sequences homologous to the consensus sites for transcription factor binding.
8.2 Directions for future study
With respect to mutational analysis of the hTRH-R the recent publication of the
sequence of the human promoter region will allow analysis of this region for naturally
occurring mutations which would alter TRH-R expression. These might arise either
by mutating out the transcription start site or mutating sites crucial for the binding of
transcription regulating proteins. The TRH-Rs of pituitary adenomas (especially in
view of the fact that a study of two TSH-secreting adenomas showed that they had no
measurable TRH binding) and of Patient 1 (see Chapter 5 in which Patient 1 was
found to have a normal TRH-R coding region despite being unresponsive to TRH
challenge) should be screened. Stable cell lines expressing the inactivating mutations
identified in Patient 2 (Chapter 5) should be established to determine whether there is
low level binding from either mutation and also whether a truncated receptor translated
from Met75 is detectable in the cell membrane, either by radioligand binding or
immunodetection of an epitope-tagged receptor construct. In order to help identify a
cause for the poor expression of the hTRH-R as compared to the rTRH-R (Chapter 6)
stable cell lines should be established in order to maximise the reproducibility of the
experiments, as transient expression of the hTRH-R in particular can give quite
variable results on occasion. Stable cell lines provide a source of cells which produce
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large numbers of receptors and which therefore increase the ability to detect
experimentally-induced alterations in receptor function for example. It would therefore
be advantageous to establish cell lines stably expressing the potentially constitutively
active T265 mutations of the hTRH-R (Chapter 6) which would allow more accurate
determination of the effects of these mutations on receptor function. Such cell lines
would be especially useful for the detection of changes in ligand-independent basal IP
turnover. If these mutants do indeed prove to be active in the absence of ligand the
effects of such receptors on cell morphology could be determined. Overactive
receptors may enhance mitogenesis and tumorigenicity in cell cultures as described for
the aiB-adrenergic receptor (Allen et al, 1991) which suggests that GPCRs may be
involved in cellular transformation and tumour formation. Constitutively active
GPCRs are also useful in the screening of compounds for inverse agonist activity
(Barker et al, 1994), that is for the ability of a substance to switch off the
conformationally active (in the absence of stimulating ligand) form of the receptor . A
further experiment which would identify increased basal IP turnover would be to
transfect cells with increasing amounts of receptor (WT or mutant) and then plot basal
IP levels against Bmax. Increasing the dose of DNA transfected will increase the
number of expressed receptors. If the mutant receptor is constitutively active to even a
small degree this should become detectable as the receptor number increases. In
comparison the WT receptor should show no significantly increased ligand-
independent IP accumulation. Stable cell lines will be established using an IRES
vector as described in Chapter 6.
The TRH-R promoter region can be further analysed by performing a 'footprint' assay
which detects regions of DNA protected by binding of added DNA binding proteins.
A ribonuclease protection assay will be carried out to identify any additional
transcription initiation sites in addition to that found in the experiments carried in the
Chapter 7 study. Mutation/deletion of the putative promoter region will allow
determination of the effects of protein binding sites on the level of transcription and in
fact whether substances such as oestradiol, glucocorticoids and phorbol esters are
acting either directly or indirectly to alter TRH-R mRNA levels. In order to establish a
transgenic mouse model of a TRH-R gene knockout, the exact location of the
transcription start site must be known so that this portion of the gene can be deleted by
homologous recombination and so produce a gene which cannot transcribe TRH-R
RNA. It will be very interesting to investigate the effects of absent TRH-induced
effects on foetal development and whether this would be a lethal genetic condition or
not.
Appendix I
Composition of buffers and stock solutions used in experimental procedures
Buffer Component Concentration (pH)
SSCP loading dye formamide 95%




SDS-PAGE sample buffer dithiothrietol lOOmM
SDS 2%
(lx) Tris.Cl (pH 6.8) 50mM
bromophenol blue 0.1%
glycerol 10%
lOx tris-glycine electro¬ Tris base 250mM
phoresis buffer glycine 2.5M
SDS 1%
6x sample buffer (agarose glycerol 30%
gels) bromophenol blue 0.25%
xylene cyanol 0.25%
lOx TBE Tris base 890mM
Boric acid 890mM
EDTA 200mM
TE Tris.Cl lOmM (7.8-8.0)
EDTA 0.1 mM
lOx TRH-R RBA buffer Tris.Cl 20mM (7.2)
MgCl2 2mM







fatty acid free BSA 0.1%
LB (Luria-Bertani) broth LB broth base 2.5%
LB agar LB agar base 5.0%
SOC buffer bacto tryptone 2%








Buffer Component Concentration (pH)




lOx Trypsin-EDTA trypsin 0.5%
EDTA 2%
Sodium acetate soduim acetate 2M (5.0)
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Appendix II
Suppliers of consumables and equipment used
Suonlier Address
Ambion (AMS Biotechnology, UK, Ltd) Oxon, UK
Amersham Chester-le-Street, UK
Applied Biosystems Warrington, UK
BIO-RAD Hemel Hempsted, UK
BIO-101 (Stratech Scientific Ltd) Luton, UK
Boehringer Mannheim Lewes, UK
Cambridge Biosoft Cambridge, UK
Costar Cambridge, UK
CP Laboratories Bishop's Stortford, UK
Falcon Cowley, UK
Flowgen High Wycombe, UK
GIBCO-BRL Paisley, UK
Hoechst-Roussel Canada Inc Montreal, Quebec, Canada
Hybaid Teddington, UK
Invitrogen NV leek, the Netherlands
Kodak Cambridge, UK
Kontron Instruments Cumbernauld, UK
MBI Fermentas (IGi Immunogen Intnl, Sunderland, UK
DuPont UK, Ltd Stevenage, UK
National Diagnostics Atlanta, GA, USA
New England Biolabs Hitchin, UK
Novagen Madison, WL, USA
Peninsula Belmont, CA, USA
Perkin Elmer Cetus Norwalk, CT, USA
Promega Madison, WI, USA
Qiagen Ltd Dorking, UK
R&D Systems Europe, Ltd Abingdon, UK
SEMAT St. Albans, UK
Sigma Poole, UK
Stratagene Ltd Cambridge, UK
Vilber Lourmat Cedex 2, France
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thyrotrophin-releasing hormone (TRH) receptor in functional and clinically
non-functional pituitary adenomas. Clinical Endocrinology 44: 341-347.
2 Anderson L. Alexander C L, Faccenda E and Eidne K A. (1995) Rapid
homologous desensitization of the thyrotropin releasing hormone receptor
expressed in single human embryonal kidney 293 cells. Biochemical Journal
311: 385-392.
3 Collu R, Tang JQ, Gastagne J, Lagace G, Masson M, Huot C, Deal C, Delvin
E, Faccenda E, Eidne K A and Vliet G V. A novel mechanism for isolated
central hypothyroidism: inactivating mutations in the thyrotropin-releasing
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2. Cook J V, Faccenda E, Anderson L, Couper GG, Eidne K A and Taylor P L
(1993) Effects of Asn87 and Asp318 mutations on ligand binding and signal
transduction in the rat GnRH receptor. Journal of Endocrinology 139: 1-4.
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Attendance at scientific meetings:
1. Faccenda E, Melmed S and Eidne K A. Human PRL-, GH- and TSH-
secreting pituitary adenomas harbor structurally intact dopamine type 2 and
thyrotropin releasing hormone receptors. 77th Annual Meeting of the
Endocrine Society, June 14-17, 1995: Washington DC, USA.
2. Faccenda E. Anderson L and Eidne K A. Effects of threonine 265 mutations
in the putative G-protein coupling region of the rat and human TRH receptors.
10th International Congress of Endocrinology, June 12-14, 1996: San
Francisco, CA USA.
3. Faccenda E, Anderson L, Milligan G and Eidne K A. Site-directed
mutagenesis on regions in the putative G-protein coupling domain of the rat
and human TRH receptors. British Neuroendocrine Group Annual Meeting,
2-3 July, 1996: Edinburgh, UK.
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